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Abstract 
Almost all bacteria are surrounded by a peptidoglycan cell wall. This cell wall imposes 
the shape of the bacterial cell and enables the cell to resist turgor pressure, localise 
proteins and coordinate cell division. Despite being ‘essential’, bacteria can grow and 
divide indefinitely in a wall-less state known as the L-form. Conventionally, L-form 
bacteria in the laboratory are grown at high concentrations of osmoprotectant such as 
salt or sucrose due to their sensitivity to turgor. However, L-forms have been isolated 
from various environments, including from persistent infections where such isotonic 
conditions may not be relevant.  
Here I show that L-forms derived from the Gram-positive model organism Bacillus 
subtilis can be readily adapted to media containing very low concentrations of 
osmoprotectant (sucrose or salt), lending support to theories regarding the natural role 
of L-forms. Regeneration of the wall of the adapted strains revealed a raft of phenotypic 
changes including, but not limited to: cell branching, misplaced septa and increased cell 
length. Whole genome sequencing of these mutant strains revealed several mutations. 
Among the mutations identified was a partial deletion of the gene coding for the actin 
homologue, MreB. In the walled state, MreB directs and coordinates the peptidoglycan 
synthesis machinery as a means to control the morphology of the cell. Characterisation 
of the mutation in mreB revealed that loss of this important protein is sufficient to 
enable the growth of L-forms in low osmolarites. 
The cell wall of Gram-positive bacteria also contains teichoic acids (TA). TAs linked to the 
lipids in the cell membrane (Lipoteichoic acids; LTA) are essential for the viability of the 
pathogen Staphylococcus aureus. In contrast, LTA is dispensable in B. subtilis, where loss of 
the primary synthase, LtaS, acts as a suppressor mutation in strains that lack the MreB 
homologue, Mbl.  
Based on the observation that loss of ltaS improved the growth of a Δmbl mutant in 
B. subtilis a screening method was previously developed from which 5 candidate 
actinomycete strains producing potential inhibitors of LtaS were identified. Preliminary 
experiments narrowed the focus to one strain that reproducibly produced an active 
compound, which was purified and characterised. Various properties of the compound 
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were consistent with it acting as an inhibitor of LtaS. Mass spectrometry (MS) and 
MS-MS data suggested a potential identity for the inhibitor that could plausibly 
represent a substrate analogue. Treatment with the compound impaired the growth of 
S. aureus. 
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1. Introduction 
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1.1 The cell envelope 
1.1.1 Overview 
The bacterial cell envelope acts as the interface between the external environment and 
the internal bacterial environment. It both protects the cell from the hazardous external 
environments and allows the cell to interact with its surroundings. In addition it provides 
a framework that enables positioning and ordering of the cellular contents. 
This envelope is a complex structure that consists of two main elements: the cell wall 
and the cell membrane. In Gram negative organisms, an additional external cell 
membrane is present. Gram positive bacteria lack this external cell membrane, though 
their cell envelope is further enriched by the presence of teichoic acids (TAs). The 
differences between the two envelopes is depicted in figure 1.1. 
These various components will be discussed, largely in the context of the Gram positive, 
soil dwelling, model organism Bacillus subtilis, and the roles they play in allowing 
bacteria to respond to dynamic and challenging environments. Further, the effect loss of 
some of these components play on bacterial physiology and the unique insights they 
provide will also be addressed.  
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Figure 1.1. Schematic representation of the cell envelope of Gram-positive (A) and 
Gram-negative (B) bacteria. Diagram omits the presence of the various proteins 
associated with the cell envelope for the purposes of simplification.   
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1.1.2 Peptidoglycan 
The peptidoglycan is a semi-rigid structure that surrounds and constrains the cell 
membrane. Whilst the basic composition of the peptidoglycan is shared between most 
bacteria, the structure varies. The variation in structure was first identified in 1884 by 
Hans Christian Gram, who found that staining could separate bacteria into two groups; 
those that stained negatively (Gram-negatives) and those that stained positively (Gram-
positives). Bacteria that are Gram positive have a single membrane that is surrounded 
by a thick cell wall. By contrast, Gram-negative organisms have a thin cell wall that is 
sandwiched between an inner and an outer cell membrane (Madigan et al., 2009).  
1.1.2.1 Composition 
Peptidoglycan is a polymer composed of glycan strands containing alternating subunits 
of the aminosugars β-(1-4) N-acetylglucosamine (GlcNAc [NAG]) and β-(1-4) acetyl 
muramic acid (MurNAc [NAM]). These are linked by glycosidic bonds that are catalysed 
by transglycosylases. The glycan strands are linked together through the crosslinking of 
peptide residues found on the MurNAc subunits by the transpeptidase activity of the 
Penicillin-binding-proteins (PBPs). The pentapeptide residues on MurNAc consist of L-
alanine, D-isoglutamine, meso-diaminopimelic acid and two D-alanine residues. It is 
between the penultimate D-alanine residue and the ε-amino group of the meso-
diaminopimelic acid that the crosslinking reaction takes place. It is through this reaction 
that the terminal D-alanine is lost (Vollmer and Bertsche, 2008). Exactly how the glycan 
strands are arranged is unknown. The most common view is that the glycan strands lie 
parallel to the cell surface, with the main body of glycan strands running along the 
transverse of the longitudinal axis (Turner et al., 2014). The alternative possibility is that 
the glycan strands are perpendicular to the cell surface (Dmitriev et al., 1999, Dmitriev 
et al., 2003, Meroueh et al., 2006). However, at least in E. coli, there is insufficient 
peptidoglycan present to fully cover the cell in this fashion. In addition, the average 
length of the glycan strands is too great to fit within the periplasm (Vollmer and Holtje, 
2004, Harz et al., 1990).  
The synthesis of peptidoglycan has been extensively studied for many decades, with 
many comprehensive reviews available (Vollmer and Bertsche, 2008, Typas et al., 2012, 
Scheffers and Pinho, 2005, Barreteau et al., 2008). For this work the synthesis of 
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peptidoglycan in B. subtilis will be used as an example. It can be thought that 
peptidoglycan synthesis pathway can be divided broadly into two steps: synthesis of the 
precursors within the cell and the assembly of the polymer outside the cell. GlcNAc is 
synthesised within the cell from fructose-6-phosphate in a series of reactions by the 
enzymes GlmM and GlmU. In turn, GlcNAc acts as the precursor for the synthesis of the 
UDP-MurNAc pentapeptide by enzymes encoded by the murA-F and murZ genes. The 
resulting products are then linked to undecaprenyl-pyrophosphate (C55-PP/bactoprenol), 
a carrier molecule that is embedded within the membrane. Upon linkage, the resulting 
molecule is called lipid I. The addition of UDP-GlcNAc to lipid I by MurG results in the 
creation of a Lipid II molecule. So far, all these steps have taken place inside the cell. 
Lipid II is flipped across the membrane to the exterior of the cell in a process thought to 
be mediated by MurJ (Ruiz, 2008, Meeske et al., 2015), though other candidates have 
been implicated in the past (Ehlert and Holtje, 1996). That B. subtilis remains viable 
following the loss of murJ, suggests the other candidates, such as rodA and ftsW also 
possess flippase activity(Fay and Dworkin, 2009, Scheffers and Tol, 2015). Once outside 
the cell, the precursors are incorporated into the pre-existing cell wall by the PBPs. The 
PBPs are responsible for both the transglycosylation and transpeptidation reactions. 
Different PBPs have varying roles in the synthesis of the cell wall, as reflects their varying 
localisation patterns. For example, PBP2B localises to the division septa, whereas PBP2A 
localises to the sites of cell elongation. It is thought that their interaction partners, as 
well as substrate availability help to regulate the activity of these enzymes (Rowland et 
al., 2010, Lages et al., 2013, Garner et al., 2011).  
The peptidoglycan (PG) cell wall is not a static structure, and must be constantly 
remodelled and sculptured for a number of reasons, the least of which are cell 
elongation and division. In rod-shaped bacteria such as B. subtilis or E. coli new PG 
material is inserted in helices along the lateral cell wall (Vollmer and Bertsche, 2008). 
The process of elongation alternates with division. Unlike elongation which involves the 
addition of new glycan strands and peptide crosslinking, PG synthesis during division 
creates a plate of new PG that is part of the division septum. The presence of the new 
wall material leads to the separation of the cell membranes, resulting in the creation of 
the daughter cells.  It is currently unclear whether the Z-ring constriction at the septum 
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provides the force necessary for the separation of the membranes, or whether it instead 
acts as scaffold, directing the synthesis of the peptidoglycan, with the newly synthesised 
PG causing the scission of the two cells (Meier and Goley, 2014, Osawa et al., 2008, Lan 
et al., 2009). Complete separation of the two daughter cells requires the actions of 
autolytic enzymes which degrade the material connecting the two cells. In addition, 
autolytic enzymes are distributed across the cell surface where they play specific roles in 
cell morphogenesis. Regulation of autolysins and PBPs in Gram-positive bacteria is 
thought to involve many different components (Goehring and Beckwith, 2005, Smith et 
al., 2000, Stewart, 2005). Two of these are the teichoic acids and the actin-homologue, 
MreB. These two components will be discussed later. 
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 Figure 1.2. Cartoon schematic of peptidoglycan synthesis pathway in B. subtilis. 
Enzymes in the pathway are highlighted in red.   
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1.1.2.2 Roles 
As touched on previously, the peptidoglycan plays a number of key roles in the survival 
of the bacterial cell. To this end, the cell wall is often regarded as essential, with some 
level of peptidoglycan found in almost all bacteria, with the exception being a few 
genera of bacteria such as Mycoplasma. However, under certain conditions bacteria can 
grow and divide in a wall-less state known as L-forms. These L-forms will be discussed 
later. Its importance is highlighted by the fact that it is the main target for antibiotics as 
well as a primary antigen for the immune system. 
In addition to the direct roles that will be discussed below, the peptidoglycan mediates 
many secondary roles as it is frequently a binding site for the surface proteins of 
Gram-positive bacteria (in Gram-negative bacteria the proteins tend to be embedded in 
the outer membrane). This anchoring of proteins to the cell wall is mediated by a class of 
enzymes known as sortases (Perry et al., 2002, Ruzin et al., 2002). The surface proteins 
play a myriad number of roles, including mediating the interactions between the cell and 
its surroundings. For instance, many of the surface proteins are directly involved in 
colonisation of the appropriate environmental niche; many pathogens and commensals 
possess proteins that bind to specific eukaryotic molecules. Similarly, other proteins in 
these organisms act to shield and hide the antigens of the cell surface from the immune 
system of the host.  
Many of the attached proteins act to sense changes in their external environments. This 
could involve changes in nutrient availability, solute concentrations, or the presence of 
other bacteria as is the case with quorum sensing.  
1.1.2.2.1 Turgor 
One of the key roles of the cell wall is to resist turgor pressure, preventing lysis of the 
cell in hypotonic conditions. Turgor pressure arises due to the difference between the 
internal solute concentrations and the external osmolarity. Unlike the Eukaryotes, 
bacteria lack systems for active water transport; instead the cellular water content is 
governed by osmosis. Soil bacteria such as B. subtilis face constant changes in their 
external osmolarity due to precipitation and evaporation. After rainfall, the external 
osmotic pressure is likely to drop, resulting in the influx of water into the cell as a result 
of osmosis. Bacteria have adopted ways to cope with such changes, and these will be 
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described later. However, the first line of defence is the PG wall; it possesses sufficient 
strength and elasticity to resist the turgor pressure long enough for additional coping 
mechanisms to come into play. 
1.1.2.2.2 Shape 
A wide array of bacterial shapes exist - from rods and spirals to cocci (Leeuwenhoek, 
1695). These shapes are thought to be selectable features that affect nutrient uptake, 
motility and predation, amongst others. All of the morphologies arise from the cell wall, 
and how it is sculpted.  Upon removal of the cell wall in isotonic conditions, the bacteria 
lose their characteristic morphologies and instead become spherical protoplasts. 
Similarly, the prepared sacculi of bacteria retain the same shapes from which it was 
originally isolated (Vollmer et al., 2008). The shapes of daughter cells formed by the 
peptidoglycan are identical to the cell shape of the parent, an indication for involvement 
of a genetic component. In species with complex cell shapes the cell shape is governed 
by the cytoskeleton protein MreB. MreB and its role in cell shape regulation and 
peptidoglycan synthesis will be discussed at length later. 
1.1.2.2.3 Protein localisation 
The cell shape imposed by the peptidoglycan enables the correct localisation of many 
proteins. Some of these proteins specifically bind to regions of the membrane with 
certain curvatures; the membrane curvature is imposed by the peptidoglycan cell wall. 
For instance, the Min system localises to the cell pole and prevents septal formation at 
sites away from the midcell. Localisation of MinCD to these sites is dependent on the 
presence of DivIVA. It has been demonstrated that the localisation of DivIVA to the cell 
poles is not dependent on the presence of any other proteins. Instead DivIVA recognises 
the negative curvature of the membrane at the poles (Lenarcic et al., 2009). In 
comparison, the B. subtilis spore coat assembly protein SpoVM preferentially binds to 
membrane with positive curvature. This ensures the protein accumulates on the 
membrane of the spore, rather than on the mother cell (van Ooij and Losick, 2003, 
Ramamurthi et al., 2009, Gill et al., 2015).  
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1.1.3 Cell membrane 
In Gram-positive organisms a single cell membrane lies beneath the cell wall. This 
contrasts with Gram-negative bacteria, which sandwich their cell wall between an inner 
cell membrane and an outer cell membrane.  At its simplest, the membrane can be 
considered to consist of a phospolipid bilayer that is studded with proteins. This semi-
permeable membrane acts to separate the internal environment of the cell from the 
external environment, yet at the same time allows the cell to sense and interact with its 
surroundings. The membrane is a highly complex and ordered system. This complexity 
and how it allows the cells to structure its internal composition and react to external 
stimuli will be discussed below.  
In B. subtilis the phospholipids that make up the cell membrane are synthesised by the 
type II fatty acid synthesis pathway (FAS II). Unlike the FAS I system in higher eukaryotes 
which consists of a polypeptide expressed from a single gene, the FAS II system is 
composed of many different gene products. Whilst the pathway is best elucidated for 
E.coli, the following description of the pathway will be discussed in the context of B. 
subtilis as there are significant differences in the fatty acid composition of the two 
species. In bacteria, the substrate for fatty acid synthesis is acetyl Co enzyme A (acetyl-
CoA), itself a product of glucose metabolism. Conversion of acetyl-CoA into the 
intermediate, malonyl-CoA is catalysed by the coordinate functions of the acetyl-CoA 
carboxylase proteins (Acc). There are four of these proteins in B. subtilis; AccA, AccB, 
AccC and AccD. In bacteria it is not thought that malonyl-CoA has any other use outside 
of the FAS II pathway, therefore this is the step that commits the bacteria into producing 
fatty acids (Cronan and Waldrop, 2002). The malonyl group is then removed from the 
CoA subunit and transferred onto the acyl transfer protein (ACP) by the transacylase, 
FabD. It is onto the ACP that all subsequent intermediate molecules are attached to 
during fatty acid synthesis. In the next stage, FabH catalyses the first condensation 
reaction in which acetyl-CoA is used as the primer and the malonyl-ACP is the acceptor. 
FabH is the primary regulator of fatty acid diversity due to the substrate specificity of the 
enzyme (Choi et al., 2000). Replacement of the endogenous FabH with that from 
another species results in fatty acids with a different structure (Li et al., 2005). To 
produce branched chain fatty acids α-keto acids are used as the primers instead of 
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acetyl-CoA. The α-keto acids arise following the deamination and decarboxylation of the 
amino acids proline, leucine and isoleucine. Outside of the use of the α-keto acids, the 
synthesis of branched chain fatty acids proceeds in the same way as the straight chain 
fatty acids. After the first condensation reaction, the fatty acid precursor then enters the 
elongation cycle. The first step of the cycle involves the β-Ketoacyl-ACP reductase, FabG. 
The action of FabG is dependent on the presence of NADP (Toomey and Wakil, 1966). 
The intermediate produced by the actions of FabG is then dehydrated by either FabZ or 
FabA. The cycle is then completed by the actions of the reductase FabI/K/L/V, depending 
on the species (Heath et al., 2000). New rounds of elongation are then initiated by the 
actions of FabB. Some of the intermediate products are used for additional functions in 
bacteria, such as the production of the cofactor, biotin (Lin et al., 2010). The properties 
of the fatty acids affects the fluidity of the membrane. The properties of the fatty acids 
affects the fluidity of the membrane. The fluidity refers to the viscosity of the 
membrane; the level of viscosity is important for the motility, mobility and function of 
membrane embedded proteins. The level of membrane fluidity is affected by the 
temperature of the environment in which the bacterial cell is found - the warmer the 
environment, the more fluid a membrane will become. The fluidity of the membrane is 
also affected by the composition of the membrane. As alluded to earlier, the bacterial 
cell can produce different types of fatty acids, which will affect the fluidity of the cell.  
For example, branched chain fatty acids are more fluid than those with a straight chain; 
this arises because the branching limits the number of intermolecular interactions. The 
same phenomena occurs in regards to the other properties of the fatty acid such as the 
chain length, where longer chains result in an increased number of intermolecular 
interactions, and therefore a decrease in the fluidity (Parsons and Rock, 2013). In 
response to changes in temperature, the membrane fluidity will be altered to maintain a 
constant level of viscosity in a process called homeoviscous adaptation.  
 
The products of the elongation cycle are intercepted by glycerol-3-phosphate 
acyltransferases that transfer the acyl-group from ACP to glycerol-3-phosphate, resulting 
in the production of phosphatidic acid. This stage represents the interface between fatty 
acid synthesis and membrane expansion. Phosphatidic acid is converted into CDP-
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diacylglycerol (CDP-DAG) by CdsA. CDP-DAG acts as the branch point between the 
generation of zwitterionic phospholipids and acidic phospholipids. The diversity of head 
groups and the electrostatic charges they possess has been shown to be necessary for 
integral membrane proteins to adopt the correct topology (Zhang et al., 2005, Xie et al., 
2006).   
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Figure 1.3. Pathways of the phospholipid synthesis pathways. (A) The initiation of fatty 
acid synthesis. Enzymes involved are displayed in red. BCFA: branch chained fatty acids, 
derived from amino acids; SCFA: straight chain fatty acids, derived from metabolism. (B) 
Schematic of phospholipid head group synthesis. Enzymes involved are displayed in red; 
putative enzymes are indicated with a question mark. CMP = cytidine monophosphate; 
Glycerol-3-P = Glycerol-3-phosphate. For brevity, the schematic of fatty acid elongation 
was omitted.    
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1.1.3.1 Composition and organisation 
Historically, the membrane was predicted to have a homogeneous distribution of the 
lipids and proteins, as predicted by the fluid mosaic model (Singer and Nicolson, 1972). 
Recent work instead suggests a new model in which the lipid and protein components of 
the membrane are distributed in a laterally heterogeneous manner. The heterogeneity 
of the membrane allows for the orchestration of many cellular events including cell 
division, chromosome segregation and osmosensing (Fishov and Norris, 2012). As 
mentioned, a primary component of the membrane are the phospholipids. The 
phospholipids contained in the membrane bilayer are not identical. They may have 
different head groups, which may vary in size and charge, and tails may differ, with 
varying lengths, saturation and branching. All these differences will contribute towards 
how the phospholipid interacts with other lipids, but also with the membrane associated 
proteins, which would in turn influence the formation of discrete lipid domains within 
the membrane.  
This segregation of lipids has been demonstrated in both E. coli and B. subtilis, and 
almost certainly extends to other species. The relative quantities of the lipids does vary 
between E. coli and B. subtilis, with the membrane of B. subtilis comprising of roughly 
20% phosphatidylethanolamine (PE), 40% phosphatidylglycerol (PG), 25% cardiolipin (CL) 
and 15 % lysyl-phosphatidylglycerol.  
The first domains discovered were those involving the segregation of the anionic 
phospholipid, cardiolipin. CL in B. subtilis is synthesised by ClsA at the septum (Nishibori 
et al., 2005). In addition to its presence at the septum CL is observed to localise at the 
cell poles (Mileykovskaya and Dowhan, 2009). One hypothesis for the segregation of CL 
to the poles concerns the shape of the lipid. The hydrophobic tail of CL has a wider 
cross-section than the hydrophilic head, resulting in a cone shape. Due to this shape the 
most energetically stable environment tends to be the pole, where the membrane is 
pinned to the cell wall due to osmosis pressure resulting in a negative curvature (Huang 
et al., 2006).  
As mentioned, CL is not the only species whose distribution is coordinated in the 
bacterial membrane. It has been demonstrated using fluorescent cationic styryl dyes 
that preferentially associate with PG or CL that PG assembles into helical domains along 
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the long axis of the cell. Evidence suggests that these helical domains are linked to the 
helices formed by the peptidoglycan synthesis machinery, with MinD, FtsA and SecA 
using the presence of PG as a cue for localisation (Barak et al., 2008). 
In addition to the various distributions of the PG and CL, there is evidence suggesting the 
presence of lipid rafts within the bacterial membrane. These rafts had been previously 
identified in eukaryotes, where they help organise signal transduction proteins, amongst 
others. It was observed that proteins similar to the eukaryotic proteins were present in 
bacteria and that these proteins were not homogeneously distributed within the cell 
membrane. Further, these proteins do not colocalise with PG or CL, instead localising 
with polyisoprenoids. As with PG and CL, the rafts enable the colocalisation of proteins 
with similar, or shared pathways, such as the signal transduction proteins (Lopez and 
Kolter, 2010).  
  
Perhaps one of the key roles the membrane plays is in the regulation of osmosis. The 
membrane acts as a partially permeable membrane that generally restricts the 
movement of most solutes, but permits the movement of water. Therefore, when a cell 
encounters hypotonic or hypertonic conditions water will rapidly cross the membrane in 
an attempt to diffuse or concentrate the cell contents.  As the cell swells or contracts the 
distribution and coordination of the lipids will change. These changes are recognised by 
osmosensing proteins which act to normalise the cellular osmolarity. In E. coli, one of 
these osmosensing proteins is ProP, which responds to hypertonic conditions. ProP 
localises to the cell poles (Romantsov et al., 2007). Here, it associates with CL, with the 
phospholipid affecting the response of the protein to changes in osmolarity (Tsatskis et 
al., 2005). 
CL was used as an example to demonstrate the multiplicity of roles individual 
phospholipids may play and the complexity of the membrane. Other phospholipids play 
important roles in structuring the cell through interacting with each other, with proteins 
and with small molecules.  
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1.1.4 Teichoic acids 
The simplest diagrams of the Gram positive cell envelope will only feature a cell 
membrane surrounded by a PG cell wall. This is not the case, with anionic polymers 
called teichoic acids making up 30-60% of the cell wall. The TAs come in two types: those 
linked to the PG (Wall teichoic acids; WTA) and those linked to the lipid head groups of 
the membrane (Lipoteichoic acids; LTA). Not all Gram positive organisms have 
conventional LTA or WTA, though they generally possess functionally similar anionic 
structures instead. Interestingly, the replacement of LTA is associated with high GC 
content of the genome. In many species such as B. subtilis and S. aureus, the teichoic 
acids are polymers of polyglycerol phosphate (Gro-P). However, Gro-P is not the only 
substrate for TA synthesis, with subunits of ribitol phosphate and galactose not 
uncommon among different species (Neuhaus and Baddiley, 2003). 
Whilst structurally similar in most bacteria, LTA and WTA are synthesised in distinct, 
separate pathways. This is even the case in bacteria such as B. subtilis where the repeat 
units are exactly the same. After synthesis the teichoic acid may be further modified 
through d-alanylation of the Gro-P subunits, a process carried out by enyzmes encoded 
by the dlt operon. Levels of d-alanylation vary across species and between WTA and 
LTAs. D-alanylation is further modulated in response to changes in pH, temperature and 
changes in the external osmolarity.  
TAs have been implicated in a number of roles, though the functions remain somewhat 
unclear despite decades of research. TAs have been proposed to be involved in the 
cation homeostasis (Archibald et al., 1961, Heptinstall et al., 1970), biofilm formation 
(Gross et al., 2001, Holland et al., 2011), release of secreted proteins (Nouaille et al., 
2004), adhesion (Wobser et al., 2014, Baur et al., 2014), pathogenicity (Fittipaldi et al., 
2008, Morath et al., 2001), antibiotic resistance (Kovacs et al., 2006, Bertsche et al., 
2013) and autolysin regulation (Biswas et al., 2012). In pathogens, the TAs, particularly 
LTA, have been demonstrated to be antigenic and are recognised by the innate immune 
system (Fedtke et al., 2004). In addition, the WTA and LTA have been shown to have 
important roles in the regulation of cell elongation and division (Schirner et al., 2009). 
These functions will be discussed at length later. As the structures of WTA and LTA are 
basically the same, it is thought the different roles are due to the spatial distribution of 
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these molecules, as opposed to any biochemical difference. It has been speculated that 
the charged nature of the TAs results in a microenvironment surrounding the cell that 
acts as periplasmic space similar to that seen in Gram negative organisms. It is thought 
that d-alanylation affects some of these functions, both positively and negatively, 
probably by altering the electromechanical properties of the cell envelope (Neuhaus and 
Baddiley, 2003). It has also been suggested that d-alanyl-LTA provides a source of free 
energy for chemical processes in the wall, though this hypothesis has not been proven 
(Neuhaus and Baddiley, 2003).  
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1.1.4.1 Wall teichoic acid 
WTA is far better understood than the LTA, with most of the enzymes involved known; 
the synthesis of WTA has recently been comprehensively reviewed in (Brown et al., 
2013). Unlike the synthesis of PG, WTA synthesis takes place within the cell cytoplasm, 
with the completed polymer exported across the membrane and then attached to the 
pre-existing wall (figure 1.4). WTA synthesis is carried out by enzymes encoded by the 
tag operon. The first gene in the pathway, tagO, encodes a protein that catalyses the 
attachment of GlcNAc to the undecaprenyl pyrophosphate (C55-PP) carrier. TagA then 
attaches the linkage unit N-acetylmannosamine (ManNAc). ManNAc is created in an 
epimerisation reaction from GlcNAc by the enzyme MnaA. The building blocks of the 
WTA, CDP-GroP are synthesised by TagD, the first of these subunits are attached to the 
ManNAc residue by TagB. These initial steps are conserved in all the WTA synthetic 
pathways characterised thus far. However, the rest of the description will concern the 
synthetic pathway present in B. subtilis. Further extension of the WTA is catalysed by 
TagF, which links more of the CDP-GroP subunits until the chain is 45-60 residues in 
length. Glycosylation of the subunits is carried out by TagE. The extent of the 
glycosylation is dependent on the growth conditions. After the polymer is synthesised it 
is exported across the membrane to the exterior of the cell by the ABC transporter 
TagGH. Outside of the cell, the WTA is attached to PG in a process that was for some 
time poorly understood. It is now believed that members of the LytR–Cps2A–Psr (LCP) 
protein family encoded by tagT, tagU and tagV act as phosphotransferases to attach the 
polymer to the PG (Hubscher et al., 2008). Addition of d-alanyl esters is carried out by 
proteins encoded by the dlt operon. It is thought that the d-alanyl esters are added first 
to LTA, before they are transferred onto WTA (Neuhaus and Baddiley, 2003). 
Deletion of any of these genes prevents the formation of WTA. Initially, it was believed 
that WTA was essential for cell survival (Bhavsar et al., 2001, Bhavsar et al., 2004). 
However, it was later demonstrated that deletions of the genes were viable, provided 
that the first gene in the pathway, tagO, was deleted (D'Elia et al., 2006a). Deletions of 
the later genes in the pathway in the absence of ΔtagO were non-viable, probably due 
to a build-up of a toxic intermediate or sequestration of an important metabolite (D'Elia 
et al., 2006b). Loss of WTA in B. subtilis results in cells that are affected in cell 
41 
 
elongation. The cells are able to divide, but are unable to maintain the normal rod 
shape. Localisation studies found that the synthetic enzymes localised to the sites of 
nascent PG synthesis along the lateral cell axis. This localisation was highly similar to that 
of the cytoskeleton proteins of the MreB family, which are believed to regulate PG 
synthesis and cell shape (Kawai et al., 2011, Formstone et al., 2008). This agrees with 
earlier work that demonstrated using radiolabelling that WTA was attached only to 
newly synthesised PG in B. subtilis (Mauck and Glaser, 1972). Work in S. aureus has 
shown further evidence for a functional interaction between the WTA and the PG 
synthesis machinery. Deletion of S. aureus WTA results in delocalisation of PBP4 and 
FmtA, and reduced PG crosslinking (Farha et al., 2013, Atilano et al., 2010).   
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Figure 1.4. Pathway of wall teichoic acid synthesis in B. subtilis. Enzymes involved are 
indicated in red. WTA=wall teichoic acid; ManNAc=N-acetylmannosamine; GlcNAc=N-
acetylglucosamine; Gro-P=glycerol phosphate.   
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1.1.4.2 Lipoteichoic acid 
Unlike WTA, the synthetic pathway of LTA is poorly understood and characterised, with 
the genes involved only identified in the last 5 to 10 years.  The majority of the research 
into LTA has been performed in a S. aureus background as it has been found to be 
important for the growth and pathogenicity of this organism. However, comparative 
work in B. subtilis has found the pathways between the two species to be largely similar. 
As with WTA, the LTA in B. subtilis is composed of repeat units of Gro-P, although the 
Gro-P involved in LTA synthesis is derived from the head groups of the membrane lipid, 
phosphatidylglycerol. The Gro-P is anchored into the membrane by 
diglycosyldiacylglycerol (Glc2-DAG). Glc2-DAG is synthesised inside the cell by UgpP 
which catalyses the attachment of UDP-glucose to diacylglycerol (DAG). In S. aureus, the 
Glc2-DAG anchor is thought to be flipped across the membrane by the transmembrane 
protein and putative flippase LtaA (Grundling and Schneewind, 2007a). No homologues 
of LtaA have been identified in B. subtilis, where the movement of the Glc2-DAG across 
the membrane remains a mystery. The gene responsible for the attachment of Gro-P to 
the anchor, ltaS, was identified first in S. aureus, with a homologue identified by a BLAST 
search in B. subtilis. The BLAST search identified a further two homologues of ltaS: yqgS 
and yfnI (Grundling and Schneewind, 2007b). These are thought to play specialised roles 
in sporulation and stress, respectively. An additional homologue was also found, yvgJ, 
though this was later shown to be a primase rather than a synthase (Wormann et al., 
2011). LtaS in both S. aureus and B. subtilis consists of five transmembrane domains with 
an extracellular catalytic C-terminal domain (Schirner et al., 2009). It is currently thought 
the attachment of subunits by the enzyme occurs at the distal end of the growing LTA 
molecule. As the subunits and the LtaS are both located in the membrane, it has been 
postulated that the terminal end of the LTA molecule remains close to the membrane. 
As with WTA, LTA can be d-alanylated. This is one of the few pathways shared between 
the two TAs, with the gene products of the dlt operon also responsible for d-alanylation 
of LTA.  
Much like the differing synthetic pathways, it has been shown that LTA and WTA have 
different physiological roles. Loss of ltaS is lethal in S. aureus, with growth only possible 
at permissive temperatures or by development of suppressor mutants in osmotically 
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stabilising conditions. In B. subtilis, ltaS is dispensable, though a fitness cost is incurred. 
Further deletion of the homologues, yqgS and yfnI, renders the cell sicker, but is not 
lethal for B. subtilis. However, upon deletion of ltaS in B. subtilis, the cells develop a 
filamentous phenotype. In addition, it was shown that a double mutant of ltaS and the 
homologue yqgS blocks sporulation. In both vegetative and sporulating cells, LtaS and 
YqgS localise mainly to the sites of cell division. This supports the idea that LTA is 
involved in the regulation of division, whereas WTA is involved in elongation. Exactly 
how LtaS and LTA contribute to division is unclear. It is thought that LTA may increase 
the availability of magnesium to the division machinery. The role of LTA in cation 
homeostasis is supported by the observation that even very low concentrations of Mn2+ 
was extremely toxic to B. subtilis cells that were LtaS-null (Schirner et al., 2009). This 
suggests that LTA is able to bind the cations, preventing access to the cell. 
In species such as S. aureus, the ltaS deletion mutants are viable when grown in high 
sucrose or salt media. They can also be rescued by increases in the cellular 
concentration of the signalling molecule cyclic-diadenosine-monophosphate (c-di-AMP). 
This molecule has been implicated in the regulation of the transport of potassium and 
other ions (Corrigan et al., 2011). It has therefore been postulated that LTA may play a 
role in the osmoprotection of the cell.  
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 Figure 1.5. Pathway of LTA synthesis in B. subtilis. Enzymes involved are indicated in 
red. Unknown proteins are indicated with a question mark. LTA=lipoteichoic acid; 
Gro-P= glycerolphosphate; PhG=phosphatidylglycerol; Glc-6-P=Glucose-6-phosphate; 
Glc-1-P=Glucose-1-phosphate; UDP-Glc=UDP-Glucose; DAG=Diacylglycerol.   
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1.2 The bacterial cytoskeleton 
For a significant period of time, the cytoskeleton was considered a uniquely eukaryotic 
characteristic. In the eukaryotes the cytoskeleton plays a role in cell shape 
determination, motility, chromosome segregation and the architecture of intracellular 
space. However, it has since emerged that bacteria possess a homologous system.  
The first homologue identified in bacteria was FtsZ. FtsZ is a highly conserved tubulin-
like protein that forms the Z-ring at the site of septum formation (Adams and Errington, 
2009). This was followed by the discovery of another filamentous protein – MreB. 
Crystallisation of MreB showed a clear structural homology to the eukaryotic actin, even 
though there is very little homology at a nucleotide level or in the primary structure. 
MreB belongs to a super family of other actin-like proteins, which includes important 
proteins such as FtsA. However, for the purposes of this work only MreB and its 
homologues in B. subtilis will be discussed. More recently, a homologue to the 
intermediate filaments was identified in Caulobacter crescentus. Crescentin, as the 
homologue was called, was found to be a cell shape determinant in this species. It 
should be noted that the level of homology between crescentin and the intermediate 
filaments is very low; the only conserved characteristics are a nucleotide hydrolysing 
activity and some structural features (Ausmees et al., 2003).  
1.2.1 MreB 
The mreB genes were among the first to be associated with the regulation of cell shape 
in E. coli and B. subtilis. The mreB genes are highly conserved, but also widely 
distributed. They are found in most non-spherical bacteria, and are absent in almost all 
of the coccoidal bacteria. Those bacteria which lack a copy of MreB, but are still rod-
shaped, tend to grow via more uncommon methods, such as through addition of new PG 
at the cell poles (Flardh, 2010). This contrasts with the conventional mode of elongation 
seen in E. coli and B. subtilis in which new material is added along the lateral cell axis. 
Deletion of mreB in rod-shaped bacteria results in the loss of this cell shape, with the 
bacteria instead adopting a spherical shape (Wachi et al., 1987). Taken together, this 
was a strong indication that MreB is involved in the addition of cell wall material along 
the lateral cell axis. MreB null mutants are very sick, though can be stabilised with the 
addition of high concentrations of magnesium(Formstone and Errington, 2005). This 
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suggests a possible role for the MreB in stabilising the membranes, though admittedly 
the actual role of the magnesium has yet to be elucidated. Original localisation studies 
indicated that MreB forms helical filaments along the lateral cell axis; the helical 
distribution of MreB matched that of nascent peptidoglycan synthesis (Daniel and 
Errington, 2003, Jones et al., 2001). At the same time, it was observed that many of the 
interaction partners as well as components of the elongation complex were similarly 
distributed, though it must be said that the localisation of some of these proteins was 
more tenuous than others. It is thought that through the interaction partners of MreB 
such as MurG, MraY, RodZ, MreC and MreD (Muchova et al., 2013, van den Ent et al., 
2006, Defeu Soufo and Graumann, 2005), MreB is able to couple the cytoplasmic and 
extracellular cell wall synthesis steps. These proteins are also involved in cell shape 
determination. They are known to act as a bridge between MreB and other members of 
the elongation complex. Unfortunately, they are far less understood than MreB. From 
the results described it was therefore presumed that the MreB filaments were directly 
involved in the morphogenesis of rod shaped bacteria by coordinating the locations of 
peptidoglycan synthesis.  
In 2011, this paradigm was contested by the release of a number of papers. These 
papers used more sophisticated microscopy techniques to re-examine the nature of the 
MreB assemblies in both E. coli and B. subtilis. The papers showed that instead of helical, 
stationary filaments, MreB instead form dynamic patches that move in a circumferential 
motion rather than in a helical movement. This movement appears driven not by actin-
like dynamics, but rather by the action of the cell wall synthetic enzymes (Garner et al., 
2011, Dominguez-Escobar et al., 2011, van Teeffelen et al., 2011). The conflicting 
observations were ascribed to various limitations regarding the techniques for the 
visualisation of MreB. The results raised many questions, namely, how do the short 
patches of MreB control the rod shaped morphology of the cells; it is difficult to imagine 
how the patches would be able to measure or coordinate the cell geometry, particularly 
as MreB has been demonstrated to be essential for the recovery of a rod shape in cells 
growing a cell wall de novo (Billings et al., 2014, Errington, 2015). More recently, both 
in vitro studies and high-resolution imaging techniques found that MreB could form 
extended filaments. It was demonstrated in vitro that MreB could form filaments that 
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could assemble into antiparallel proto-filaments (van den Ent et al., 2014). It was also 
shown that MreB can interact with the membrane via a membrane insertion loop or an 
N-terminal amphipathic helix (Salje et al., 2011); these interactions would be increased 
within a proto-filament. Alongside the biochemical work, use of new microscopy 
techniques such as structured illumination microscopy (SIM), stimulation emission 
depletion (STED) microscopy and total internal reflection fluorescence-SIM (TIRF-SIM) 
was able to shed new light on the nature of MreB within the cell (Olshausen et al., 2013, 
Reimold et al., 2013). The papers once again found that MreB forms extended filaments 
of variable length whose movement is based upon the activity of peptidoglycan 
synthesis. The extended filaments they observed using the various microscopy 
techniques moved in a circumferential motion, as reported in the work from 2011. 
However, some of these filaments were orientated in such a way as to appear helical 
using traditional fluorescent microscopy. The model they propose states that MreB does 
indeed form extended filaments, with these filaments connecting spatially separated 
complexes of PG synthesis machinery. The extended filaments are suggested to allow 
the protein to ‘sense’ information regarding the geometry of the cell (Olshausen et al., 
2013). This model has been further enriched by recent work into the geometrical control 
of the cell shape by MreB. As mentioned earlier, MreB can directly interact with the 
membrane. In liposomes, this interaction is sufficient to impose curvature on the 
membrane (Salje et al., 2011). In the more recent work it was found that MreB 
preferentially localises to regions of negative curvature whilst depleting from areas of 
positive curvature. It was seen that this localisation was coupled with localised cell wall 
synthesis. Bursts of localised peptidoglycan synthesis result in the cell straightening, and 
the loss of negative curvature. In silico experiments agreed with the hypothesis that PG 
synthesis at negatively curved sites helps to straighten cells (Ursell et al., 2014). 
The assembly of MreB into filaments appears to be further controlled by the availability 
of the PG precursor molecule lipid II.  Depletion of lipid II either genetically or through 
use of antibiotics results in the disassociation of MreB from the membrane. The 
disassembly of the MreB filaments causes cell elongation to cease (Schirner et al., 2015). 
Whilst PG synthesis would presumably be halted due to the absence of a substrate, 
autolytic enzymes also make up the elongation complex organised by MreB, and would 
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continue degrading the PG at these sites. This mechanism therefore provides a nice 
system through which the activity of these enzymes could be regulated. Consistent with 
this study, recent work has indicated that MreB is linked to regions with increased 
membrane fluidity, as are the lipid II molecules (Strahl et al., 2014, Janas et al., 1994, 
Ganchev et al., 2006). These regions of increased fluidity are believed to be created by 
MreB, though is unclear how, as MreB in B. subtilis (in which this work was performed) 
lack the membrane interacting domains that have been shown to generate lipid domains 
(Garcia-Saez et al., 2007, Cornell and Taneva, 2006). It is hypothesised that the regions 
of increased membrane fluidity may facilitate catalytic activity or protein diffusion, 
though this is just speculation.  
1.2.2 Mbl and MreBH 
Gram negative bacteria tend only to have a single copy of mreB on their genome. 
B. subtilis, like many Gram positive organisms carries two homologues of mreB; mbl 
(mreB-like) and mreBH (mreB homologue). MreB and Mbl have roughly equal 
abundance in the cell, whereas MreBH is significantly less abundant (Jones et al., 2001). 
The mreB gene is defined primarily by its genomic position in an operon alongside mreC 
and mreD. The other two homologues are organised into monocistronic units (Kobayashi 
et al., 2003). As with deletions of MreB, loss of any of the homologues is lethal. Like with 
MreB-null strains, growth can be restored through supplementation of the growth 
media with magnesium, though the magnesium dependence of MreBH is far more 
subtle, requiring Mg2+ concentrations less than 100 μM (Carballido-Lopez et al., 2006). 
Interestingly, MreBH is essential for growth in low magnesium conditions (Carballido-
Lopez, 2006). In addition to the single deletions, the only viable double mutation has 
deletions of mreBH and mbl (Kawai et al., 2009, Defeu Soufo and Graumann, 2006). 
Deletions of mbl were found to be viable in the absence of magnesium at first 
(Abhayawardhane and Stewart, 1995, Jones et al., 2001), though it appears now that 
this instead provokes the development of suppressor mutations (Schirner and Errington, 
2009, Schirner et al., 2009). It was discovered that the gene responsible for LTA 
synthesis, ltaS, is one of the genes identified to be lost in response to deletion of mbl. It 
remains unclear exactly how disruption of LTA enables Δmbl cells to grow in the absence 
of Mg2+ supplementation; the strongest hypothesis is that the loss of LTA increases the 
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access of Mg2+ to the cell (Schirner et al., 2009). Another of genes whose mutation 
suppresses the magnesium dependence of Δmbl was rsgI. rsgI encodes the anti-sigma 
factor of σI, a σ70-type sigma factor that is involved in the response to external stress. As 
with the mutation in ltaS it remains unclear how derepression of σI results in the 
suppression, though modifications to the cell wall are suspected. What is remarkable, 
however, is that ΔrsgI enables triple mutations comprising ΔmreB, Δmbl and ΔmreBH to 
be constructed, something which is not possible in a wild type background (Schirner and 
Errington, 2009). The triple mutant was observed to adopt a spherical shape as was an 
increase in the membrane fluidity (Strahl et al., 2014).  
All three of the MreB homologues are believed to interact with each other, but also to 
colocalise to the elongation complex discussed earlier (Carballido-Lopez, 2006, Defeu 
Soufo and Graumann, 2006, Challis, 2014, Formstone and Errington, 2005). The three 
homologues have overlapping functions, making it difficult to prise apart their individual 
functions. The different single mutations do not result in identical phenotypes, with the 
cells instead taking on different morphologies depending on which of the homologues 
was deleted. When MreB is lost cells become fatter, but remain straight; loss of Mbl 
results in fatter, twisted cells; loss of MreBH causes cells to become straight and thin.  
It has also been demonstrated that the homologues have different roles in the 
regulation of the autolytic enzymes CwlO and LytE. As mentioned earlier, the cell wall is 
a highly dynamic structure that is constantly growing and remodelled. Where the PBPs 
attach new PG, the autolytic enzymes are able to remove the PG. As with PG synthesis 
machinery, the spatial and temporal activities of the autolytic enzymes must be tightly 
regulated. Loss of regulation would have disastrous results. In B. subtilis it has been 
demonstrated that CwlO and LytE play an essential role in the elongation of the cell 
(Bisicchia et al., 2007). Loss of both the enzymes results in cell death, likely as a result of 
an inability to elongate (Hashimoto et al., 2012). It was found that the two autolytic 
enzymes are differentially regulated by the MreB homologues, with MreB and MreBH 
controlling LytE activity, whereas Mbl controls the activity of CwlO (via the FtsEX 
complex) (Dominguez-Cuevas et al., 2013). In addition to the differential control, it was 
discovered in the same work that the autolytic enzymes have differing roles in the 
control of bacterial morphogenesis. Loss of LytE affects the control of the cell diameter, 
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whereas disruption of CwlO appears to affect the control of the longitudinal axis. Such 
phenotypes are broadly similar to the morphologies seen when MreBH and Mbl are 
deleted respectively. These results strongly indicate that the MreB and its homologues 
possess differentiated roles in the control of bacterial morphogenesis. It makes sense 
that the Gram positive bacteria have additional MreB homologues to allow them to 
more tightly coordinate the structure of the cell wall, particularly as they lack the ability 
to do so from an outer membrane like in Gram negative organisms.  
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Figure 1.6. Model of the MreB homologues and their orchestration of the cell wall 
elongation machinery. MreB and its homologues form helical filaments that colocalise 
underneath the cell membrane. Here they interact with transmembrane proteins such 
as MreC and RodZ, which in turn coordinate the cell wall synthesis machinery (the PBPs). 
The MreB homologues also coordinate the activity of the autolysis enzymes.   
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1.3 Regulation of osmolarity in bacteria 
Most bacteria will face changes in the osmolarity of its external environment. B. subtilis 
will face drastic changes of osmolarity in the soil due to the effects of precipitation and 
evaporation, whereas bacteria such as urinary pathogenic E. coli (UPEC) will experience 
changes as a result of the concentration or dilution of urine. As the external osmolarity 
rises or falls water will pass across the membrane to either concentrate or dilute the 
cytoplasm. Bacteria strive to maintain a constant cytoplasmic volume so as to enable 
optimum cell function and structure. Unlike eukaryotes, prokaryotes lack a means to 
actively transport water across their membranes. Instead, prokaryotes must instead 
modulate the levels of solutes within their cytoplasm. Broadly speaking the milieu of 
components within the cell cytoplasm can be divided into two camps. Firstly, there are 
the molecules that contribute that affect the osmolarity of the cell, but are involved in 
an essential cell process or are toxic to the cell. The second camp are known as the 
compatible solutes (Whatmore et al., 1990). These are soluble molecules and ions that 
can be accumulated to very high levels without affecting protein functions or cellular 
physiology (da Costa et al., 1998, Arakawa and Timasheff, 1985). As osmotic pressure is 
a physical function arising from the water activity, both affect the intracellular 
osmolarity. However, the cell is able to alter the levels of compatible solutes in response 
to changes in the external osmolarity, whereas the other solutes remain largely stable. 
The various routes by which the levels of compatible solutes can be controlled will be 
discussed below. Before that, the key role of the cell wall in withstanding the effects of 
changing osmolarities must be reiterated. As mentioned in 1.1.2.2.1 the cell wall 
provides the first line of defence in withstanding the effects of the influx of water. 
Without a cell wall large influxes of water will inflate the cell cytoplasm to the extent 
that the cell membrane loses its integrity, resulting in cell lysis. 
Bacteria respond to osmotic changes through modulating the cytoplasmic 
concentrations of the compatible solutes. These compatible solutes come in several 
guises and include both organic and inorganic molecules. The inorganic molecules are 
generally limited to K+ and Na+ ions, whereas the list of organic molecules used as 
compatible solutes is far more extensive. Organic compatible solutes include molecules 
such as glycine betaine, proline and glutamate. The organic solutes used varies widely 
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from species to species (da Costa et al., 1998). K+ is the most ubiquitous, being 
maintained in B. subtilis at basal levels of around 350 mM due to its involvement in 
many key functions. Upon osmotic upshock, the concentration of K+ can increase as high 
as 650 mM as the bacterial cell utilises uptake systems to accumulate K+ to counteract 
turgor. However, high concentrations of K+ are difficult to sustain and are detrimental to 
the bacterial physiology. As such, following an initial osmotic upshock, bacteria will 
begin to accumulate the organic solutes, replacing the K+ in combatting the turgor 
pressure (Whatmore et al., 1990).  
Bacteria will respond to changes in osmolarity first on a protein based level, then as time 
progresses the cell will respond at a transcriptional level (Wood, 1999). The initial 
protein response largely concerns the osmosensing proteins distributed throughout the 
membrane. These proteins generally are dual-functional, with an additional role as a 
transporter. The dual function is necessary as changes in the hydration of the cell affects 
the functions of many proteins. 
Upon an osmotic upshock the cell will start to dehydrate, resulting in cytoplasm 
shrinkage and even plasmolysis. Loss of cytoplasmic volume is known to inhibit many 
cellular functions. It was originally thought that the turgor was necessary for driving cell 
wall synthesis and cell expansion, though this no longer appears to hold true, as turgor is 
not significantly affected during osmotic upshocks (Rojas et al., 2014). It remains unclear 
how osmotic stress limits cell growth, though various deleterious effects on the 
molecule crowding in respiration, transcription, translation, precursor synthesis and 
replication have all been suggested (Wood, 1999, Wood, 2015).  
Most of the membrane transporters become inactivated, except for the 
osmotransporters. The osmotransporters are bifunctional proteins in that they also 
possess an osmosensory function. The three models for understanding these 
osmoregulator proteins are ProP from E. coli, BetP from Corynebacterium glutamicum 
and OpuA from B. subtilis and Lactobacillus lactis. As the name suggests, ProP is involved 
in proline transport, though it has an equal affinity for glycine betaine. BetP and OpuA, 
on the other hand, transport glycine betaine exclusively. Despite being the best studied 
systems, both in vivo and in vitro, the exact mechanisms through which they are 
activated have not been elucidated. It is known that the C-terminal domain of all three 
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of these proteins, whilst not conserved, is a sensor for the direct or indirect changes as a 
result of changing osmolarities. There is a long list of potential stimuli which include the 
osmolarity gradient across the membrane, membrane thickness, bilayer curvature and 
the cytoplasmic osmolarity amongst others. Current work using proteoliposomes 
(liposomes prepared from protoplasts) suggest that the cytoplasmic osmolarity is the 
driving force in the activation of BetP and ProP (Rubenhagen et al., 2001). Unlike the 
other two model proteins, activation of OpuA is thought to be a result of changes in the 
ionic strength of the cytoplasm (Biemans-Oldehinkel et al., 2006). An alternative 
explanation for the results is that the activation of the transport functions is driven by 
the hydration of the proteins (Wood, 2011). Importantly, they do not appear to require 
the presence of additional protein; important as many proteins are inactivated by 
changes in osmolarity. As much of this work has been carried out in artificial systems it is 
probable that the regulation of the activation is far more complex. There is some 
evidence that the membrane plays an important role in the activation of these proteins, 
as the osmolarity required to activate the proteins in the proteoliposome systems varies 
depending on the quantity of anionic lipids in the liposome. In addition, both BetP and 
OpuA contain C-terminal domains that are thought to be able to interact with both the 
membrane and the rest of the protein, thereby acting as an osmoswitch. ProP on the 
other hand exhibits a preference for cardiolipin domains within the membrane; absence 
of CL causes attenuation of activation (Tsatskis et al., 2005).  
Upon activation, the proteins transport the compatible solute of choice into the cell. 
Osmotransports are unique to any one protein family, with BetP belonging to the 
betaine-carnitine-choline transporter family, ProP belonging to the major transport 
facilitator superfamily (MFS) and OpuA being an ATP binding cassette (ABC) transporter.  
In the same vein, the bioenergetic mechanism by which the compatible solutes enter 
the cell is not specific either; BetP is a Na+-compatible solute symporter; ProP is an H+-
compatible solute symporter; OpuA is an ABC transporter. Overall, the transporters are 
believed to adhere to the alternate access mechanism of transport. In this mechanism 
the compatible solutes binds to a cleft in an outward facing domain of the protein. 
Solute binding triggers a conformational change in which the protein will adopt an 
intermediate structure occluding the solute within the protein. The protein then 
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undergoes a second conformational change which results in the solute gaining access to 
the cell cytoplasm (Kaback et al., 2007).   
In addition to accumulating glycine betaine from the environment, the cell can make its 
own (Boch et al., 1994). Glycine betaine is synthesised from either choline or glycine 
betaine aldehyde. These precursor molecules still have to be taken up from the external 
environment, usually via the same osmotransports described earlier, and as a result of 
the same stimuli. However, expression of the genes required for the conversion of the 
precursors into glycine betaine are only mildly upregulated in response to osmotic stress 
(Boch et al., 1994). The process of conversion has been best studied in E.coli, though the 
synthetic genes have been identified in B. subtilis. The synthesis from choline consists of 
a two-step oxidation step, featuring glycine betaine aldehyde as an intermediate step. 
The first step is catalysed by GbsB, a choline dehydrogenase, whereas the second step is 
catalysed by GbsA, a glycine betaine aldehyde dehydrogenase (Boch et al., 1996). A 
similar system for the generation of proline exists in B. subtilis. In addition to directly 
taking up proline from the environment, B. subtilis can instead take up oligopeptides via 
the App and Opp oligopeptide transporters. Uptake of proline-rich oligopeptides is 
followed by degradation by the amino-peptidases PapA and PapB into the amino acid 
subunits, thereby resulting in an increase in cellular proline (Zaprasis et al., 2013). 
The bacterial response to osmotic downshocks is somewhat simpler, but less well 
understood. Upon entry into a hypotonic environment water will cross the membrane 
and cause the cell volume to increase. This increase in size is constrained by the cell wall 
which possesses some elasticity to deal with the increase in internal pressure. In E. coli it 
has been demonstrated that the cell wall is able to swell by up to 12% to accommodate 
the influx of water (Yao et al., 1999). However, to maintain the integrity of the cell 
envelope the cell must release excess solutes so as to minimise the influx of water. 
Bacteria are able to do so via mechanosensitive (MS) channels. These channels are 
ubiquitous across the prokaryotic kingdom and may be divided into two families; MscL 
and MscS. MscL proteins are highly conserved whereas the MscS proteins are far more 
varied, with the different forms only united by a conserved pore domain close to the 
C-terminus (Booth and Blount, 2012, Levina et al., 1999, Naismith and Booth, 2012). 
Often, a bacteria will only carry a single copy of MscL, but several different variants of 
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the MscS protein. These different copies are probably expressed in response to different 
stimuli (Booth and Blount, 2012). In E. coli it has been demonstrated that MscS and MscL 
are essential for survival in hypotonic conditions, whilst the MscS variants it carries 
merely affect the threshold of osmotic pressure that the cells can survive (Levina et al., 
1999, Schumann et al., 2010). The cell death that arises from cells lacking the MS 
channels is a mix of cells that undergo catastrophic lysis and some that form lesions 
from which the essential macromolecules diffuse out (Reuter et al., 2014). 
Returning back to the function of the MS channel proteins; it is thought that the MS 
channels open in response to lateral tension in the lipid bilayer that arises due to an 
increase in turgor pressure (Sukharev et al., 1999). It should be noted that exactly how 
the proteins sense the changes in membrane tension is still disputed.  Typically, the 
MscS proteins form a pore of 12-16 Å in diameter (Sukharev, 2002, Wang et al., 2008). In 
contrast, the MscL proteins form a much larger pore, some 30 Å in diameter 
(Cruickshank et al., 1997). It is thought that the MscL channel is opened as a last line of 
defence (Berrier et al., 1996), an opinion that would be supported by the huge channel 
size, which could have deleterious effects on the cell; artificially opening the channel has 
catastrophic effects for a cell (Ou et al., 1998, Maurer and Dougherty, 2001, Batiza et al., 
2002). The open channels allow for excess solutes to rapidly escape the cell by diffusion, 
thereby reducing the disruptive effects of extreme turgor pressure.  
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Figure 1.7. Cartoon depiction of the bacterial response to isotonic (A), hypertonic (B) 
and hypotonic (C) environments. Black arrows indicate the net movement of water. Red 
arrows indicate the movement of compatible solutes. CS=compatible solutes; 
PC=precursors. 
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1.4 L-form bacteria 
1.4.1 L-form biology 
It may come as some surprise that cell wall is dispensable under certain conditions. The 
bacteria that are able to grow and divide indefinitely in the absence of the cell wall are 
called ‘L-forms’ (Klieneberger, 1935), so named after the Lister Institute where they 
were originally discovered. Bacteria are able to survive without a cell wall as protoplasts, 
though they are unable to grow and divide indefinitely. The ability to grow in the L-form 
state does not appear to be limited to any one species, with many bacterial species 
displaying an ability to grow in this manner (Mercier et al., 2014, Gilpin et al., 1973, 
Williams, 1963). As L-forms lack a cell wall, they generally require high osmolarity media 
to ameliorate the effect of turgor on the cell (Onoda et al., 1987). In laboratory settings, 
L-forms can be generated via a number of different routes. Historically, the most 
common method to generate L-forms was to disrupt the cell wall synthesis with drugs 
such as the β-lactams. This method has largely fallen out of favour, with a genetic route 
the more common route for L-form development (Leaver et al., 2009). To induce an 
L-form state genetically it requires the overproduction of the cell membrane (Mercier et 
al., 2013). In B. subtilis this is achieved either through the depletion of MurE or the 
overexpression of accDA. The exact mechanism by which depletion of the PG synthesis 
protein MurE results in membrane overproduction remains unclear. The role of 
overexpression of accDA is far clearer, with the proteins directly involved in fatty acid 
synthesis (Mercier et al., 2013, Cronan and Waldrop, 2002). Alongside the primary 
mutation driving membrane overproduction a secondary mutation appears essential. In 
B. subtilis this mutation is often in the gene ispA. IspA catalyses the formation of farnesyl 
pyrophosphate in the isoprenoid synthetic pathway (Fujisaki et al., 1990). Farnesyl 
pyrophosphate is used as the substrate for synthesis of two lipid molecules: heptaprenyl 
diphosphate (HPP) and C55-PP. HPP is in turn required for the synthesis of menaquinone, 
which is involved in the electron transport chain. C55-PP is required for the synthesis of 
lipid II and WTA. It appears that the loss of ispA counteracts an increase in cellular levels 
of reactive oxygen species (ROS), which inhibit L-form growth. The requirement for the 
mutation can be bypassed by including ROS scavengers in the growth medium (Kawai et 
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al., 2015). The exact reason for an increase in ROS in L-forms is unclear, but the current 
hypothesis is that disruption of PG synthesis in L-forms results in fluxes in the TCA cycle.  
Remarkably, most if not all of the traditional cell division machinery or cytoskeleton is 
redundant in the L-form state (Leaver et al., 2009, Mercier et al., 2012). Instead of 
dividing by binary fission, L-forms reproduce through the release of irregularly sized 
progeny through membrane blebbing or tubulation. Reproduction by the generation of 
intracellular vesicles has also been reported (Briers et al., 2012). It was initially thought 
that like binary fission, a protein or proteins must be directing and coordinating the 
reproduction of L-forms. Surprisingly, this turns out not to be the case. Instead it 
appears that L-forms are able to reproduce as a function of excess membrane 
production. It has been demonstrated both in vivo and in vitro that the production of 
excess membrane results in an increase in the surface area relative to the cytoplasmic 
volume.  This imbalance results in increased tortional stress on the cell, which is resolved 
through the spontaneous release of membrane. Some of the released membrane will 
trap sufficient quantity of the cellular material to grow and reproduce itself (Mercier et 
al., 2014, Hanczyc et al., 2003). This agrees with bottom-up approaches in which similar 
reproductive events are observed when the additional fatty acids are added to simple 
vesicles (Zhu and Szostak, 2009) or when the internal volume is reduced by evaporation 
(Budin et al., 2012). This is perhaps not the case for the reproduction via vesicle 
formation mentioned previously, though it is likely some form of membrane dynamics is 
involved. As a result of such a simplistic mechanism of division, relying on the 
biophysical properties of the membrane, it has been suggested that L-forms could 
represent a form of division that existed prior to the evolution of the peptidoglycan cell 
wall (Svetina, 2009, Errington, 2013).  
It has been demonstrated in both the recent genetic studies as well as in the historical 
research that L-forms are able to revert back to the walled state when the ability to 
produce PG is restored (Onoda et al., 1987, Leaver et al., 2009), though the frequency of 
L-forms reverting back to the walled state is low (Dominguez-Cuevas et al., 2012). It had 
been thought that morphogenesis in bacteria required a pre-existing peptidoglycan 
template (Holtje, 1998). Use of the L-form system has demonstrated that L-forms are 
able to recover their cell shape when peptidoglycan synthesis is allowed to recommence 
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(Dominguez-Cuevas et al., 2012). It has also been shown that upon transition into the 
walled state reacquisition of the cell shape is rapid, indicating that the cell shape is 
programmed into the peptidoglycan synthesis machinery. In the same work it was 
demonstrated that the cytoskeletal protein is essential for restoring the rod shape in 
E. coli (Billings et al., 2014).  
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Figure 1.8. (A) Cartoon depicting the difference between bacterial growth as rods, 
protoplasts and L-forms. Purple arrows indicate the factors that permit the growth in 
each form. (B) Mechanism of L-form division as suggested by (Mercier et al., 2013). 
1). L-form produces excess membrane leading to an imbalance in the surface area to 
membrane ratio. 2).The resulting torsional stress causes spontaneous shape 
deformations. 3). Deformities are resolved spontaneously by the release of excess 
membrane, resulting in the creation of daughter cells.   
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1.4.2 L-forms in disease 
Despite the apparent fragility of L-form bacteria, they have been implicated in a host of 
various diseases. That L-forms could represent an infectious agent should not be that 
surprising. The cell envelope and in particular the cell wall represent the bulk of the 
pathogen-associated molecular patterns (PAMPs) recognised by the Toll-like receptors 
of the innate immune system (Murphy et al., 2008). Further, the peptidoglycan is the 
target for many of the most commonly used antibiotics and is a target for components 
of the host defences such as lysozyme. It can therefore be imagined that the L-form 
state represents a stress response to the adverse conditions encountered during 
infection. This is supported by the fact that L-form division is driven by the biophysical 
properties of the membrane as opposed to the division and cytoskeletal proteins that 
are apparently dispensable in this growth state. This renders the form of L-form division 
a highly redundant process.  
Since their discovery in the 1930s, L-forms have been suspected in causing persistent 
bacterial infections and also as the aetiological agent in a number of chronic 
inflammatory diseases.  However, the role of L-forms in disease is highly controversial. 
Much of the work is inconclusive at best, and highly dubious at worst. Much of the body 
of literature regarding L-form infections largely consists of case reports in which non-
culturable, filterable bodies, presumed to be L-forms, were observed in various tissue 
biopsies or samples. These bodies are reported from a variety of body sites and a 
number of different diseases. These diseases range from common bacterial infections, 
through to multifactorial diseases such as multiple sclerosis and cancer (Domingue and 
Woody, 1997, Domingue, 2010). As stated previously, the work into L-form involvement 
in disease is generally circumstantial. It’s debatable whether the bodies observed truly 
represent L-forms, and if they do, an actual involvement in the disease state is yet to be 
proven (Lantos et al., 2014).  
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1.4.3 L-form infection of plants 
In addition to the speculation regarding L-forms with disease, L-forms have been found 
in association with plants. Unlike their relationship with mammals, it appears that the 
relationship between L-forms and plants is symbiotic in nature. B. subtilis has long been 
known to have a growth promoting effect on plants, with the inclusion of various strains 
in different commercially available biocontrol formulations (Nagorska et al., 2007, Lahlali 
et al., 2013). The primary appearance of B. subtilis in its relationship with plants is the 
formation of biofilms on the root system. It has been demonstrated that B. subtilis can 
be induced to grow in a biofilm by the release of L-malic acid and other exudates by 
plants (Chen et al., 2012). These biofilms are thought to be the main way B. subtilis is 
able to protect plants from pathogens (Morikawa, 2006), though the exact mechanism 
of protection is not known. The most likely explanation for protection is either by 
blocking the colonisation of the plant by the pathogen or by the release of antimicrobial 
compounds.  
In addition to the formation of biofilms, B. subtilis as well as other species such as the 
plant pathogen Pseudomonas syringae have been shown to infect plants as L-forms. 
Such infection have been reported in strawberry plants (Ferguson et al., 2000), Chinese 
cabbage (Walker et al., 2002), radishes, soybeans (Aloysius and Paton, 1984) and French 
dwarf beans (Paton and Innes, 1991). The level of infection appears to remain minimal, 
with the growth of the plant remaining unaffected. L-form distribution throughout the 
plant is apparently not uniform, with the L-forms favouring cells that have few 
chloroplasts present. Within the plants, L-forms apparently remain biologically active, 
with bacterial products able to be detected in the plant (Ferguson et al., 2000, Aloysius 
and Paton, 1984). When treated with non-pathogenic bacteria such as B. subtilis, only 
the cells in the L-form state are able to successfully infect the plant. Treatment of the 
plants with either L-forms derived from plant pathogens or non-pathogenic organisms 
fail to elicit a hypersensitive reaction in the host plant. L-form infection appears to 
protect the plant from infection from both the walled version of the bacteria, but also 
from infection by other pathogens such as the fungal cause of grey mould; Botrysis 
cinera (Walker et al., 2002, Waterhouse et al., 1996). This phenomena remains 
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unexplained, with no clear mechanism through which the L-forms would be able to 
protect the plant.  
How L-forms are able to penetrate the outer leaflet of plant cells remains entirely 
unknown. In addition, how L-forms arise in these plants naturally is unknown – what 
environmental triggers exist to stimulate L-form generation and how these L-forms 
survive long enough in the soil to be taken up by the plants. Interestingly, it has been 
reported previously in E. coli that many of the genes expressed in unstable L-forms are 
typical of genes expressed when grown as part of a biofilm (Glover et al., 2009). This 
perhaps indicates that L-forms could develop spontaneously as a function of the biofilm 
lifestyle, though this is mere speculation.  
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1.4.4 L-forms and osmolarity 
Taken together, it suggests that L-forms may be more robust than what would be 
expected from the laboratory observations. The appearance of L-forms in a variety of 
natural conditions indicates that the L-forms are more tolerant to low osmolarities than 
one would expect. This is because the high levels of osmoprotectant used in the 
laboratory to maintain L-forms are generally unachievable in the environment. It would 
be expected in these conditions that the influx of water into the L-form cells would 
result in uncontrolled swelling and lysis as the L-form cell is unable to withstand turgor. 
Therefore, it can be assumed that L-forms will never be in ‘hypotonic’ or ‘hypertonic’ 
conditions, but will always be isotonic conditions due to this inability to withstand 
turgor. This raises issues regarding the regulation of the internal contents of the L-form 
cell, as discussed earlier all cells maintain a pool of K+. The K+ ions are involved in cellular 
processes, but also contribute to the cell turgor. When walled cells encounter hypotonic 
conditions they must release some of the internal osmolytes to withstand the effects of 
the water entering the cell. However, the cells must retain some of their osmolytes, K+ 
included, for cellular functions to continue. The presence of the peptidoglycan helps the 
cells to maintain a degree of turgor under these conditions. 
L-forms do not have this luxury, instead to survive in such conditions, presumably cells 
must either reduce their internal osmotic pressure, or the membrane integrity must be 
maintained, preventing the expected lysis.  Remarkably, a number of papers have 
suggested that L-forms derived from a range of species can be adapted to grow in low 
osmolarities. It should be noted that the ability to survive and grow varied depending on 
the species and the osmoprotectant used. The definition of hypotonicity varied in the 
different reports as well (Dienes and Sharp, 1956). In the adapted L-forms changes in the 
ratio of saturated to unsaturated fatty acids in the membrane was observed, as was 
changes in the cytoplasmic ion content and the protein profiles of the strains (Leon and 
Panos, 1976, Montgomerie et al., 1972, Montgomerie et al., 1973).   
Unfortunately, the work into the ability of L-forms to survive in low osmolarities were 
performed at a time where the suite of genetic tools we now enjoy were unavailable. In 
addition, the L-forms utilised in the work were not characterised to the same level as 
today; it is unclear whether the L-forms were ‘true’ L-forms or whether some residual 
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PG was present in the cells (Gilpin and Patterson, 1976). Regardless of these limitations, 
they demonstrate several interesting mechanisms through which L-forms of various 
species could adapt to survive and propagate in hypotonic conditions. It should be noted 
however that the changes reported in the L-forms could be either a cause or an effect of 
their growth in a medium with lower osmolarity. A role for the fluidity of the membrane 
is probably more as the cause of survival due to the observation that addition of the 
polyamine spermine enables protoplasts to withstand turgor (Harold, 1964, Mager, 
1959). The authors assert this is a result of spermine binding to the lipid head groups of 
the cell membrane, as the spermine could be displaced, and osmotic fragility restored by 
addition of salts and cations. However, spermine possesses a number of alternative 
roles, including in transcription and stress responses (Yoshida et al., 2004, Rhee et al., 
2007). It is possible that the changes in the cytoplasmic ion content (along with the 
protein profile) could represent the modulation of the levels of compatible solutes, 
though again this remains a speculation.  
  
68 
 
1.5 Exploitation of Actinobacteria for antibiotic discovery 
1.5.1 Actinobacteria diversity 
Actinobacteria are some of the most diverse and complex bacteria on the planet. They 
are Gram positive microorganisms that can be found in almost all marine and terrestrial 
environments, including from those that are uniquely hostile to life, such as the Atacama 
Desert in Chile (Okoro et al., 2009). As a result of habitation in these niches, the 
Actinobacteria encounter ever changing environments and nutrient scarcity. The first 
examples of Actinobacteria had a fungus-like growth, with branching filaments. It is to 
this morphology the genus owes its name. Despite this, the Actinobacteria are now 
known to encompass a broad range of different morphologies. At the simplest the 
phylum contains genera such as the Corynebacterium which exist as unicellular rods. 
Other genera like the Mycobacterium have greater complexity; growing as filamentous 
cells. Generally, the most complex of the Actinobacteria are the Streptomyces. These 
form mycelium composed of extensively branching, filamentous hyphae that reproduce 
through the production of aerial branches that develop into spores. Many of the species 
in the phylum are pathogenic, though for the majority of the members this is not the 
case; the Streptomyces are largely non-pathogenic, existing as decomposers in the soil 
or the water where they contribute to the ‘earthy’ smell of soil due to the production of 
metabolites called geosmins. The geosmins are one example of the complex secondary 
metabolism present in the Actinobacteria that results in a vast wealth of natural 
products (Madigan et al., 2009).  
1.5.2 Secondary metabolism in Actinobacteria 
One of the reasons that Streptomyces as well as other Actinobacteria are so widespread 
is as a result of their complex secondary metabolism. The exact role of many of the 
secondary metabolites is unclear. The function of some of the metabolites such as the 
pigments and geosmins remain a complete mystery (Davis and Chater, 1990, Gust et al., 
2003), though an actual function is almost certain. Other metabolites are far clearer in 
their function. For example, siderophores are produced by many Streptomyces strains as 
a means to scavenge iron from their environment (Challis and Ravel, 2000, Neilands, 
1995). In addition to these secondary metabolites Actinobacteria are a major source of 
naturally derived medicines, including antibiotics, antifungals, antiparasitics and 
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antineoplastic drugs. It is presumed that the production of these compounds enables 
the bacteria to outcompete its neighbours in the environmental niches they occupy 
(Laskaris et al., 2010). This is supported by the observation that expression of the gene 
involved in synthesis of these compounds is frequently linked to phosphate or glucose 
exhaustion. However, it has been argued that the natural compounds could have an 
alternative function such as a signalling molecule (Kitani et al., 2011).  
The genes responsible for secondary metabolism are grouped in the genome into 
individual biosynthetic clusters. These clusters can be thought of as modular assemblies, 
with a simple building block type of relationship between the genes and the chemical 
structure of the secondary metabolite. The biosynthetic clusters can be split into three 
types of modules; those containing polyketide synthases (PKS); those containing non-
ribosomal peptide synthases (NRPS); or those containing both PKS and NRPS (Cane et al., 
1998). These modules are in turn split into domains based on activities. For instance, all 
PKS modules will include a keto synthase, an acyl-transferase and an acyl carrier protein, 
but can include a ketoreductase, a dehydratase and so on. The differences in the 
number of modules as well as their specificities enables the Streptomyces to produce a 
huge range of secondary metabolites (Diminic et al., 2014). There are currently two 
models for how the complexity of the PKS modules evolved (NRPS diversity has been 
less studied and therefore less well understood). The first proposed model is the 
amplification model, in which a module become amplified over time, with 
recombination events and random mutations leading to development of diversity 
(Jenke-Kodama et al., 2006). The other model is that diversity arises due to single 
crossover recombination events that results in the exchange of domains (Zucko et al., 
2012). The ability to recombine between different modules and different biosynthetic 
clusters has facilitated the horizontal gene transfer of the most advantageous secondary 
metabolites. Hence why the same classes of antibiotics reappear again and again in 
different species of Streptomyces.    
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1.5.3 Antibiotic discovery 
As touched upon, the secondary metabolism of Actinobacteria and in particular 
Streptomyces has proved to be an incredibly bountiful source for the discovery of a 
number of antibiotics. The history of antibiotic discovery from Actinobacteria began in 
1943 with the isolation of Streptomycin from Streptomyces griseus by Waksman and 
Schatz (Waksman and Schatz, 1943). Following this landmark work, many of the most 
familiar antibiotics in the therapeutic arsenal were isolated from the Actinobacteria. This 
list of antibiotics includes but is not limited to vancomycin, tetracycline, chloramphenicol 
and daptomycin. The discovery of these important antibiotics occurred between the 
1950s and the 1980s. During the 1990s the search for natural products dried up. The 
decline in research occurred for a number of reasons. Firstly, there was a problem with 
rediscovery of already known compounds; those antibiotics that were readily discovered 
in the past now proved to be hindrances, acting now as background noise. Secondly, 
discovery of new antibiotics became less and less lucrative; natural product screening is 
very costly as thousands of strains need to be grown and screened to elicit a single novel 
compound (Baltz, 2008). In addition, bacterial infections became a disease of the 
developing world, resulting in a minimal return on the money invested in research and 
development. Finally, there was a shift in focus towards more modern drug discovery 
methods such as in silico screening and the use of combinatorial chemistry. 
Unfortunately, these modern techniques have largely failed to generate new antibiotics. 
One of the best described abortive efforts to use the combinatorial chemistry approach 
was that carried out by GlaxoSmithKline (Payne et al., 2007). There are several reasons 
for the failure; the chemical libraries lack the complexity seen from natural products; 
most of the targets that are essential for bacterial survival are not easily druggable; the 
best antibiotic targets such as the growing peptidoglycan or the ribosomes are difficult 
to screen against in vitro.  
The lack of new antibiotics has been coupled with an explosion in the cases of antibiotic 
resistance. We now face growing resistance from both Gram positive and Gram negative 
pathogens in both community and hospital based infections. Of particular concern are 
the ‘ESKAPE’ pathogens: Enterococcus faecium, Staphylococcus aureus, Klebsiella 
pneumoniae, Acinetobacter baumanii and Pseudomonas aeruginosa. These species 
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cause the bulk of infections in the USA, but frequently possess resistance to the frontline 
drugs, and are thus able to ‘escape’ the effect of the antibiotics. Many of these species 
are becoming pan-resistant either through the adoption of multiple drug resistant 
cassettes (as is the case with MRSA) or through intrinsic resistance resulting from the 
modulation of the envelope permeability (as is the case with Acinetobacter baumanii) 
(Boucher et al., 2009). Increasing levels of resistance result in therapeutic failures, with 
rises in mortality and morbidity. To tackle this issue we urgently require new antibiotic 
therapies against these microorganisms. 
 However, several advances have started somewhat of a gold rush for natural product 
discovery. The greatest impact has been in the spread of high-throughput sequencing. 
This sequencing was originally used to screen pathogens for potential drug targets; 
sequencing can instead be used to discover novel biosynthetic clusters in Actinobacteria. 
Streptomyces coelicolor was the first antibiotic-producing actinomycetes species 
sequenced (Saitou and Nei, 1987). Within the genome of S. coelicolor a significant 
number of biosynthetic clusters identified. Similarly, sequencing of Steptomyces 
avermitilis revealed the presence of 25 putative biosynthetic clusters composed of over 
300 genes. In total, it appeared 6.6% of the genome of S. avermitilis was involved in the 
synthesis of secondary metabolites (Ikeda et al., 2003). The number of biosynthetic 
clusters in these two species is not unique, with many Streptomyces species carrying 
multiple clusters (Gomez-Escribano et al., 2015, Iftime et al., 2015, Komaki et al., 2015). 
The problem is that very few of the predicted secondary metabolites are observed when 
the strains are grown in the standard media. It is therefore of great interest to be able to 
identify and characterise the unknown compounds. There are three main routes by 
which novel compounds may be investigated. The first approach is the simplest – 
growing the strains on alternative media as a means to express the secondary 
metabolites in the original species. The second approach is to clone the biosynthetic 
gene clusters into cosmid or bacterial artificial chromosome vectors before 
transformation into alternative host strains. These strains are typically those that are 
well characterised, are fast growing, genetically tractable or are able to produce a 
particular class of secondary metabolite readily. An additional benefit of this route is 
that the compound of interest can be more readily identified when it is being produced 
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against a background of known compounds (Penn et al., 2006). An example of this 
method is the cloning of a 53kb biosynthetic cluster from a marine Micromonospora 
strain into Streptomyces albus and Streptomyces lividans. Expression of the cluster in 
these hosts resulted in the production of a compound with anti-tumour properties 
(Lombo et al., 2006). Thirdly, identification of the biosynthetic clusters enables the 
ability to make structural predictions of the secondary metabolite. Such a method 
accelerates chemical dereplication and improves the identification of the compound in 
the milieu of secondary metabolites. This approach was validated in 2000, when the 
structure of the siderophore coelichelin was predicted in the S. coelicolor genome and 
subsequently identified in vitro (Challis and Ravel, 2000).   
In addition to using novel techniques to search known strains for new antibiotics, it is 
possible to search for new strains of actinobacteria. The pharmaceutical industry has 
screened soil samples for 50 years, but this represents only a small fraction of the 
diversity of the actinobacteria. Ongoing work is exploring the levels of actinobacteria 
diversity around the globe; from regions as high as the Tibetan plateau to as deep as the 
Mariana trench (Zhang et al., 2010, Pathom-Aree et al., 2006). Exploration of novel 
environments such as the marine sediments has already paid off; the antibiotic 
abyssomicin was isolated from a novel species of Verrucosispora that originated from 
the Sea of Japan (Bister et al., 2004). 
1.5.4 Lipoteichoic acid synthase as an antibiotic target 
With ever increasing levels of resistance there is a pressing need for new antibiotics with 
activities against novel targets. Most of the pre-existing antibiotic targets concern 
aspects of the peptidoglycan cell wall. This is largely because the cell wall fulfils all the 
criteria that make an optimal antibiotic target (Projan and Shlaes, 2004). Firstly, under 
most conditions the cell wall is essential for the growth and survival of the bacterial cell. 
In addition, this essentiality means that many of synthetic enzymes required for 
synthesis are conserved across the prokaryotic kingdom, resulting in broad spectrum 
activity to antibiotics. Secondly, the cell wall is unique to bacteria – homologues are not 
present in humans. This reduces the level of toxicity and side effects of the antibiotics. 
Finally, the cell wall is easily accessible, lying on the exterior of the cell. This contrasts 
with alternative antibiotic targets such as transcription and translation lie within the cell. 
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Cells can alter the envelope permeability, or increase expression of exporters, resulting 
in non-specific resistance to some of these compounds.  
Lipoteichoic synthase fulfils many, though not all of the criteria listed. As discussed 
earlier, LTA is essential for the growth of many important Gram positive pathogens, 
including S. aureus. However, it is not present in Gram negative organisms and is non-
essential in other Gram positive species. In species or conditions where LTA is 
dispensable, antibiotics targeting the synthesis may be useful anti-virulence agents 
(Weidenmaier et al., 2004, Collins et al., 2002). Further, disruption of LTA and the 
related WTA has been demonstrated to affect the efficacy of other antibiotics, probably 
through the change in the electrochemistry of the cell envelope. Similarly, disruption of 
WTA in MRSA has been shown to sensitise the bacteria to β-lactams (Farha et al., 2013). 
The resistance in MRSA is conferred by acquisition of a gene coding for a resistant copy 
of the PG transpeptidase PBP2A. The function of this protein depends on the numerous 
factors including WTA. It is thought that loss of WTA disrupts the cooperative effects of 
the numerous factors, which include additional PBPs (Sewell and Brown, 2014). Taken 
together; a compound targeting LtaS may also be useful in a combination treatment 
with conventional antibiotics in treating many Gram positive infections. Whilst not 
present in all bacteria, LTA is unique to bacteria. This addresses the problem of potential 
antibiotic toxicity in the eukaryotic hosts.  
In regards to the final criteria – the target accessibility – the LTA is positioned in the cell 
envelope, tethered to the lipid head groups of the cell membrane. Importantly, the 
synthase is embedded within the membrane, with an extracellular catalytic group. This 
renders the catalytic group highly accessible to any potential compounds.  
Despite the potential for antibiotic development, the majority of discovered compounds 
that act against teichoic acid synthesis target components of the WTA pathway 
(Swoboda et al., 2009, Lee et al., 2010, Hancock et al., 1976, Farha et al., 2014). Only a 
single compound, a small molecule called 1771, is believed to possess an inhibitory 
effect against LtaS in S. aureus. No spontaneous mutations were identified in the work 
and were therefore unable to definitively confirm a mechanism of action. However, 
production of LTA was reduced in a heterologous expression system when treated with 
the compound (Richter et al., 2013).  
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Aims 
Previous work has demonstrated that L-forms are able to persist and grow in conditions 
that would be expected to be lethal for the cells (Domingue and Woody, 1997, Amijee et 
al., 1992, Gilpin and Patterson, 1976). The principal aims for this part of the project are 
two-fold. First, to develop a reproducible method for the adaptation of L-forms to low 
osmolarities. Second, to identify and characterise any mutations that enable L-forms to 
survive in these challenging situations. This work hopes to address some fundamental 
questions regarding the molecular biology of L-forms, as well as the maintenance and 
regulation of the cell membrane and cytoplasm. It is hoped that this work will inform our 
understanding of osmotic regulation and support the development of models to explore 
the role of L-forms in the natural environment.  
The second part of this work will utilise a novel screening method (Errington J, 2009) to 
identify inhibitors of the attractive antibiotic target, LtaS, from a unique collection of 
actinomycetes. The primary aim of this project is to identify and characterise a potential 
inhibitor using the screening method and to demonstrate its effect on LtaS in B. subtilis 
and S. aureus. 
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2. Materials and methods 
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2.1 Solutions and media 
Tables of solutions and media are given in appendices 1 and 2. 
2.2 Strains and plasmids 
Strains and plasmids used in this work are given in tables 2.1 and 2.2 respectively. 
Table 2.1. 
Name Genotype Source 
Bacillus subtilis 
168CA trpC2 (Kunst et al., 1997) 
Marburg 
NCIB 3610 
 Laboratory strain 
JB57 trpC2 ltaS::spc (Schirner et al., 2009) into 
168CA 
JB24 trpC2 yfnI::cat (Schirner et al., 2009) into 
168CA 
JB25 trpC2 yqgS::spc (Schirner et al., 2009) into 
168CA 
JB26 trpC2 yvgJ::erm (Schirner et al., 2009) into 
168CA 
JB84 trpC2 mbl::cat (Schirner et al., 2009) 
LR2 ispA* ΩspoVD::cat Pxyl-murE (Leaver et al., 2009) 
LR2-M Tn ispA Pspac-hepT ΩspoVD::cat Pxyl-murE (Leaver et al., 2009) into 
Marburg background 
YK1694 ispA*  amyE::Pxyl-accDA (Mercier et al., 2013) 
JB104 ispA* ΩspoVD::cat Pxyl-murE amyE::PrpsD-
gfp spc 
(Syvertsson, unpublished) 
into LR2 
JB105 ispA* ΩspoVD::cat Pxyl-murE amyE::PrpsD-
mCherry spc 
(Syvertsson, unpublished) 
into LR2 
M1 ispA* ΩspoVD::cat Pxyl-murE amyE::PrpsD-
mCherry spc 
yhaG- yhaH- scoC- yhaI- yhaJ- 
This work 
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JB112 ispA* ΩspoVD::cat Pxyl-murE yhaG::erm NBRP (NIG,Japan): 
B. subtilis into LR2 
JB113 ispA* ΩspoVD::cat Pxyl-murE yhaI::erm NBRP (NIG,Japan): 
B. subtilis into LR2 
JB132 ispA* ΩspoVD::cat Pxyl-murE scoC::zeo This work 
JB155 ispA* ΩspoVD::cat Pxyl-murE aprE::scoC spc This work 
JB156 ispA* ΩspoVD::cat Pxyl-murE 
amyE::PrpsD-mCherry spc  
yhaG- yhaH- scoC- yhaI- yhaJ-aprE::scoC spc 
This work 
JB114 ispA* ΩspoVD::cat Pxyl-murE mreB-pit-ftsE- This work 
JB115 ispA* ΩspoVD::cat Pxyl-murE mreB-rpoB - This work 
JB116 ispA* ΩspoVD::cat Pxyl-murE ydbL- This work 
JB117 ispA* ΩspoVD::cat Pxyl-murE hom-SPβ- This work 
JB118 ispA* ΩspoVD::cat Pxyl-murE This work 
JB119 ispA* ΩspoVD::cat Pxyl-murE gbsB- This work 
JB120 ispA* ΩspoVD::cat Pxyl-murE This work 
JB121 ispA* ΩspoVD::cat Pxyl-murE nusG-ppsB- This work 
JB122 ispA* ΩspoVD::cat Pxyl-murE ypzK- This work 
JB125 ispA* ΩspoVD::cat Pxyl-murE This work 
JB126 ispA* ΩspoVD::cat Pxyl-murE This work 
3725 Ωneo3427 ΔmreB (Formstone and Errington, 
2005) 
JB133 ispA* ΩspoVD::cat Pxyl-murE Ωneo3427 
ΔmreB 
3725 into LR2 
JB134 JB114 ispA* ΩspoVD::cat Pxyl-murE 
Ωneo3427 ΔmreB 
3725 into JB114 
JB135 JB115 ispA* ΩspoVD::cat Pxyl-murE 
Ωneo3427 ΔmreB 
3725 into JB115 
JB139 168CA gbsB::erm This work 
JB140 LR2 gbsB::erm This work 
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JB155 ispA* ΩspoVD::cat Pxyl-murE aprE::scoC spc This work, pJB2 
transformed into LR2 
JB156 M1 aprE::scoC spc This work, pJB2 
transformed into M1 
JB158 ispA* ΩspoVD::cat Pxyl-murE Ωneo3427 
mreBΔ20 
This work 
PG67 aprE::Pspac-yfp-zapA-spc (Richter et al., 2013) 
JB162 ispA* ΩspoVD::cat Pxyl-murE aprE::Pspac-yfp-
zapA-spc 
PG67 into LR2 
JB163 JB114 aprE::pspac-yfp-zapA-spc PG67 into JB114 
JB164 JB115 aprE::pspac-yfp-zapA-spc PG67 into JB115 
JB175 ispA* pxyl-murE-spc Ωneo3427 ΔmreB  
aprE::pspac-gfp-mreB-cat 
(Weigel et al., 2003); 
pAPMreB1 into LR2 
JB176 ispA* pxyl-murE-spc Ωneo3427 ΔmreB 
aprE::pspac-gfp-mreBΔ20-cat 
This work 
RM119 168CA ΔmurC::spc pLOSS-Pspac-murC erm (Mercier et al., 2013) 
JB180 ispA* ΩspoVD::cat Pxyl-murE murC::spc 
pLOSS murC-erm 
RM119 into LR2 
JB181 ispA* ΩspoVD::cat Pxyl-murE murC::spc 
pLOSS murC-erm Ωneo3427 ΔmreB 
RM119 into JB133 
JB182 JB115 ispA* ΩspoVD::cat Pxyl-murE 
murC::spc pLOSS murC-erm 
RM119 into JB115 
JB189 JB114 ispA* ΩspoVD::cat Pxyl-murE 
murC::spc pLOSS murC-erm 
RM119 into JB114 
PDC594 168CA ftsE::neo (Dominguez-Cuevas et al., 
2013) 
JB-PDC594 168CA ftsE::(neo::spc) PDC594 transformed with 
pKV71 
JB183 ispA* ΩspoVD::cat Pxyl-murE ftsE::(neo::spc) LR2 transformed with JB-
PDC594 
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JB184 ispA* ΩspoVD::cat Pxyl-murE Ωneo3427 
ΔmreB ftsE::(neo::spc) 
JB133 transformed with 
JB-PDC594 
2566 168ED amyE::Pxyl-gfp-mreB-spc (Challis, 2014) 
 JB185 trpC2 amyE::Pxyl-gfp-mreB-spc 2566 into 168CA 
JB186 trpC2 amyE::Pxyl-gfp-mreBΔ20-spc This work 
JB187 trpC2 Ωneo3427 ΔmreB amyE::Pxyl-gfp-
mreB-spc 
2566 into 3725 
JB188 trpC2 Ωneo3427 ΔmreB amyE::Pxyl-gfp-
mreBΔ20-spc 
JB186 into 3725 
 
Escherichia coli 
DH5α F-ψ80lacZΔM15 Δ(lacZYA-argF) U169 recA1 
endA1 hsdR17 (rk-,mk+) gal- phoA supE44 λ- 
thi-1 gyrA96 relA1 
Invitrogen 
Staphylococcus aureus 
RN4220 ΔrbsU ΔtcaR Δφ11 Δφ12 Δφ13 r-m- (de Azavedo et al., 1985) 
Actinomycetes spp. 
DEM30616  This work 
DEM30345  This work 
DEM20435  This work 
DEM30618  This work 
DEM20657  This work 
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Table 2.2 
Name Genotype Construction Reference 
pAPMreB1 Pspac-mgfp-mreB cat 
bla 
 (Jahn et al., 2015) 
pAPNC213 spc bla  (Morimoto et al., 
2002) 
pBEST501 bla neo  (Itaya et al., 1989) 
pHM457 bla cat zeo  (Lautru et al., 
2005) 
pJB1 scoC::zeo (oJB33/oJB34) and 
(oJB35/oJB36) ligated into 
pHM457 
This work 
pJB2 aprE::scoC spc (oJB77/oJB78) ligated into 
pAPNC213 
This work 
pJB3 aprE::pspac-gfp-mreBΔ20 
cat 
(oJB84/oJB85) 
amplification of pAPMreB1 
This work 
pJB4 Pxyl-gfp-mreBΔ20 bla 
spc 
(oJB84/oJB85) 
amplification of pSG1729 
This work 
pMUTIN4 erm  (Vagner et al., 
1998) 
pSG5451 Pxyl-gfp-mreB bla spc  (Formstone and 
Errington, 2005) 
pVK71 neo::spc replacement  (Arbeit et al., 
2004) 
2.3 Oligonucleotides 
The oligonucleotides used in this work are given in appendix 3. 
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2.4 Media supplements 
The media supplements and their respective concentrations are given in table 2.3 
Antibiotics Stock solution Final concentration  
Ampicillin   50 mg/ml 100 μg/ml 
Chloramphenicol 10 mg/ml 5 μg/ml 
Erythromycin 20 mg/ml 0.5 μg/ml 
Kanamycin 25 mg/ml 2 μg/ml 
Phleomycin   2 mg/ml 1 μg/ml 
Spectinomycin 100 mg/ml 50 μg/ml 
Tetracycline 
Zeomycin 
10 mg/ml 
100 mg/ml 
10 μg/ml 
10 μg/ml 
Inducers    
IPTG   1 M up to 3 mM 
Xylose   25% up to 0.1% 
 
2.5 Experimental methods 
2.5.1 DNA methods 
2.5.1.1 Oligonucleotides 
Oligonucleotides were purchased from Eurogentec. Aliquots were stored at -20°C at a 
concentration of 10 μM. 
2.5.1.2 Polymerase chain reaction (PCR) 
PCR reactions were carried out according to the manufacturers’ recommendations.  
GoTaq polymerase (Promega) was used to confirm insertions or deletions. Q5 (NEB) 
polymerase was used for creating genetic constructs.  
2.5.1.3 Purification of PCR products 
PCR products were purified using QIAquick PCR purification kit (Qiagen) according to the 
manufacturer’s recommendations 
2.5.1.4 Purification of plasmids 
Plasmids were purified using QIA miniprep kit (Qiagen) according to the manufacturer’s 
recommendation. 
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2.5.1.5 Agarose gel electrophoresis of DNA fragments 
Agarose gel electrophoresis of DNA fragments was performed on 0.8-1.2% agarose gels 
containing 0.1 mg/ml ethidium bromide in 1x TAE buffer. Prior to loading samples were 
mixed with loading dye. The voltage used for electrophoresis was 90-120 V. Bands were 
visualised using a G-box transilluminator (Syngene) with built in camera. 
2.5.1.6 Restriction endonuclease digests 
Digests were carried out following the manufacturers’ recommendations. Digests were 
carried out for 1-3 hrs in the appropriate buffer and temperature. The restriction 
enzymes were removed using a QIAquick PCR purification kit (Qiagen). 
2.5.1.7 Ligation of DNA fragments 
Ligation of DNA fragments was catalysed by T4 ligase (Roche) in the supplied buffer. The 
reaction volume was typically 10-20 μl and was incubated for 1-2 hr at room 
temperature. 
2.5.1.8 In-Fusion cloning 
Construction of some plasmids was facilitated by In-Fusion cloning. DNA fragments were 
fused using In-Fusion HD cloning kit (Clontech), according to the manufacturer’s 
recommendations. 
2.5.1.9 DNA sequencing 
PCR products or plasmids were sent to the sequencing service of Dundee University for 
sequencing.  
2.5.1.10 Full genome sequencing 
Bacterial genomes for full genome sequencing were sent to GATC Biotech ltd or given to 
the Wipat research group for sequencing on their MiSeq platform. 
2.5.1.11 Analysis of full genome sequencing 
Genome sequencing data was analysed using the commercial software CLC genomics 
workbench (Qiagen). The sequence data was imported and mapped to the appropriate 
reference genome.  
83 
 
2.5.2 Protein methods 
2.5.2.1 Preparation of protein samples 
Cultures were grown in 5 ml PAB or LB media. Protein overexpression was induced using 
1 mM IPTG or 0.5% xylose where appropriate. Cells were grown to an OD600=0.6 at 37°C 
before harvesting by centrifugation. Cells were resuspended in 200 μl 50 mM Tris HCl 
pH 7.3 containing protease inhibitor (Roche). The samples were either held on ice and 
the cells broken by sonication (30 seconds, amplitude 40) or lysed using 10 μl 10 mg/ml 
lysozyme and 5 μl DNase. The soluble fraction was separated from the insoluble fraction 
by centrifugation at 13,000 rpm for 15 minutes.  
2.5.2.2 SDS-polyacrylamide gel electrophoresis 
 Samples were prepared by mixing with NuPAGE LDS sample buffer (Invitrogen) and 
NuPAGE reducing agent (Invitrogen). Samples were heated at 85°C for 10 minutes then 
loaded on Novex midi gels 4-12% Bis-Tris (Invitrogen). The electrophoresis was 
performed in 1x MOPS buffer (Invitrogen) at 200V. 
2.5.2.3 Coomassie Staining 
For Coomassie staining, gels were washed briefly with dH2O and then stained by the 
addition of 10 ml Coomassie stain. Gels were incubated with the stain overnight. Destain 
of the background was achieved by incubating the gel at room temperature in destain 
solution (10% methanol, 10% propan-2-ol, 10% acetic acid, 5% glycerol).  
2.5.2.4 Western Blotting 
Following electrophoresis, the gel was soaked in transfer buffer. The transfer onto 
nitrocellulose membrane (GE Healthcare) was performed using a Hoeffer Scientific semi-
dry transfer cassette according to the manufacturer’s instruction at 0.8 mA/cm2 for 1 hr. 
Following the transfer the nitrocellulose membrane was incubated with shaking in 
blocking solution (PBS + 0.1 Tween20 + 5% milk powder) overnight at room 
temperature. The next day the membrane was washed briefly in PBS + 0.1% Tween20 
(PBST) then incubated for 1 hr with shaking in blocking solution containing the primary 
antibody diluted to an appropriate concentration. After incubation the membrane was 
washed 3 times for 10 min in PBST then incubated for 1 hr in blocking solution 
containing the secondary antibody diluted to an appropriate concentration. The 
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membrane was then washed 3 times for 10 min in PBST. The ECL+ kit (GE Healthcare) 
was used, following the manufacturer’s recommendations to visualise the protein bands 
of interest. 
2.5.3 Manipulations in Escherichia coli 
2.5.3.1 Preparation of competent cells 
E.coli DH5α competent cells were prepared using the RbCl method. Here, cells were 
grown to an OD600 of 0.3-0.4 in 2TY medium, then chilled on ice for 10 minutes. After 
chilling, cells were pelleted and then resuspended in 0.3 (v/v) RF1. The mixture was 
incubated on ice for 15 minutes, then pelleted and resuspended in 0.1 (v/v) RF2. 
Aliquots of the competent cells were frozen rapidly in liquid nitrogen and stored at -80°C 
for future use. 
2.5.3.2 Transformation of competent E.coli cells 
Aliquots of competent cells were removed from -80°C and thawed on ice. After thawing, 
100 μl of competent cells were added to plasmid or ligation reaction mixture. The cells 
were incubation on ice for 30 minutes and then heat shocked at 42°C for 90 seconds 
after which the cells were returned to ice for 1 minute. 200 μl of LB medium was added, 
and the cells were incubated at 37°C for 1 hour. After incubation the cells were plated 
on agar containing the appropriate antibiotics. 
2.5.3.3 E.coli colony PCR 
To screen E.coli transformations for correct clones, colonies were picked and 
resuspended in 50 μl dH2O and incubated at 100°C for 10 minutes. After cooling to room 
temperature, 10 μl of the cell suspension was used in a standard PCR reaction employing 
the GoTaq polymerase.  
2.5.4 Bacillus subtilis methods 
2.5.4.1 Preparation of competent B. subtilis cells 
To make B. subtilis competent for transformation, a 5ml culture was grown in minimal 
media overnight. The next day 300 μl of the culture was used to inoculate 5 ml fresh 
minimal media and was incubated with shaking at 37°C for 3 hours. At this point, 5 ml 
starvation medium was added and the culture incubated for a further 2 hours at 37°C. 
400 μl of the now competent cells were used immediately for transformation. 
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2.5.4.2 Transformation of competent B. subtilis 
400 μl of competent cells were mixed with 5 μl plasmid/ligation product or 10 μl 
genomic DNA. The mixtures were incubated at 37°C for 1 hour before plating agar 
containing the appropriate antibiotics.  
2.5.4.3 Preparation of genomic DNA for transformation 
Genomic DNA for transformation was prepared as described by (Ward and Zahler, 
1973). In brief, the strain of interest was streaked onto a nutrient agar plate and grown 
at 37°C overnight. The next day, a small scoop from the plate was suspended in 4 ml PAB 
and incubated with shaking at 37°C for 4 hours. The culture was then pelleted, 
resuspended in 1 ml SSC. 10 μl lysozyme solution (10 mg/ml) was added and the solution 
incubated at 37°C for 20 minutes. 1 ml 4 M NaCl was then added and the mixture 
filtered (0.45 μm pore size).  
2.5.4.4 Preparation of genomic DNA for PCR 
To prepare genomic DNA for use in PCR, cells were grown overnight at 37°C in LB. The 
next day 2 ml of overnight culture was pelleted and resuspended in 100 μl 50 mM EDTA 
solution containing 10 μl lysozyme solution (10 mg/ml) and 5 μl RNase (10 mg/ml). The 
suspension was incubated at 37°C for 1 hour then 500μl nuclei lysis solution (Promega) 
was added and the mixture incubated for 5 minutes at 80°C. The mixture was allowed to 
cool down to room temperature, then 200 μl protein precipitation solution (Promega) 
was added and the mixture vortexed vigorously for 20 seconds. They were incubated on 
ice for 10 mins before centrifugation at 13,000 rpm for 10 mins. The resulting 
supernatant was carefully decanted into a fresh Eppendorf tube containing 600 μl 
isopropanol. The tube was gently inverted until the DNA formed a visible precipitate. 
The DNA was pelleted by centrifugation at 13,000 rpm for 10 minutes and the 
supernatant removed. The pelleted was washed with 600 μl 70% ethanol before being 
centrifuged for a further 5 mins at 13,000 rpm. The DNA was air dried, then resuspended 
in 100 μl H2O and incubated at 65°C for 15 minutes or at 4°C overnight. Typically, for PCR 
2-5 μl of template was used. 
2.5.4.5 Preparation of genomic DNA for whole genome sequencing 
To prepare DNA for whole genome sequencing, cells were grown in 10 ml PAB until 
OD600=3.0 at which point the cells were harvested and washed with 10 ml TES. The cell 
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pellet was resuspended in 0.5 ml TES before being stored overnight at -20°C. The next 
day the cells were removed from the freezer and placed at room temperature. Once 
defrosted 25 μl lysozyme (10 mg/ml) and 5 μl RNase (10 mg/ml) were added and the 
mixture at 37°C for 30 mins. At this point 50 μl pronase and 30 μl sarkosyl was added, 
with the mixture incubated for a further 30 mins at 37°C. Following this treatment 600 μl 
phenol-chloroform was added and the components mixed by shaking. The tubes were 
then centrifuged at 10,000 rpm for 10 minutes to separate the phases. The upper 
aqueous phase was aspirated off into a clean Eppendorf tube. The process of adding 
phenol-chloroform was repeating 3 times.  In the final repetition, the phenol-chloroform 
is replaced with just chloroform. After the final cleaning step 3 volumes of 100% ethanol 
was added to 1 volume of the aqueous phase and mixed by gentle inversion. The DNA 
was picked up by moving a heat-sealed sterile Pasteur pipette in a clockwise motion 
around the Eppendorf. After collection the DNA was washed by dipping the pipette into 
70% ethanol, the ethanol was evaporated off the by placing the pipette near a Bunsen 
flame. The DNA was resuspended by moving the pipette in an anticlockwise motion in 
an Eppendorf containing a volume of H2O appropriate for the quantity of DNA. The 
concentration and purity of the DNA was measured using a Nanodrop 
spectrophotometer (Thermoscientific). For whole genome sequencing 30μl of DNA and 
concentration of 200 ng/μl with for purity an OD260/280 ratio 1.8-2.0 and an OD260/230 
ratio 2.0-2.2 were required. 
2.5.4.6 Construction of deletion strains 
Genes were deleted through replacement of the gene with an antibiotic resistance 
marker. Integration of the antibiotic resistance marker was achieved either through 
transformation with a plasmid system or a ligation product. For both of these methods 
approximately 2500bp up- and downstream of the target gene was amplified using the 
appropriate primer pair. For transformations with plasmids the upstream and 
downstream regions were sequentially cloned either side of the antibiotic resistance 
cassette. Following each step the plasmid was transformed into competent E.coli DH5α. 
Transformants were selected using ampicillin. Insertion of the flanking regions was 
verified using PCR. Following plasmid construction the deletion plasmid was 
transformed into competent B. subtilis cells. Transformants were plated on the 
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appropriate antibiotic and the deletion verified by PCR. Plasmids used for deletion were 
pBEST501 (Itaya et al., 1989) and pHM457 (Murray et al., 2006). For transformations 
with ligation products, the PCR products were digested with the appropriate restriction 
endonuclease and ligated to the appropriate antibiotic resistance cassette. Competent 
B. subtilis cells were transformed with the ligation product. Transformants were selected 
using the appropriate antibiotic and the deletion verified by PCR. The antibiotic 
resistance cassettes were derived by PCR amplification from plasmids [cat from 
pAPNC213cat (Morimoto et al., 2002); erm from pMUTIN4 (Vagner et al., 1998); neo 
from pBEST501 (Itaya et al., 1989); spc from pAPNC213 (Morimoto et al., 2002)].  
2.5.4.7 Construction of mreBΔ20 
Construction of the partial 60bp deletion of mreB was based off a pre-existing ΔmreB 
strain that featured an upstream neo cassette (Challis, 2014, Webb et al., 2009, 
Formstone and Errington, 2005). Using the primers featured in this work (LENm1-m4) 
the partial deletion was amplified from JB114/115 and ligated to neo cassette digested 
from the pBEST501 plasmid. 
2.5.4.8 Construction of fusion protein GFP-MreBΔ20  
Construction of the fusion protein was based off a pre-existing plasmid carrying a 
functional gfp-mreB [pSG1729 (Strahl et al., 2014)]. The partial deletion in mreB was 
introduced using an In-Fusion cloning kit (Clontech), according to the manufacturer’s 
instructions. In brief, the plasmid was amplified using primers JB84 and JB85. The 
binding site of these oligonucleotides lay either side of the deletion region, as a result 
fusion of the PCR product resulted in the loss of the region. The fused plasmid was 
transformed into competent E.coli DH5α cells and the sequence of the plasmid 
confirmed by PCR and sequencing. Transformation of competent B. subtilis cells with the 
plasmid resulted in strain JB166, which carried gfp-mreBΔ20 under a xylose-inducible 
promoter at the aprE locus.  
2.5.4.9 Preparation of B. subtilis L-forms 
L-forms were generated via an intermediate protoplast preparation step as described in 
(Wu and Errington, 1998). Briefly, B. subtilis cells were grown in 4 ml LB at 37°C until an 
OD600 between 0.3 and 0.5 was reached. The cells were harvested by centrifugation and 
resuspended in 2 ml NB/MSM containing 2 mg/ml lysozyme. The suspension was then 
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incubated at 37°C with gentle shaking for 45 min-1 hr until >99% of cells were 
protoplasts (as estimated using light microscopy). 10 μl of the protoplast culture was 
used to inoculate 10 ml fresh MSM/NB containing 200 μg/ml PenG (Sigma). Protoplasts 
were allowed to develop as L-forms through stationary incubation at 30°C for 24-72 hrs. 
2.5.4.10 Growth of B. subtilis L-forms on solid and liquid media 
For growth in liquid media L-forms were inoculated 1/1000 into 10 ml of either MSM/NB 
or MNM/NB containing 200 μg/ml PenG (Sigma) and incubated at 30°C. For growth on 
solid media, L-forms were streaked on MSM/NA containing 200 μg/ml PenG (Sigma) and 
incubated at 30°C.   
2.5.4.11 Growth of L-forms in low osmolarities 
L-forms were prepared and then grown in 0.5 M MSM/NB or 0.5 M MNM/NB until they 
reached mid-late exponential phase (OD600=0.5-1.0). L-forms were inoculated into 10 ml 
media containing low osmoprotectant concentrations of interest in a 1/1000 dilution 
ratio. Cultures were grown for up to 30 days at 30°C with no shaking. Growth was 
primarily monitored by eye, with the OD600 measured on average every 5 days. Presence 
of L-forms was confirmed using light microscopy. Alternatively, the walled cells were 
streaked on 0.5 M MSM/NA or 0.5 M MNM/NA plates and grown until colonies 
appeared. A loop of cells was streaked onto nutrient agar containing a reduced 
concentration of sucrose or NaCl. The plates were sealed within a plastic bag and 
incubated at 30°C for up to 30 days. 
2.5.4.12 Regeneration of L-forms to the walled state 
100 μl L-forms were used to inoculate the defined protoplast recovery medium DM3 
(Chang and Cohen, 1979) that was supplemented with 0.5% xylose. Plates were 
incubated at 30°C for up to 14 days or until colonies appeared. Colonies were restreaked 
on nutrient agar containing 0.5% xylose and the appropriate antibiotic markers. 
2.5.4.13 Fatty acid analysis 
Fatty acid composition of B. subtilis L-forms was determined from cells grown at 30°C in 
MSM/NB. Cells were harvested when cultures reached an OD600≈0.5. Cells were washed 
three times in 0.4 M NaCl followed by lyophilisation. Fatty acids were analysed as fatty 
89 
 
acid methyl ester using gas chromatography. All analyses were carried out in duplicate 
by the Identification Service of DSMZ, Braunschweig, Germany. 
2.5.4.14 Analysis of membrane fluidity 
For measurement of membrane fluidity, B.subtilis cells were grown as walled cells in LB 
supplemented with 0.5% xylose and 0.1% glucose at 37°C. B. subtilis L-forms were grown 
in MSM/NB at 30°C. When OD600=0.3 was reached, 10 μM Laurdan dye (6-dodecanoyl-2-
dimethylaminoaphthalene) was added. The walled cells were incubated for 10 minutes 
at 37°C, the L-forms were incubated at 30°C. After incubation cells were washed three 
times at 37°C or 30°C with phosphate buffered saline (pH 7) containing either 0.1% 
glucose (walled cells) or mixed in a 1:1 ratio with MSM (L-forms). The fluorescence was 
measured using a BMG optima plate reader, warmed to 37°C or 30°C, with a 350 nm 
excitation wavelength and emission wavelengths of 435 and 490 nm. Background 
fluorescence was measured using buffer supernatant removed after removal of cells by 
centrifugation. Following background subtraction, the Laurdan GP value was measured 
using the formula GP = (I435nm-I490nm)/(I435nm+I490nm) (Parasassi et al., 1990).   
2.5.4.15 Δmbl recovery screen 
Strain JB84 was grown overnight at 37°C in nutrient broth supplemented with 20 mM 
MgCl2. 5 μl of Δmbl diluted 10-4 was used to inoculate 185 μl nutrient broth in each well 
of a 96 well plate as necessary. Unless specified otherwise, 10 μl of material derived 
from the Actinobacteria to be tested was added to each well. Addition of 20 mM MgCl2 
was used as a positive control for growth and the addition of no MgCl2 was used as a 
negative control. Cells were grown for 16 hrs at 37°C in a BMG plate reader with the 
OD600 measured every 60 seconds. Unless specified otherwise all experiments had at 
least two technical repeats and two biological repeats.   
2.5.5 Experiments using Actinomycetes 
2.5.5.1 Growth of Actinomycetes on solid media 
From freezer stocks actinomycetes strains were streaked onto oatmeal agar and grown 
at 30°C. Once growth was established, strains were restreaked onto GYM agar and 
grown at 30°C. 
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2.5.5.2 Growth of Actinomycetes in liquid media 
Actinomycetes grown on solid media were used to inoculate 10 ml GYM medium. 
Cultures were grown at 30°C with orbital shaking for about 7 days. Once dense 10 ml 
cultures were used to inoculate 50 ml GYM medium. 
2.5.5.3 Growth of Actinomycetes large scale cultures 
For scaling up compound purification Actinomycetes strains of interest were grown in 
20 L bioreactors. Actinomycetes were grown in feeding flasks containing 500 ml GYM 
media for 4 days at 30°C with orbital shaking.  
2.5.6 Compound purification 
2.5.6.1 Compound collection 
Secondary metabolites of the Actinomycetes strains were harvested from either solid or 
liquid media. For harvesting from solid media, agar plates were passed through a 50 ml 
syringe and frozen at -20°C. Crushed agar was defrosted and centrifuged at 9000 rpm for 
30 mins, then the released liquid was passed through low-binding 0.45 μm filters. The 
resulting extract was stored at -20°C until needed. For collection from liquid media, 
cultures were centrifuged at 9000 rpm for 10 mins. The supernatant was passed through 
low-binding 0.45 μm filters and stored at -20°C until needed.  
2.5.6.2 Ethyl acetate extraction 
An aliquot of culture supernatant (~30 ml) obtained from a 500 ml fermentation of 
DEM30616 was mixed with an equal volume of ethyl acetate in a rotary flask. The 
aqueous phase was then removed into a separate rotary flask. From both phases the 
ethyl acetate was removed in a rotary evaporator heated to 37°C. Prior to the complete 
evaporation of ethyl acetate in the solvent phase dH2O was added to keep compounds 
present in solution.  
2.5.6.3 Reverse phase chromatography 
Reverse phase chromatograpy was performed on an Isolera Prime flash purification 
system (Biotage). 50ml crude extract was loaded onto a C18 30 g silica SNAP Biotage 
cartridge and eluted with methanol+0.1% formic acid (325 ml; 13 CV) at a flowrate of 
25 ml/min and a fraction size of 10 ml. Methanol was removed from the 96 well plate in 
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a centrifugal evaporator run at 27°C 1725 rpm and 40 mBar pressure for 45 minutes 
prior to testing of the compounds.  
2.5.6.4 Preparative and analytical HPLC 
Both types of HPLC were performed on an Agilent 1260 Infinity system. For preparative 
HPLC, 900 μl was injected whilst for analytical HPLC 5 μl was run. Both volumes were run 
on a Phenomenex 150x4.50 mm column with an attached precolumn. The column was 
eluted with acetonitrile+0.1% formic acid at a flow rate of 1 ml/min over 48 minutes. UV 
absorption was measured using a diode array detector (DAD) at 254, 210, 350, 230, 400, 
273, 300 and 250 nm. During preparative HPLC compounds were eluted into 96 well 
plates based on fixed time intervals. Acetonitrile was removed from the 96 well plate in 
a centrifugal evaporator run at 27°C 1725 rpm and 40 mBar pressure for 45 minutes 
prior to testing of the compounds.  
2.5.6.5 Mass spectroscopy  
Purified compounds were analysed by mass spectroscopy using a Voyager DE-STR 
instrument (Applied Biosystems). Compounds were identified using searches of the 
Dictionary of Natural Products.  
2.5.7 Microscopy 
2.5.7.1 Phase contrast and Fluorescence microscopy 
Both walled cells and L-forms were visualised at various points in their growth. For 
L-forms, 2 μl of culture was mounted directly onto a microscope slide. Walled cells were 
mounted on microscope slides covered with a thin film of 1.2% agarose in SMM (Glaser 
et al., 1997). Membranes were stained by addition of 0.4  µg.ml−1  FM5-95  dye  
(Invitrogen), nucleoids were stained by addition of 1 μl DAPI (Sigma) solution (1 mg/ml) 
to 10 μl of the culture prior to mounting. Images were acquired using either a Sony 
CoolSnap HQ2 cooled CCD camera (Roper scientific) attached to a Zeiss Axiovert M200 
microscope or Qimaging Rolera em-c2 cooled CCD camera attached to a Nikon Eclipse Ti 
microscope. Metamorph (MolecularDevices) was used to manipulate the images, which 
was limited to cropping the images and altering the brightness and contrast. Photoshop 
(Adobe) was used to apply scale bars to the images. The ImageJ (Schneider et al., 2012) 
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plugin, ObjectJ, was used to analyse the microscope images. This included cell counting 
and measurement of cell size.  
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3. Osmoresistant L-form generation and 
characterisation 
  
94 
 
3.1 Introduction 
3.1.1 L-forms 
In the majority of bacterial species the cell membrane is constrained by a cell wall 
composed of peptidoglycan. This complex mesh of interlocked glycan strands acts to 
protect the bacterium from external assault, to restrain the cell membrane against the 
effects of turgor and to provide shape to the cell. Despite the key roles the cell wall 
plays, remarkably it is dispensable under certain conditions. Many bacteria of a variety 
of species can grow and propagate in the absence of the cell wall as ‘L-forms’ 
(Klieneberger, 1935, Mercier et al., 2014). In laboratory settings, L-forms can be 
generated through disruption of the cell wall by antibiotics such as the β-lactams or 
fosfomycin (Mercier et al., 2014) or by blocking peptidoglycan synthesis genetically 
(Leaver et al., 2009). Without the cell wall to resist turgor pressure L-form growth 
requires the presence of high osmolarity media (typically in the form of sucrose or NaCl) 
to reduce the turgor pressure and prevent massive lysis. In the absence of the 
peptidoglycan, the cell shape is no longer maintained with the L-forms typically adopting 
an enlarged, amorphous and roughly spherical shape. This morphology is similar to that 
observed in protoplasts as a result of inflation by turgor pressure. 
Despite the requirement for high concentrations of osmoprotectant, L-forms are not a 
laboratory artefact, as the dramatic phenotypic shift to the L-form state may be a 
natural response to compounds that affect wall integrity or to escape phage or immune 
system predation.   L-forms have been found in plant material (Waterhouse et al., 1996, 
Ferguson et al., 2000) and also from clinical isolates, particularly from patients with 
persistent or recurrent bacterial infections (Domingue and Woody, 1997). 
A paradox begins to emerge - L-forms are exquisitely sensitive to changes in osmolarity, 
yet can be isolated from environments in which the high concentrations of 
osmoprotectant cannot be found. Several, mostly older, studies describe L-forms that 
have been adapted to minimal levels of osmoprotection. The adapted L-forms were 
characterised biochemically and shown to have lower concentrations of internal Na+ and 
K+ (Montgomerie et al., 1972), changes in their fatty acid profile (Montgomerie et al., 
1973, Leon and Panos, 1976) and a higher protein content (Leon and Panos, 1976). 
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However, little is known about the molecular genetics that allow L-forms to grow and 
propagate under these adverse conditions. 
In this work we reinvestigate the remarkable ability of L-forms to grow with minimal 
osmoprotection. Here we adapt the well-defined L-forms derived from the Gram 
positive model organism B. subtilis to a range of low sucrose or salt environments and 
use modern genome sequencing methods as well as more traditional techniques to 
identify and characterise a number of mutations that enable L-forms to grow in these 
hostile conditions. 
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3.2 Results 
3.2.1 Growing L-forms in decreasing concentrations of osmoprotectant is not an 
effective method for osmoadaptation 
As shown, L-forms have been a well-studied phenomena. However, much of this 
research took place during the pre-genomic era where many of the tools required for in-
depth investigation did not yet exist. Following the landmark paper in 2009 (Leaver et 
al., 2009) in which the genetic changes required for L-form development in B. subtilis 
were elucidated it has become possible to generate and investigate L-forms in a highly 
reproducible and robust fashion.  
L-forms derived from the Gram-positive model organism B. subtilis are typically grown in 
nutrient broth enriched with MSM (20 mM magnesium chloride, 0.5 M sucrose and 
20 mM maleic acid). This growth medium is well defined, having been used in both 
L-form and protoplast studies for many years. 
The osmolarity of nutrient broth and nutrient agar is currently unknown. However, work 
relating to osmotic regulation indicates that these media is of low osmolarity and is 
therefore unlikely to contribute significantly to the overall osmolarity of the media 
(Schirner et al., 2015). In turn, the 20 mM concentrations of MgCl2 and maleic acid are 
unlikely to have significant bearing on the overall osmolarity of the media. As such, it 
can be considered that the primary source of osmotic stabilisation in L-form cultures is 
from sucrose. Throughout the experiments the concentrations of MgCl2, maleic acid and 
nutrient broth were maintained as a means to control for only the contributions of the 
sucrose within the media. 
This initial investigation utilised the strains JB104 and JB105. These two strains are 
derived from the well characterised LR2 strain (Leaver et al., 2009) which carries murE 
under a Pxyl promoter alongside a point mutation in ispA in the 168CA laboratory strain 
background.  JB104 and JB105 carry GFP and mCherry respectively under a constitutive 
PrpsD promoter (Grundy and Henkin, 1992). The presence of the fluorescent markers 
allowed for rapid and robust verification that the ‘output’ bacteria were the same as the 
‘input’ bacteria.  
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As discussed in the introduction, we hoped to establish whether L-forms could grow in 
more biologically relevant conditions than those normally used in the laboratory. Whilst 
there is evidence that B. subtilis can grow as an L-form in nature, the LR2 strain is in the 
168CA background, a laboratory adapted strain. To examine if the strain background 
affects the ability to grow in low osmolarities the mutations in LR2 were recreated in the 
B. subtilis Marburg strain (LR2-M). The Marburg strain lacks many of the mutations that 
arose in the domestication of 168CA laboratory strain and retains the ability to produce 
biofilms (Zeigler et al., 2008). These differences notwithstanding the two strains from 
the different backgrounds behaved similarly and were treated the same both when 
grown as walled cells and L-forms in the normal conditions.  
The first approach of the L-form adaptation experiment was to dilute L-forms, step-wise, 
into a medium with a lower concentration of sucrose. The experiment started with a 
parent L-form culture derived from the walled cells as described in 2.4.5.8 and grown 
until dense in 0.5 M MSM/NB. The parent culture was then used to make 1/1000 
inoculations into test tubes containing 5 ml 0.4 M MSM/NB. These were grown for 
roughly 10 days at 30°C. The adaptation experiments were set up with replicates of 10. 
To control for any factors affecting L-form growth that were not related to the osmotic 
conditions, L-forms from the parent culture were also used to inoculate 3 tubes of 5 ml 
fresh 0.5 M MSM/NB cultures. To minimise the risk of contamination the growth rate 
was only tracked in three of the 10 tubes during each adaptation experiment. As shown 
in figure 3.1A L-form growth in 0.4 M MSM/NB was robust, though at a lower rate than 
growth in 0.5 M MSM/NB. The presence of L-forms within all the cultures was verified 
using light microscopy. To further verify the L-forms, fluorescence microscopy was used 
to detect the presence of the constitutively expressed GFP or mCherry. Excluding 
occasions of contamination with walled bacteria (typically cocci, though instances of 
rods and yeast were observed) L-forms were observed in 100% of all 0.4 M MSM/NB 
cultures. 
For easy storage and characterisation of the adapted L-forms, L-forms grown in 0.4 M 
MSM/NB were plated on DM3 protoplast recovery media (Chang and Cohen, 1979) 
supplemented with xylose. This medium supports the L-forms and alongside the xylose 
facilitates regeneration of cell wall and therefore reversion of the bacteria back to the 
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walled state. Correct isolation was verified using the constitutively expressed GFP and 
mCherry markers. Stocks of the adapted L-forms were stored at -80°C only after they 
have been reverted back to the walled state.  
Following growth in 0.4 M MSM/NB L-forms were used to inoculate medium containing 
0.3 M MSM/NB. In addition, the L-forms were also used to inoculate fresh 0.5 M and 
0.4 M MSM/NB for use as controls. Where contamination arose fresh L-forms were 
prepared from the freezer stocks of the walled strains regenerated from L-forms 
adapted to 0.4M sucrose and were used to reinoculate fresh media.  
Again growth in the ‘0.3 M sucrose’ medium was observed in 100% of cultures (barring 
occurrences of contamination). As before, the presence of L-forms was verified using 
light and fluorescence microscopy, and a portion of the adapted cells were reverted 
back to the walled state via streaking on DM3 plates containing xylose for storage.  
The step from 0.3 M to 0.2 M sucrose was repeated additional times, with occurrences 
of growth averaging at 5% (range=0-20%) in the separate cultures. None of the L-forms 
seen in the step down to 0.2 M sucrose achieved high optical densities, and neither 
could they be propagated further on DM3 media or in fresh L-form media. 
This work suggested that the limit to which L-forms could readily grow in reduced levels 
of sucrose ranged between 0.3 M and 0.2 M sucrose. To confirm this and to resolve the 
boundary with greater resolution L-forms derived from LR2 were used to inoculate a 
range of sucrose concentrations between 0.3 M and 0.2 M. As can be seen in figure 3.1D 
growth becomes progressively less robust until it is effectively abolished at a 
concentration between 0.2125 M and 0.2 M sucrose.  
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Figure 3.1. Growth of LR2 L-forms in varying concentrations of MSM/NB. L-forms 
derived from LR2 were grown in 0.5 M MSM/NB until dense. L-forms from this culture 
were used to inoculate a range of concentrations from 0.5 M to 0.05 M (A). After 
incubation, growth was only observed in cultures containing 0.5 M MSM or 0.4 M MSM. 
The same experiment was repeated using the L-forms grown in 0.4 M MSM/NB (B). After 
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11 days, L-forms were observed in media containing sucrose concentrations as low as 
0.3 M. L-forms grown in 0.3 M MSM/NB were used to a fresh range of sucrose 
concentrations (C). L-forms were able to grow in sucrose concentrations of 0.2M, though 
these L-forms were not able to be propagated further. Graphs are illustrative of the 
growth of 12 biological replicates, each with 12 technical replicates. D). L-form growth in 
a range of sucrose concentrations after 10 days incubation.  
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To characterise the L-forms that have adapted to grow at sucrose concentrations below 
0.3 M, the strains, stored at -80°C as walled cells, were grown on nutrient agar plates 
supplemented with 0.5% xylose. On plates no differences between the adapted strains 
in colony morphology was observed (Figure 3.2), examination of the strains by light 
microscopy also revealed no clear differences. Finally, there were no significant 
differences in the growth rates between the various adapted strains and the parent 
strain. Taken together, this indicated strongly, but not absolutely, that the L-forms had 
not acquired adaptive mutations and instead any changes were likely to have been 
transient.   
This method of adaptation was ultimately abandoned. The primary reason was the 
inability to grow and recover L-forms at sucrose concentrations below 0.3 M. Secondly, 
the extended periods of growth and repeated inoculations rendered the risk for 
contamination high. Finally, the prolonged periods of growth would likely result in the 
accumulation of multiple mutations within the Bacillus genome. Such a build-up of 
mutations has the potential to confound attempts to analyse any whole genome 
sequencing performed.  
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Figure 3.2. Regenerated L-forms derived from LR2 (A) and LR2-M (B) isolated from the 
adaptation experiments are phenotypically identical in both liquid and solid media. 
L-forms from the adaptation experiment were regenerated on DM3 protoplast recovery 
media and restreaked on nutrient agar containing the appropriate selection marker(s), 
frozen in liquid nitrogen and stored at -80°C. For measurement of the growth rates, 
bacteria were diluted from overnight cultures into fresh LB media on a 96 well plate. 
Bacteria were grown for 6 hours and the OD600 measured in a plate reader heated to 
37°C. For growth on solid media the strains were streaked on nutrient agar 
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supplemented with 0.5% xylose. Each letter in the strain name refers to each biological 
replicate in the adaptation experiment, whilst the number refers to the sucrose 
concentration the strain was isolated from. 
  
106 
 
3.2.2 Direct inoculation of low sucrose media can be used to generate 
osmoadapted L-forms 
As an alternative route for generation of osmoresistant L-forms, it was considered 
whether L-forms could be directly inoculated into media containing low levels of 
sucrose. Such a method was preferable to that described in the previous section as it 
would reduce the long growth times during each stage of adaptation. It would also 
reduce the level of manipulation required, thereby limiting the opportunities for 
contamination to be introduced.  
This method was attempted with both the LR2 derivatives mentioned previously and an 
accDA overproduction strain (though the majority of the experiments utilised the LR2-
based strains). accDA encodes an acetyl-CoA carboxylase, an enzyme involved in the FAS 
II pathway. Overexpression of accDA results in membrane overproduction, which can 
enable growth in the L-form state. In normal growth conditions these strains proliferate 
as L-forms in an identical fashion (Mercier et al., 2013). However, it was not known 
whether their behaviour in low osmolarities would be identical to each other. Apart 
from the requirement for xylose for growth as an L-form the accDA overexpression 
strain was handled exactly the same as the L-forms derived from the LR2 strains.  
L-forms were grown in 0.5 M MSM/NB until they reached either mid-exponential or 
stationary phase and were then diluted 1/10 into MSM/NB containing either 0.1 M, 
0.05M or no sucrose. As a result of these dilutions there were significant alterations to 
the final sucrose concentration in the media. These final concentrations are listed in 
table 3.1. For the sake of clarity the original sucrose concentrations will be used when 
describing the experiment.  
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Start sucrose concentration Final sucrose concentration 
0.1 M 0.136 M 
0.05 M 0.091 M 
No sucrose 0.045 M  
Table 3.1. Sucrose concentration pre- and post- direct 10-1 inoculation from L-forms 
grown in 0.5M MSM/NB. Final sucrose concentration assumes minimal technical error in 
pipetting.  
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As with the previous adaptation experiment, the optical density was only tracked in a 
single culture and only in those exhibiting sign of growth (where media was observed to 
become turbid). As hoped, with the reduction in handling with the current method a 
reduction in the level of contamination was observed. 
Crucially, growth was observed in a number of the flasks, across a number of the sucrose 
concentrations. An interesting phenomenon was observed in a small minority of the 
media containing no sucrose. In these cultures turbidity was observed 2-3 days post 
inoculation, and examination by light microscopy confirmed the presence of L-forms. 
However, the majority of these L-forms appeared phase negative, suggesting that they 
were more likely empty vesicles. This view was confirmed by the collapse in optical 
density over the 48 hours after examination. Subsequent examination by microscopy 
failed to detect any intact or viable L-forms within the culture. This observation suggests 
that proliferating L-forms were releasing empty vesicles as opposed to viable progeny. 
In two cases accDA L-forms derived from strain JB150 (Pxyl-accDA) were able to grow in 
0.1 M sucrose (Figure 3.3), though these L-forms were not able to be regenerated to 
grow in walled state nor propagated when re-diluted into the same (0.1 M sucrose) 
medium. However, what made these bacteria unique was that under the microscope 
these L-forms appeared to be clumping into dense clusters. Initially, this behaviour was 
thought to be unique to the accDA strain, though later work with osmoadapted L-forms 
derived from LR2 also exhibited this behaviour at a low frequency. The reason and 
significance of forming dense clumps was not known and not investigated further, 
though it is possible that many cells lysed and released a large amount of DNA, trapping 
some cells and perhaps even protecting them from lysis.  
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Figure 3.3. Despite observations of some growth, Growth in 0.1 M MSM/NB was 
observed following direct inoculation with L-forms derived from the accDA strain 
(JB150). Under the microscope L-forms appeared clustered together, along with a large 
number of dead L-forms. L-forms are assumed to be alive when phase bright and when 
recognisable as L-forms. Optical density was measured after 7 days. Scale bar=3 μm 
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In contrast to the accDA L-forms, one of the cultures derived from LR2 showed sustained 
growth in 0.1 M MSM/NB (figure 3.4), and could be propagated when diluted in fresh 
0.5 M MSM/NB. Furthermore, after plating on DM3 (+xyl) protoplast recovery medium 
the walled cells could be isolated. Again presence of the fluorescent marker (in this case 
mCherry) and the selection marker was checked, which confirmed that the walled cells 
from the ‘recovery’ plates were regenerated L-forms. From the recovery plate four 
colonies were isolated and stored at -80°C. The four strains isolated from the colonies 
were called M1, M2, M3 and M4. 
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Figure 3.4. A). Growth of the isolated M1 strain in 0.1 M MSM/NB at 30°C over two 
weeks. B). L-form validation was achieved by the continued presence of a constitutively 
expressed copy of the fluorescent marker mCherry.  
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3.2.3 The ability of L-forms to survive resuspension in hypotonic conditions does 
not appear to be growth phase dependent 
In the direct inoculation experiment described earlier it was considered whether the 
ability of L-forms to survive in the low osmolarity medium used was growth phase 
dependent; whether the ability to grow was dependent on early exponential growth for 
instance. To investigate this, the ability of L-forms derived from LR2 grown in 0.5 M 
MSM/NB to survive following suspension in either 0.1 M MSM/NB or H2O was examined. 
L-form cultures were grown in triplicate for 3, 5, 7 and 9 days in 10 ml 0.5 M MSM/NB. 
The L-forms from each culture were centrifuged, and the resulting pellet was 
resuspended in either 0.3 M MSM/NB or in just water. 
As can be seen in figure 3.5 the age of a culture has no bearing on the ability of the 
L-forms to survive the initial hypotonic shock. The caveat of the experiment is that it did 
not track whether the L-forms were able to grow following resuspension. Therefore, it 
remains possible that the age of an L-form culture could affect the ability to grow, just 
not survive. 
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Figure 3.5. The age of an L-form culture has no effect on the levels of lysis following 
resuspension in low osmolarites. L-forms were diluted 10-3 into 10 ml 0.5 M MSM/NB 
and grown at 30°C. Every two days the OD600 was measured and 2 ml of the L-form 
culture pelleted. The pellet was resuspended in 2 ml of either 0.5 M MSM/NB, 0.1 M 
MSM/NB or H2O and incubated at 30°C for 10 minutes. After 10 minutes the OD600 was 
measured. Little to no lysis is observed following resuspension in 0.5 M MSM/NB, whilst 
identical levels of lysis are observed between the two low osmolarities. The data were 
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normalised against an OD600=1 at 0.5 M MSM/NB (B). Error bars are representative of 
the standard deviations of three replicates.  
115 
 
3.2.4 The adapted L-form strain retains the ability to grow in low osmotic 
conditions after regrowth as walled cells and in high sucrose 
It was of interest to examine whether the L-forms that have adapted to grow with 0.1 M 
sucrose retained the ability to grow in low sucrose indicative of a mutation(s), or if what 
was observed was instead a transient adaptation. To test this, L-form cells in the 0.1 M 
sucrose culture (henceforth called M1) was firstly used to inoculate fresh 0.5 M 
MSM/NB and grown until dense,  then diluted by either 1/10, 1/100 or 1/1000 back into 
0.1 M MSM/NB. As a control the parental strain, JB105 was diluted by the same factors 
into 0.1 M MSM/NB. Even at dilutions of 1/1000 the L-form M1 strain was able to 
regrow in the low osmolarities, whereas the parental strain was unable to do so (figure 
3.6). This provided the first evidence that the M1 strain had indeed picked up a mutation 
or mutations enabling it to grow in low sucrose environments. 
The second piece of evidence was provided by the walled cells that were regenerated 
from L-forms adapted to grow in 0.1 M MSM/NB. The four colonies that had been 
isolated from the regeneration (M1, M2, M3 and M4) were investigated in case the 
adapted L-form culture was a mixed population. From these four strains L-forms were 
prepared as described in 2.4.5.8 and grown in 0.5 M MSM/NB until dense. The L-forms 
of these strains were then used to inoculate 0.1 M MSM/NB alongside the parental 
JB105 strain. All four of the strains were able to grow in the low sucrose media whereas 
the parental strain was not (figure 3.7A). This was further evidence that the isolated 
L-forms had indeed picked up a mutation or mutations that enabled growth in low 
sucrose environments. 
Additionally, the ability of the adapted L-forms to grow in sucrose concentrations of 0.05 
M was tested; no growth was observed, therefore the lowest concentration that L-forms 
could adapt to was 0.1 M sucrose (data not shown).  
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Figure 3.6. L-forms isolated from a 0.1 M MSM/NB culture can regrow in low 
osmolarities environments following growth in 0.5 M MSM/NB. The M1 strain isolated in 
the previous experiment was grown in 0.5 M MSM/NB for three days at 30°C. Cells were 
diluted into the low sucrose media by a factor of 10-2. L-form growth was tracked via 
measurement of the OD600.  
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3.2.5 The isolated osmoadapted L-forms M1-M4 have similar growth rates and 
similar cell morphologies indicating that the parent L-form culture did not 
represent a mixed population 
 It was possible that the osmoadapted L-form culture contained a mixed population of 
mutants. To probe this issue the four colonies obtained from regenerated  L-forms in 
0.1 M MSM/NB  (M1-M4), which all retained the ability to grow in low sucrose 
conditions, were characterised by comparing their growth rates and cell morphology. 
All four of the strains had the same slower growth rate than the parental strain, with 
growth improved but not restored by the addition of 20 mM MgCl2 (figure 3.7). 
Microscopic analysis showed that all four of the strains exhibited the same striking 
morphological aberrations, in particular the strains appear to produce minicells as well 
as perturbations in the ability to maintain a uniform peptidoglycan wall. 
Taken together, it seems likely that the four strains are identical and that they do appear 
to possess at least one mutation, which also hinders their growth and development in 
the walled state.  
  
118 
 
119 
 
Figure 3.7. The four strains isolated from the DM3 recovery plate are phenotypically 
similar, but distinct from the parent strain. Following growth in low osmotic conditions 
L-forms were recovered on DM3 plates and the cell wall regenerated. Four colonies 
were stored to assess if the original culture was contained a mixed population. All four 
of the strains were able to regrow in low sucrose (A) and all four had a similar growth 
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Early exponential phase Late exponential phase 
i 
v 
iii 
ii 
iv 
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rate when grown in LB as walled cells, though this growth rate was lower than the 
parental JB105 strain (B). C). Microscopy of the four strains during early and mid-
exponential phase. The strains isolated from the osmoadaptation experiment M1 (ii), 
M2 (iii), M3 (iv) and M4 (v) all had similar morphologies to each other. These differed 
from the morphology of the wild type strain (JB105; i). Scale bar = 3μm.  
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3.2.6 Development of an adaptation method for the generation of osmoadapted 
L-forms proves successful 
The above described adaptation method did prove successful, allowing for isolation of 4 
mutants (probably clonal). To improve the efficiency of the ‘adaptation’ experiments, it 
was considered whether the method described in 3.2.1 could be adjusted so that 
instead of growing L-forms at each lower concentrations of sucrose for a prolonged 
period of time, the L-forms were instead adapted to progressively lower concentrations 
of sucrose for only 1-2 hours at each intermediate concentration. For this method a 
50 ml L-form culture of the strain LR2 was grown until dense. Cells were harvested by 
centrifugation for 10 minutes at 3000 rpm. The supernatant was then discarded and the 
cell pellet was resuspended in 20 ml 0.4 M MSM/NB.  The culture was incubated at 30°C 
for 1.5 hrs and 100 μl was removed to inoculate 10ml fresh 0.4 M MSM/NB; this was 
then grown at 30°.  The main culture was centrifuged again at 3000 rpm for 10 mins, 
with the pellet resuspended in 20 ml 0.3 M MSM/NB and then incubated at 30°C once 
again for 1.5 hrs. This whole process was repeated at the sucrose concentrations listed 
in table 3.2 until the L-form pellets were resuspended in media containing no sucrose.  
 
 
[Sucrose] or [NaCl] 
0.5 M 
0.4 M 
0.3 M 
0.2 M 
0.1 M 
0.075 M 
0.05 M 
No addition 
Table 3.2. The concentration of osmoprotectant at each stage in the adaptation 
experiment. The concentrations listed do not reflect the effect the addition of residual 
osmoprotectant from a previous step on the overall molarity.  
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All the cultures were grown at 30°C for up to a month to see if growth develops. 
Unsurprisingly, the L-forms at the 0.4 M and 0.3 M sucrose concentrations grew rapidly 
and robustly. In the majority of cases no growth was observed in any of the flasks 
containing sucrose concentrations below 0.3 M. However in three independent 
experiments L-form growth was observed in flasks containing minimal sucrose, in two of 
these experiments L-forms were observed growing in several of the different 
concentrations, some containing as little as 0.05 M sucrose. The concentrations that the 
5 isolated L-form strains were able to grow in following adaptation is listed in table 3.3. 
Strain name Osmoprotectant Concentration (M) Lineage 
JB114 Sucrose 0.075 A 
JB115 Sucrose 0.05 A 
JB116 Sucrose 0.1 B 
JB117 Sucrose 0.1 - 
JB118 Sucrose 0.05 B 
JB119 NaCl 0.1 C 
JB120 NaCl 0.1 D 
JB121 NaCl 0.05 C 
JB122 NaCl 0.05 D 
JB123 NaCl 0.1 - 
JB124 NaCl 0.1 - 
JB125 NaCl 0.1 - 
JB126 NaCl 0.1 - 
Table 3.3. Strains isolated from the adaptation experiment. Strains are listed with the 
osmoprotectant used and the concentration of osmoprotectant from which they were 
isolated. The lineage refers to the starting culture the L-forms were derived from. 
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As stated earlier, in the literature L-forms have been successfully grown with a variety of 
different osmoprotectants, amongst these osmoprotectants NaCl has been one of the 
most commonly used. It was speculated whether changing the osmoprotectant used 
from sucrose to NaCl would facilitate adaptation to low osmolarities more readily. To 
this end, L-forms derived from the LR2 strain were prepared as described, but the 
sucrose was replaced with 0.5 M NaCl thereby making MNM/NB. L-form growth in this 
media was slower than in sucrose, but still comparable; under the microscope cells 
grown with either osmoprotectant were indistinguishable (figure 3.8). The adaptation 
protocol established earlier was repeated with the sucrose concentrations substituted 
with equal concentrations of salt. The type of osmoprotectant used does not seem to 
have a significant effect on the ability of L-forms to adapt to low osmolarities – L-forms 
were able to adapt to minimal salt concentrations at a rate comparable to those 
adapted to low sucrose concentrations. In total eleven adapted L-form strains were 
isolated from six independent adaptation experiments. The salt concentrations that 
these strains are adapted to is listed in table 3.3.  
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Figure 3.8. L-forms grown in MSM/NB (A) and in MNM/NB (B) are indistinguishable. 
L-forms were grown from protoplasts in MSM/NB before inoculation of the two media. 
L-forms were grown for 72hrs at 30°C then examined by light microscopy. Scale bar = 
3 μm.  
A 
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3.2.7 Adapted L-forms can be successfully regenerated into the walled rod form 
Unlike the experiments described in 3.2.2 the osmo-resistant L-form mutants obtained 
in 3.2.6 were not introduced back in either 0.5 MSM/NB or MNM/NB. This was not 
intentional, but instead an unfortunate oversight. Instead, all the adapted cultures were 
directly plated onto the DM3 regeneration media to allow reversion to the walled state 
and remarkably, all the adapted strains were able to regenerate cell wall and grow as 
rods. The parent strain used for these experiments was LR2, without the GFP or mCherry 
tags used in the previous experiments. As such the identity of the regenerated strains 
was confirmed just by seeing if the bacteria retained their resistance to 
chloramphenicol, a marker linked to the pxyl-murE construct. All the strains were able to 
grow on nutrient agar containing the appropriate concentrations of xylose and 
chloramphenicol. Following this confirmation all the strains were given a name (table 
3.3) and stored at -80°C for further analysis.  
3.2.8 Most of the adapted L-forms retain the ability to grow in low osmotic 
conditions after regrowth as walled cells and in high sucrose or salt 
To see whether the new osmo-resistant mutants retained their resistance after being 
reverted back into the walled state, the regenerated osmo-resistant mutants, now in 
walled form, alongside the parental strain LR2, were prepared as L-forms and grown in 
0.5 M MSM/NB or MNM/NB where appropriate. Once the L-form cultures became 
dense they were diluted 1/100 into media containing either 0.1 M sucrose or 0.1 M NaCl 
as required and grown at 30°C for up to a month. Two of the L-form strains were unable 
to regrow in 0.1M salt despite repeated attempts; therefore for these two strains it 
must be assumed that they experienced a transient adaptation that allowed them to 
grow in low osmolarities. The remaining adapted L-form strains were able to grow with 
minimal osmoprotection (Figure 3.9), whereas the parent (LR2) could not, suggesting 
that these strains had picked up a mutation or mutations that enabled them to grow in 
these conditions. How reliably and robustly L-forms could grow in low osmolarities 
varied from strain to strain. The strains JB114, JB115 and JB118 were able to grow 
following inoculation into low osmotic media in ˜95-99% of the cases, for the other 
strains the ability to grow, was limited to roughly 50% of all inoculations.  
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Figure 3.9. The L-form strains isolated from the adaptation experiment are able to 
regrow in low sucrose (A) or salt (B) concentrations. All the strains were grown in either 
0.5 M MSM/NB or MNM/NB where appropriate before 10-3 dilutions into either 0.1 M 
MSM/NB (A) or 0.1M MSM/NB (B). OD600 was measured after 7 days incubation at 30°C. 
Errors bars represent the standard deviation of three replicates. 
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3.2.9 Growth of the adapted strains is identical to the parent strain under 
normal L-form growth conditions 
As the adapted strains were able to grow in low osmotic media it was wondered 
whether the adaptations in these strains affected their ability to grow under normal 
growth conditions. To this end, L-forms were diluted to an OD600=0.05 in either MSM/NB 
or MNM/NB and grown for 3 days at 30°C. All the strains had a growth rate roughly 
comparable to the parental LR2 strain (data not shown). It’s possible that subtle 
differences do exist between the strains, though as a result of the heterogeneity of 
L-form division any differences have to be significant to be observed.  
3.2.10 Mutants grown in the walled state exhibit a diverse array of growth rates 
After the initial characterisation of the adapted strains in the L-form state the behaviour 
of the strains in the walled state was probed. On nutrient agar plates containing xylose 
the strains exhibited a multiplicity of colony morphologies (figure 3.10), this was unlike 
the M1 strain which appeared visually similar to the parental JB105 strain. Particularly 
striking were strains JB114, JB115 and JB118 which struggled to grow, forming small 
colonies. In addition, strain JB121 grew well initially but then underwent rapid lysis on 
the plate. JB125 growth was unremarkable, but appeared to develop suppressor 
mutants rapidly, that seem to improve the growth of the strain. Supplementation of 
media with magnesium chloride has long proved to be an effective remedy at restoring 
the growth of bacteria carrying mutations affecting the cell envelope. Addition of 20 mM 
MgCl2 to the nutrient agar did indeed improve the growth of several of the strains, 
particularly those with the poorest growth. 
  
128 
 
Figure 3.10. Colony morphologies of the osmoadapted strains on nutrient agar. The 
regenerated strains were streaked on nutrient agar containing 0.5% xylose and 
incubated overnight at 37°C. The strains adapted to sucrose are shown in (A), the salt 
adapted strains shown in (B). 
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To further characterise the mutants, the growth rate in PAB medium supplemented with 
xylose was measured in the presence or absence of 20 mM Mg2+.  As can be seen in 
figure 3.11 there was a great level of variation in the growth rate of the different strains 
regardless of whether 20 mM Mg2+ Is present. In particular, the growth of several of the 
salt-adapted strains, such as JB120, JB122 and JB125 was severely attenuated, with only 
minimal recovery following the addition of 20 mM MgCl2. Growth of JB119, on the other 
hand, improved significantly with the addition of magnesium. Among the sucrose-
adapted strains, JB114 had the poorest growth rate, though this was still superior to the 
rates seen with JB120, JB122 and JB125. JB115 appeared to have growth rate that 
ranked between that seen with JB114 and the parental LR2 strain.  
Such a variety of growth rates and colony morphologies was very promising as it 
indicates that the strains have picked up a variety of different mutations. In addition the 
sensitivity to Mg2+ suggests some of these mutations involve the cell envelope – 
magnesium has been found to enable the recovery of a wide variety of mutations 
involving the wall such as mbl (Schirner and Errington, 2009), ponA (Murray et al., 1998) 
and tagO (D'Elia et al., 2006a).   
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Figure 3.11. Growth rate of the strains adapted in sucrose (A) and salt (B) in the walled 
state. Strains were diluted to OD600=0.01 in PAB+0.5 % xylose +/- 20 mM MgCl2. Cultures 
were grown with shaking at 37°C with OD600 measured every 30 minutes.  
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3.2.11 Microscopy of the mutant strains display a multitude of phenotypes 
To further characterise the strains the cells were examined using fluorescence 
microscopy during early exponential, mid exponential and stationary phases. A 
multitude of different phenotypes was observed for the various strains. The phenotype 
of the strains JB114 and JB115 was particularly arresting. As can be seen in figure 3.12, 
JB114 cells are very sick in the absence of Mg2+, with pronounced dysregulation in the 
cell shape. Magnesium dependency was also observed with JB115, which displayed a 
similar morphology to JB114 during early exponential phase. However, unlike JB114 the 
morphology of JB115 generally recovered as the cells moved through exponential phase 
into stationary phase. Whilst the overall morphology did improve, the cells began to 
develop a curious budding/branching phenotype more reminiscent of Streptomyces 
rather than Bacillus. During stationary phase, where the branching phenotype is most 
pronounced, 12% of cells exhibited some degree of the branching or budding 
phenotypes. For comparison, in the parental strain 0% of cells demonstrated this 
phenotype. Some level of branching/budding was also seen in JB115 supplemented with 
20mM MgCl2 but at much reduced levels. To see how much cell division was affected in 
these mutants, a zapA-gfp construct was introduced into the strains. ZapA is a cell 
division protein that is recruited to the Z-ring and therefore a GFP-tagged copy allows 
for visualisation of the Z-ring positioning. As can be seen in figure 3.13 both strains 
displayed aberrant positioning of the Z-ring, though in JB114 this was far more 
pronounced. Unsurprisingly, the positioning of the Z-ring in JB115 improved during 
growth as the morphology improved as described earlier. These results show that the Z-
ring does remain intact in growth, implying that the mutation is not directly involved in 
Z-ring formation. However, any substantial conclusion is not possible as the Z-ring 
mislocalisation phenotype could be arising as a result of a mutation in a protein directly 
involved in localisation of the Z-ring or as a result of a more general change affecting the 
cell shape (which would in turn affect the positioning). 
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Figure 3.12.A. Cell morphology of the wild type (LR2;A), JB114 (B), JB115 (C), JB116 (D), 
JB117 (E) and JB118 (F) during early exponential phase (OD600=0.3). Arrows in panel B 
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and C indicate misplaced septum. The arrow in panel E indicates membrane over 
production. 
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Figure 3.12.B Cell morphology of the wild type (LR2; A), JB114 (B), JB115 (C), JB116 (D), 
JB117 (E) and JB118 (F) during mid-exponential phase (OD600=1.0). Arrow in panel B 
points to a misplaced septum. The arrows in panel C indicate the clubbing/early 
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branching described in the text. The arrows in panels D and E indicate the membrane 
overproduction. 
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Figure 3.12.C Cell morphology of the wild type (LR2; A), JB114 (B), JB115 (C), JB116 (D), 
JB117 (E) and JB118 (F) during stationary phase. Arrow in panel C points to the budding 
in 10% of JB115 cells. Arrows in panels D, E and F point to membrane overexpression.  
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Figure 3.13. ZapA-gfp localisation in JB114 grown with (A) and without (B) 20mM Mg2+ 
and in JB115 grown with (C) and without (D) 20mM Mg2+ during mid-exponential phase 
and the localisation during stationary phase with the respective strains and conditions 
(E-H).  
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In contrast to JB114 and JB115, JB116 and JB117 have morphologies far more similar to 
the parental strain. Whilst their cell width and length is identical to LR2 (figure 3.12), 
they appeared to produce bundles of excess membrane, particularly towards the cell 
poles. The final sucrose adapted strain, JB118, was largely healthy, though appeared to 
suffer from lysis when grown in the absence of 20 mM magnesium. Interestingly, this 
lytic behaviour did not seem to affect the growth rate of the strain.  
The first of the salt adapted strains, JB119 is perhaps one of the healthiest of the strains. 
Some cell shape perturbations were observed, but generally the cells were highly similar 
to the parent, with identical cell length and width to LR2. Strains JB120 - JB125 were 
remarkably sick with substantial changes to the cell morphology (figure 3.14), with 
significant levels of shape perturbations and high degrees of lysis. Taken with the growth 
rate results, these results were not that surprising, except in the case of JB121. This 
strain initially grows well on nutrient agar, but then undergoes rapid lysis. In addition, 
under the microscope the cells are morphologically aberrant. Remarkably, despite these 
observations, JB121 possesses a growth rate comparable to the parent strain. JB126 
appeared as one of the healthier strains, without any significant growth defects. 
However, quantification of the cell length revealed a significant increase in both the cell 
length and width in comparison with the parent strain (figure 3.15). Cell length/width 
measurements were also made for a number of the other strains though the clear 
appearance of distinct phenotypes largely rendered these measurements unnecessary.  
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Figure 3.14.A. Cell morphology of the parent strain LR2 (A), JB119 (B), JB120 (C), JB121 
(D), JB122 (E),  JB125 (F) and JB126 (G) during early exponential phase (OD600=0.3).The 
arrows in panels E highlight the long cells present in JB122. Scale bar = 3μm. 
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Figure 3.14.B Cell morphology of the parent strain LR2 (A), JB119 (B), JB120 (C), JB121 
(D), JB122 (E), JB125 (F) and JB126 (G) during exponential phase (OD600=1.0. Scale 
bar=3μm   
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Figure 3.14.C Cell morphology of the parent strain LR2 (A), JB119 (B), JB120 (C), JB121 
(D), JB122 (E),  JB125 (F) and JB126 (G) during stationary phase. Arrow in panel E 
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highlights aberrant septa, whilst the arrow in panel G indicates membrane 
overexpression.  
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Figure 3.15.  Cell length of strain JB126 in comparison to the wild type strain (LR2) when 
grown in PAB supplemented with 20 mM MgCl2. Cell length was measured during mid-
exponential phase (OD600=1.0); at least 500 cells were measured for each strain.  
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It was feared that one or more of the phenotypes might have arisen due to mutations in 
the Pxyl promoter, which controlled the expression of the murE gene essential for the 
growth of the walled cells, resulting in a depletion of MurE. To test for this possibility 
xylose was titrated away from LR2. As expected, a reduction in xylose levels did result in 
morphological aberrations in strain LR2 (figure 3.16). However, the aberrations observed 
in the mutant strains appeared quite distinct from those seen for LR2 in the absence of 
xylose. Therefore it seemed likely that xylose or the absence of xylose was not 
responsible for the phenotypes presented above.  
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Figure 3.16. The effect of decreasing concentrations of xylose on the cell morphology of 
the wild type strain (LR2). Cells were grown in PAB supplemented with 20mM MgCl2 and 
0.5% (A), 0.25% (B), 0.125% (C) or no (D) xylose.  
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3.2.12 Genome sequencing of the adapted strains revealed a range of mutations 
After the initial characterisation of the adapted strains it was clear that a number of 
mutations were present. To identify the mutation(s) responsible for the ability to grow 
in low osmotic media, the genomes of all the strains isolated as well as the wild type 
strain were determined by sequencing using an Illumina MiSeq system. The mutations 
detected are listed in table 3.4. Mutations of interest were validated by PCR then 
sequencing the relevant regions using Sanger sequencing. The full list of mutations, 
including those present in the parent strain are given in appendix 4. 
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Gene Description Coding region change Amino acid 
change 
M1 
yhaG/trpP Tryptophan uptake 
3541bp deletion 
81% deletion 
yhaH Unknown Complete 
deletion 
scoC Transcriptional repressor Complete 
deletion 
yhaI Unknown Complete 
deletion 
yhaJ Putative bacteriocin Complete 
deletion 
JB114 
mreB Cytoskeleton 568/60bp del I192>I211del 
ftsE ABC transporter/autolysis 523/G>T E175* 
pit Phosphate transporter/proton 
symporter 
932/ins TG W331* 
nucA Membrane associated 
nuclease 
163/delA/insCG T55R 
adeC Adenine deaminase 1654/delT L552* 
accD Acetyl-CoA carboxylase 789/T>C N/A 
yvgJ Lipoteichoic acid synthesis 
primase 
194/AC>GG N65R 
JB115 
mreB Cytoskeleton 568/60bp del I192>I211del 
rpoB RNA polymerase 3181/C>A Q1061K 
nucA Membrane associated 
nuclease 
163/delA/insCG T55R 
adeC Adenine deaminase 1654/delT L552* 
accD Acetyl-CoA carboxylase 789/T>C N/A 
yvgJ Lipoteichoic acid synthesis 
primase 
194/AC>GG N65R 
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JB116 
ydbL Unknown 874/G>C A292P 
hom Homoserine dehydrogenase 568<>711/inversion 48aa inversion 
yqhY Unknown 38/delA D13* 
JB117 
 Intergenic 1731572 delA  
hom Homoserine dehydrogenase 641/90bp deletion F214>G243 del 
yqpP-
yodU 
SPβ prophage 134.4kb deletion N/A 
nucA Membrane associated 
nuclease 
163/delA/insCG T55R 
adeC Adenine deaminase 1654/delT L552* 
yrdQ Transcriptional regulator 865/T>G STOP289E 
accD Acetyl-CoA carboxylase 789/T>C N/A 
yvgJ Lipoteichoic acid synthesis 
primase 
194/AC>GG N65R 
JB118 
nucA Membrane associated nuclease 163/delA/insCG T55R 
adeC Adenine deaminase 1654/delT L552* 
yrdQ Transcriptional regulator 865/T>G STOP289E 
accD Acetyl-CoA carboxylase 789/T>C N/A 
yvgJ Lipoteichoic acid synthesis 
primase 
194/AC>GG N65R 
JB119 
acdA acyl-CoA dehydrogenase 709/ 126bp deletion  K237>Q279 del 
gbsB Glycine betaine synthesis 965<>1097/ inversion 44aa inversion 
ytzB Unknown 89/insT S31* 
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yqhY Unknown 38/delA D13* 
JB120 
nucA Membrane associated nuclease 163/delA/insCG T55R 
adeC Adenine deaminase 1654/delT L552* 
yrdQ Transcriptional regulator 865/T>G STOP289E 
accD Acetyl-CoA carboxylase 789/T>C N/A 
ytzB Unknown 89/insT S31* 
yvgJ Lipoteichoic acid synthesis 
primase 
194/AC>GG N65R 
yqhY Unknown 38/delA D13* 
JB121 
nusG Antitermination factor 227/G>A W76STOP 
ppsB Plipastatin synthetase 3218/C>G A1043G 
nucA Membrane associated 
nuclease 
163/delA/insCG T55R 
adeC Adenine deaminase 1654/delT L552* 
yrdQ Transcriptional regulator 865/T>G STOP289E 
accD Acetyl-CoA carboxylase 789/T>C N/A 
ytzB Unknown 89/insT S31* 
yvgJ Lipoteichoic acid synthesis 
primase 
194/AC>GG N65R 
yqhY Unknown 38/delA D13* 
JB122 
ribT Unknown 242G>C G81A 
adeC Adenine deaminase 1654/delT L552* 
yrdQ Transcriptional regulator 865/T>G STOP289E 
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accD Acetyl-CoA carboxylase 789/T>C N/A 
ytzB Unknown 89/insT S31* 
yvgJ Lipoteichoic acid synthesis 
primase 
194/AC>GG N65R 
yqhY Unknown 38/delA D13* 
JB125 
blt Spermidine efflux 28/ 159bp deletion T10>P63 del 
yhfC Unknown 526/ 153bp deletion L176>I229 del 
ytzB Unknown 89/insT S31* 
yqhY Unknown 38/delA D13* 
JB126 
rrnG-23S rRNA T>C N/A 
yvrJ Unknown 452bp Loss of gene 
ytzB Unknown 89/insT S31* 
yqhY Unknown 38/delA D13* 
 Intergenic 176143 delT N/A 
 Intergenic 176185^6 insC N/A 
* denotes frame shift mutation 
Table 3.4. Strains isolated from the adaptation experiment and the mutations they 
carry. Table lists the unique SNPs and structural variations identified in each strain and 
the effect these have on the translated protein. Mutations found in the wild type strain 
(LR2) are not listed.  
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The sequencing revealed a series of common SNPs that are present in most of the 
osmomutants but are absent in the parent strain. As several of the strains isolated do 
not apparently carry unique mutations, it seems likely that the diverse phenotypes 
observed in these strains resulted from the mutations identified. Where these mutations 
arose is not clear.  
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Perhaps the most interesting mutation is that seen in the strains JB114 and JB115. Both 
of these strains carried an identical 60bp in-frame deletion in mreB. That they carried 
the same mutation is not wholly remarkable, being that they were both derived from 
the same starting culture in the adaptation experiment. What is surprising is the 
mutation itself. MreB has long been associated primarily with directing and coordinating 
the various components of the cellular machinery involved in peptidoglycan synthesis 
during cell elongation (Errington, 2015). Further, it is very curious that the two strains 
have such differing phenotypes, despite the identical mutation in mreB. It is therefore 
likely that one or all of the mutations presumed to be ‘secondary’ have an effect on the 
health of the strain(s) and perhaps a role in the ability to grow in low osmotic conditions. 
JB114 and JB115 and the mutations they carry will be explored in greater detail in the 
next chapter. 
Several of the genes identified in the sequencing, such as gbsB have a known role in 
osmoprotection (Boch et al., 1996), or like acdA and blt, affect membrane fluidity (Fujita 
et al., 2007, Woolridge et al., 1997), a property that has been associated with L-form 
growth in hypotonic conditions previously (Harold, 1964). Several of these mutations 
were recreated in the wild type background (LR2). However, preliminary testing did not 
indicate a clear osmoprotective role for these mutants and were therefore not pursued 
further (data not shown).  
Many of the additional mutations such as the complete loss of the prophage SPβ from 
the genome have no clear involvement in the regulation of osmosis, and a further 
number of mutations are in genes of unknown function. These mutations have not been 
investigated further in this work. 
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3.2.13 Deletion of scoC enables growth in low sucrose environments 
As befits the first mutant to be isolated, M1 was also the first to be sequenced. As 
shown in table 3.4 this strain lost a 3.8kb region resulting in the complete loss of five 
genes (scoC, yhaG, yhaH, yhaJ and yhaI). Amongst these genes was scoC (also referred to 
as hpr or catA in the literature), a transcriptional repressor of the App and Opp peptide 
transporters (though App exists as a pseudogene in the 168CA background) (Koide et al., 
1999). It had been shown that these transporters are involved in the uptake of proline 
rich peptides, with the subsequent degradation resulting in an increase in the 
compatible solutes within the cell (Zaprasis et al., 2013).  Therefore out of the five genes 
deleted, it seemed likely that scoC was the most important, though the other genes 
were later deleted. A scoC deletion strain was therefore constructed and the L-forms 
derived from this strain were able to survive and grow in 0.1 M MSM/NB. The other 
mutations (yhaG, yhaH, yhaJ and yhaI) had no effect on the ability of LR2 L-forms to 
grow in low sucrose conditions. Oddly, complementation of scoC in the M1 with scoC 
expressed under its native promoter at the amyE locus did not abolish the ability to 
grow in 0.1 M MSM/NB, though L-form viability in these conditions was reduced (figure 
3.17). 
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Figure 3.17. The effect of ΔscoC on L-form growth in low osmotic media. A. Schematic diagram 
of the 3.8kb deletion in M1. Vertical bars represent the limits of the deletion. Confluent arrows 
between yhaI and scoC indicate overlapping exons. B. Growth of the wild type (LR2), M1, ΔscoC 
(JB132) and LR2 aprE::scoC (JB156) in 0.1 M MSM/NB after 9 days at 30°C. 
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3.3 Discussion 
In the past L-forms have been demonstrated to be able to grow in media with minimal 
levels of osmoprotection. However, as explained in the introduction, these studies were 
carried out in an age when L-form biology was poorly characterised, with low levels of 
reproducibility and challenges in ensuring ‘true’ L-forms were being used. Therefore it 
can be considered that this work provides the first evidence in a reproducible, well 
defined system that L-forms can indeed survive and grow in low osmolarities. The 
presence of a broad range of phenotypes suggests that the method allows for the 
acquisition of multiple different mutations. That many of these mutations appear to 
affect the cell envelope is of some interest. It is possible that the techniques utilised in 
this work allowed for the accumulation of mutations that might not otherwise have 
arisen in the conventional walled state, as it allowed for the development of mutants 
that were involved in stress responses, but were otherwise selected against in the 
walled state due to fitness costs. It is possible that the requirement for growth in the 
walled state by the adapted L-forms selected against strains that had developed 
mutations that allowed them to grow in low osmolarities, but not in the walled state. It 
may be of interest to repeat the established adaptation experiment in the future, but to 
sequence the genomes of the L-forms immediately after growth in low sucrose or salt 
environments. It is possible that such a protocol would enable a greater number of 
interesting mutations to be found.  
By far the most significant mutation is the 60bp in-frame deletion observed in the strains 
JB114 and JB115. This was surprising as MreB is primarily involved in peptidoglycan 
synthesis along the lateral cell wall, by directing and coordinating the elongation 
machinery (Errington, 2015). Further, it has been shown that MreB filaments dissociate 
from the cell membrane in the absence of cellular lipid II (Schirner et al., 2015), a 
molecule that is not present in L-forms derived from LR2. Alongside this work, it had 
previously been shown that mreB is redundant when cells are in the L-form state 
(Mercier et al., 2012). It therefore seemed likely that mreB would have no role in the cell 
wall-less L-forms. This no longer appears to be the case. As this is such an important and 
fascinating mutation and so will be focussed on for the remainder of the investigations 
into L-form growth in low osmotic conditions.  
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Whilst such mutations as the one seen in mreB is exciting, it is reassuring that the 
adaptation of L-forms to low osmolarities also identified several genes which have a 
known role in response of walled B. subtilis to changes in its osmotic environment. 
These genes, such as gbsB and scoC, act by mediating the levels of compatible solutes 
within the cell. Disruption of these genes would be expected to affect the ability of the 
bacterium to maintain the pools of compatible solutes. In the case of scoC, it would be 
expected that the loss of this gene would result in an increase in the level of proline 
within the cell as a result of the de-repression of the Opp transporter. How an increase 
in the levels of compatible solutes would protect the L-forms from low osmolarities is 
unclear, as generally it would be imagined that this would increase the osmotic gradient 
across the membrane. As this is mostly speculation, further investigation would require 
examining the role of the Opp system – for example, to see whether disruption or 
overexpression would result in increased or decreased resistance to low osmotic 
environments. Assuming that proline import allows for L-form to survive and grow in 
low osmotic conditions, use of radioactive proline may be helpful in following what is 
going on inside the cell.  
Due to time constraints many of the mutations identified in this work were not pursued 
further. It would be an interesting avenue of future research to explore these mutations 
in greater depth. Not only do many of the genes affected not have a clear role in 
response to osmotic response, their role in the generation of the broad range of 
morphologies is also unclear. Further research into these genes and their mutations may 
prove useful in uncovering the response of L-forms to low osmolarities, but also in 
understanding the control of cell morphogenesis in the normal walled state.  
This work had established reproducible methods that allow for the adaptation of 
L-forms to low osmolarities. Whilst this work only utilised L-forms derived from the 
Gram-positive model organism Bacillus subtilis there is no theoretical reason why the 
methods generated could not be extended to L-forms derived from other bacterial 
species. This includes pathogenic bacteria that have been implicated in L-form mediated 
chronic or recurrent bacterial infections. Current work on this issue is limited by the 
difficulty and complexity of establishing L-forms in relevant disease models. 
Development of osmotically stable versions of these strains may allow for greater ease 
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at investigation of possible roles L-forms may play in disease. It would be interesting to 
examine what mutations enable different species to grow in low osmolarities and 
whether the mutations generated would reflect the physiology of the host species. 
Similarly, such an approach may allow for fresh investigations into the relationship that 
B. subtilis plays with plants. Unlike their association with mammalian tissues, the 
relationship between L-forms and plants is thought to be symbiotic (Walker et al., 2002, 
Ferguson et al., 2000). As with the infection models, robust investigation into this 
subject has been limited, partly due to the difficulty in establishing L-form growth in 
these systems. 
As such this work provides some support towards somewhat controversial theories that 
consider L-forms an aetiological agent for a number of chronic or recurrent bacterial 
infections (Leon and Panos, 1976). One of the major criticisms of this hypothesis regards 
the fragility of the L-form cells; the results of this work would disagree with such a 
statement.  
Finally, the simple fact that wall-less cells could propagate in low osmo-protectant 
environments is somewhat surprising. The prevailing wisdom is that under normal 
conditions the peptidoglycan cell wall is essential; it is necessary to resist the effects of 
turgor pressure acting against the cell. As such, this work validates the older work 
demonstrating that L-forms could survive in low osmolarities. In addition, it suggests 
that regulation of the membrane and the internal composition of the bacterial cell may 
be far more important in relation to the cell wall in resisting the effects of turgor. 
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4. The role of MreB in osmoresistance in L-forms 
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4.1 Introduction 
4.1.1 MreB and the bacterial cytoskeleton 
The MreB proteins are homologues of the eukaryotic actin and are highly conserved and 
widespread amongst both Gram-positive and Gram-negative bacteria that have adopted 
a complex, non-spherical cell shape (Errington, 2015).  Unlike Gram-negative organisms 
that often only encode a single MreB homologue, Gram-positive organisms tend to carry 
two or three homologues. The Gram-positive model organism, Bacillus subtilis is no 
exception, carrying three paralogues of MreB – Mbl (MreB-like) and MreBH 
(MreB homologue) in addition to MreB. 
Traditionally, these proteins have been proposed to be involved in the positioning and 
regulation of the cell division machinery, thereby controlling cell shape (Daniel and 
Errington, 2003, Challis, 2014). More recently, it has been shown that MreB in B. subtilis 
is involved in the organisation of the cell membrane (Strahl et al., 2014), though it has 
been proposed that this organisation of the membrane is to facilitate colocalisation 
between MreB and the peptidoglycan precursor molecule lipid II (Schirner et al., 2015). 
The same work shows that this colocalisation is important, as lipid II stimulates the 
polymerisation of MreB into filaments. The nature of these filaments has proved to be 
somewhat controversial, with a conflict between the theory that MreB forms filaments 
along the longitudinal axis of the cell (Jones et al., 2001) and the alternative view that 
MreB instead forms discrete, dynamic processive patches that traverse the cell 
(Dominguez-Escobar et al., 2011, Garner et al., 2011). As stated earlier, B. subtilis 
possesses three MreB homologues. It has been demonstrated that all three colocalise 
and interact with each other and with other interaction partners. The three homologues 
have differentiated, but overlapping functions (Defeu Soufo and Graumann, 2004, Kawai 
et al., 2009).   
All the functions that have been ascribed to MreB are in relation to the maintenance and 
regulation of the peptidoglycan cell wall – a structure that is absent in L-form bacteria. 
Despite this, a mutation in mreB was identified in the genome of two related strains that 
possessed the ability to grow in low osmolarities as L-forms. Here I show in vitro and 
in vivo that the small deletion in mreB present in the osmo-resistant strains JB114 and 
JB115 has the same phenotypic effect as a null mutation. I show that this loss of function 
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is sufficient to enable L-forms to grow in osmolarities, including conditions in which 
supplemented osmoprotection is entirely lacking. The ability to grow under these 
conditions is unusual, as the peptidoglycan is normally essential in resisting the turgor 
pressure resulting from osmotic downshock. As discussed in the previous chapter, 
L-forms have been adapted to low osmolarities in the past. Unfortunately, due to the 
technical limitations of the time, these adaptations were not explored to the same 
depth that is possible in the current day.  
It has been shown that deletion of all three of the MreB homologues in B. subtilis 
(rendered viable by a ΔrsgI mutation) results in cells with increased membrane fluidity. 
In the historic L-form literature there have been accounts of L-forms from a variety of 
species adapted to low osmolarities (Harold, 1964, Montgomerie et al., 1973). Taken 
together, it suggested a possible membrane-associated role for MreB in permitting L-
forms to grow in low osmolarities.   
 In this work I demonstrate that membrane fluidity was unchanged between cells in the 
L-form state and the walled state. Further, I show that loss of a single copy of MreB did 
not affect the fluidity of B. subtilis cells. However, whilst membrane fluidity was not 
affected, L-forms of both the osmo-resistant mutant strain JB114 and the ΔmreB strain 
had an increase in the fatty acids of the membrane. A causal relationship between the 
thickness of the cytoplasmic membrane and the ability to survive in low osmolarities has 
not been previously established.  
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4.2 Results 
4.2.1 The 20 amino acid deletion does not appear to affect a known interaction 
site 
The structure of MreB was first resolved in 2001 (van den Ent et al., 2001). The 
knowledge of the structure has allowed for the identification of the membrane 
interacting domains and the nucleotide binding cleft, as well as the binding sites of some 
of its interaction partners and other MreB molecules (van den Ent et al., 2010, van den 
Ent et al., 2014).  
The structure was resolved from an MreB molecule belonging to the Gram positive 
organism Thermotoga maritima. Whilst there are differences, the sequence of B. subtilis 
MreB is similar enough to that of T. maritima that it is possible to map the sequence of 
MreBBS onto that of MreBTM. Using the structure of MreB it was possible to locate the 
deleted region found in the mutant strains JB114 and JB115. As can be seen in figure 4.1, 
the 20 amino acid deletion region is found in domain II of the protein and comprises part 
of two α-helices as well as the linker region connecting them. This domain is cytoplasmic 
facing, and has not been previously shown to be a binding or a polymerisation surface. 
This led us to hope that the mutant in the two strains could represent a loss or gain of 
function, possibly involved in the interaction with an unknown partner. Of course, with 
such a deletion it could not be discounted that the mutation may affect another part of 
the protein structure or could result in a non-functional protein. 
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Figure 4.1. A). The 60bp deletion at position 575 in mreB is flanked by two  direct 
repeats. The deletion is highlighted in red, whilst the direct repeats are in the two boxes. 
B). The 20 amino acid deletion is highlighted in red. The deletion is located in domain IIB. 
This region is cytoplasmic facing and has not been previously identified as an interaction 
surface. Model of B. subtilis MreB created by H. Strahl using Phyre service.  
A 
B 
164 
 
4.2.2 JB114 and JB115 can grow in both low sucrose and low salt and can even 
grow in the complete absence of osmoprotection 
To try to understand the mechanism(s) of osmoprotection/osmo-resistance, we wanted 
to see whether the two mutant L-form strains isolated from the low sucrose growth 
media were able to grow when the osmoprotectant was changed from sucrose. As 
expected, both strains grew at a rate similar to the wild type in concentrations of 0.5 M 
MNM/NB. When the concentration of NaCl in the MNM/NB was reduced to 0.05 M, 
L-forms of the JB114 and JB115 strains were still able to grow, whereas the parental 
strain, LR2 was not (figure 4.2). It therefore appears that the mutations present in these 
two strains are not specific for growth in sucrose.  
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Figure 4.2. A). Osmo-resistant L-forms originally adapted in low concentrations of 
sucrose can grow in low concentrations of salt. L-forms derived from the wild type (LR2) 
and the mutant strains JB114 and JB115 were grown until dense in 0.5 M MNM/NB. 
L-forms were diluted 10-3 in 0.05 M MNM/NB and incubated at 30°C for seven days. 
OD600 was measured on the seventh day. B). Presence of L-forms in the low salt medium 
was confirmed by light microscopy. Scale bar = 3μm 
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However, the growth rates of the two mutants in 0.05 M MSM/NB were considerably 
lower than when grown in 0.5 M MSM/NB. It was possible that the mutation in mreB 
was merely allowing the cells to survive the initial osmotic shock, and that the strains 
had picked up additional mutations enabling their growth. This seemed somewhat 
unlikely due to the fairly minimal number of mutations present in the original isolates. 
Nevertheless, we tested this possibility by sequencing the genomes of JB114 and JB115 
L-form cells grown in 0.05 M MSM/NB. Sequencing revealed a limited number of 
mutations in non-coding regions in the genomes of these cells. It can therefore be 
concluded that the mutations already present in the JB114 and JB115 strains are 
sufficient for growth in the challenging conditions. 
JB114 and JB115 had been isolated from cultures containing the sucrose concentrations 
of 0.075 M and 0.05 M, respectively. However, much of the osmo-resistance testing of 
the two mutant strains was carried out at 0.05 M, indicating that the mutations may 
allow for the strains to grow in lower concentrations than originally adapted to. To see 
whether the mutants could grow at even lower concentrations of sucrose, the strains 
JB114 and JB115 were diluted from a 0.5 M MSM/NB culture by 10-4 into media with a 
range of different osmolarities. Remarkably, both strains could grow in sucrose 
concentrations as low as 0.01 M (unsurprisingly, the wild type strain (LR2) could not 
grow in any of the concentrations tested) (figure 4.3), though the ability to grow 
appeared to diminish as the concentrations decreased. Following a 10-4 dilution from 
0.5 M MSM/NB, L-forms of both osmo-resistant strains were unable to grow in the 
medium without sucrose. As the strains were able to grow in very low sucrose 
concentrations, it was considered whether it was the initial osmotic down-shock that 
was preventing the L-forms to grow, probably causing majority of the cells to lyse. 
Therefore, instead of inoculating the sucrose-free medium with L-forms from the high 
sucrose culture, L-forms grown in 0.05 M MSM/NB was used instead. A second benefit is 
that this route removes much of the sucrose carried over from the original culture that 
would be introduced from the inoculation from 0.5 M MSM/NB. Amazingly, the L-forms 
derived from the two adapted strains were able to grow in the near complete absence 
of supplemented osmoprotectant (roughly 0.05 mM is present), though the growth was 
slow and the final optical density was low (figure 4.3).  
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Figure 4.3. The mutant strains, JB114 and JB115, are able to grow as L-forms in sucrose 
concentrations as low as 0.01 M. L-forms derived from JB114 and JB115 are able to grow 
in the complete absence of osmoprotection following a 2x10-3 dilution from L-forms 
grown in 0.05 M MSM/NB. L-forms derived from the wild type (LR2), JB114 and JB115 
were grown in 0.5 M MSM/NB until dense. The cells were diluted 10-3 into MSM/NB with 
a range of sucrose concentrations, including the complete absence of sucrose. L-forms 
were grown at 30°C for up to 24 days. OD600 was measured in the flasks with growth 
after 15 days. The wild type strain was unable to grow in any of the conditions tested, 
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the two mutant strains were unable to grow in the complete absence of sucrose. 
L-forms from the 0.05 M MSM/NB cultures were used to inoculate NB with no sucrose. 
These cultures were grown at 30°C, with the OD600 measured after 24 days growth. 
B).The presence of L-forms was verified using light microscopy in the NB containing no 
osmoprotectant. Scale bar = 3μm. 
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4.2.3 The L-forms can still grow in low osmolarities even with a murC deletion 
Most of the L-forms used in this research were generated by depleting MurE from strain 
LR2, in which murE was under the control of a xylose-inducible Pxyl promoter. However, 
it has been shown previously that these cells still contain low levels of peptidoglycan due 
to the leaky nature of the Pxyl promoter (Gartner et al., 1988). Whilst unlikely, it was a 
concern that the L-forms were able to grow in the adverse conditions as a result of 
residual amounts of peptidoglycan. To ensure this was not the case, a second gene in 
the lipid II pathway, murC, was deleted. To allow for this deletion, an additional copy of 
murC, carried on a pLOSS plasmid and under the control of a Pspac promoter was 
introduced into the LR2 background, before the native copy of murC was deleted  
(JB180). To maintain the plasmid when the cells were in the walled state, cells were 
grown with the appropriate concentrations of IPTG and the antibiotic, in this case, 
erythromycin. Removal of the IPTG and the antibiotic results in the loss of the plasmid 
and renders the walled cells carrying the ΔmurC mutation non-viable. However, in the 
L-form state where the lipid II pathway is dispensable deletion of murC should be viable. 
As expected, in the L-form state there is no discernible difference between the WT and 
the ΔmurC strains. Loss of the plasmid was verified using PCR. ΔmurC L-form strains 
were generated from strains JB189 and JB182, the ∆murC derivative of JB114 and JB115, 
respectively, and an mreB-null strain (JB181) were able to grow in 0.05 M MSM/NB, 
whereas the ΔmurC LR2 strain was unable to grow in these conditions (figure 4.4).  
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Figure 4.4. L-forms can still grow with minimal osmoprotection when the lipid II 
synthesis pathway is completely disrupted. L-forms derived from a LR2 strain carrying a 
ΔmurC and a functional copy on a pLOSS plasmid were grown in 0.5 M MSM/NB until 
dense. Loss of the pLOSS plasmid was verified by PCR. L-forms were diluted 10-3 into 
0.05 M MSM/NB and grown for 14 days at 30°C. No significant difference was observed 
between the original mutant strains and the strains in which murC is deleted.   
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4.2.4 Deletion of mreB has some effect on the growth and cell morphology of 
JB114 and JB115 
The nature of the mreB deletion present in JB114 and JB115 – a 60bp in-frame deletion 
– suggested a possible loss or gain of function as opposed to a null mutant. To examine 
this possibility, mreB was deleted from the two mutant strains, as well as the LR2 parent. 
Deletion of mreB was achieved using the established construct of Formstone and 
Errington, 2005 in which the expression of the downstream mreC and mreD genes is 
preserved (Formstone and Errington, 2005). In the walled state the JB133 mutant 
carrying the mreB deletion was largely similar to the growth rate and morphology of the 
JB115 mutant strain (figure 4.5). Whilst the growth of JB114 cells was sicker than that of 
ΔmreB in the LR2 background (JB133), deletion of mreB in the JB114 background did not 
significantly affect the growth and morphology of the strain. Taken together, this 
strongly suggested that the 60bp deletion was resulting in a non-functional protein. 
Interestingly, whilst the growth rate of JB114 did not change significantly with complete 
deletion of mreB, the mreB deletion in the JB115 background had significantly perturbed 
growth rates (figure 4.6). This observation instead suggested that the mutant copy of 
mreB may retain some functionality.  
Complete deletion of mreB had no effect on the growth of the strains as L-forms in 
MSM/NB as was expected (data not shown).  
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Figure 4.5.A. Cell morphology of the wild type (LR2; A), ΔmreB (JB133; [B]), JB114 (C), 
JB114 ΔmreB (JB134; [D]), JB115 (E) and JB115 ΔmreB (JB135; [F]) during early 
exponential phase (OD600=0.3). Cells were grown at 37°C in PAB supplemented with 
0.5% xylose and +/- 20mM MgCl2. Membranes were visualised with FM5-95 dye. Scale 
bar=3μm 
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Figure 4.5.B. Cell morphology of the wild type (LR2; [A]), ΔmreB (JB133; [B]), JB114 (C), 
JB114 ΔmreB (JB134; [D]), JB115 (E) and JB115 ΔmreB (JB135; [F]) during mid-
exponential phase (OD600=1.0). Cells were grown at 37°C in PAB supplemented with 
0.5% xylose and +/- 20mM MgCl2. Membranes were visualised with FM5-95 dye. Scale 
bar=3μm 
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Figure 4.5.C. Cell morphology of the wild type (LR2; [A]), ΔmreB (JB133; [B]), JB114 (C), 
JB114 ΔmreB (JB134; [D]), JB115 (E) and JB115 ΔmreB (JB135; [F]) during stationary 
phase. Cells were grown at 37°C in PAB supplemented with 0.5% xylose and +/- 20mM 
MgCl2. Membranes were visualised with FM5-95 dye. Scale bar=3μm 
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Figure 4.6. Growth rate of the mreB-null strains in PAB supplemented with 0.5% xylose 
and 20mM Mg2+.  
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4.2.5 The 60bp deletion can be reconstructed in the LR2 strain 
To further examine the effect of the mutation on B. subtilis, the 60bp deletion was 
recreated in a clean LR2 background. The strain was created via a three-piece ligation 
method as reported in Formstone and Errington, 2005, using an upstream insertion of 
the neo cassette to provide transcription for the essential downstream genes (figure 
4.7). As expected from the previous results in 4.2.4 there was no difference in the 
growth rate or cell morphology between the mreBΔ20 strain and the ΔmreB strain, 
providing further evidence that the in-frame deletion was effectively a null mutation.  
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Figure 4.7. Reconstruction of the 60bp inframe deletion present in JB114 and JB115. 
A). Schematic cartoon of the 60bp deletion in the LR2 background. The neo cassette was 
positioned after the terminator of radC and before the promoter region of the mreBCD 
operon. The 60bp deletion is indicated by the red vertical bar. B).The growth of the 
reconstructed mutant was lower than the wild type (LR2), and identical to the null 
mutant (JB133) when grown at 37°C in PAB.   
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4.2.6 Complementation of JB114, JB115 and mreBΔ20 with gfp-mreB restores the 
growth of the strains 
To examine whether the mreBΔ20 mutation carried by JB114 and JB115 was in any way 
dominant in the walled state, a functional copy of MreB tagged with GFP was introduced 
into the strains. The GFP-MreB construct was under a xylose inducible Pxyl promoter, 
though as a result of the requirement for xylose by the LR2 strain to grow in walled 
state, the construct was always expressed. An alternative IPTG-inducible strain was 
trialled, but expression of the construct was minimal. Expression of the GFP-MreB 
construct was sufficient to fully restore the phenotype of the two mutant strains to that 
of the wild type (figure 4.8). The discrepancy between the growth reported in figure 4.6 
is likely to have occurred as a result of the development of suppressor mutations. 
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Figure 4.8. Morphology (A) and growth rate (B) of JB114 and JB115 can be restored by 
complementation with a functional GFP-MreB construct. A). Morphology of cells JB114 
(JB137; [B]) and JB115 (JB138; [C]) is restored to that of the wild type (LR2; JB136; [A]) by 
expression of gfp-mreB. Cells were grown in PAB supplemented with 0.5% xylose at 
30°C. Scale bar=3μm B). Growth rate of JB114 and JB115 is restored to that of the wild 
type (LR2) when complemented with a functional copy of gfp-mreB (JB137 and JB138 
respectively). Cells were grown at 37°C in PAB supplemented with 20mM MgCl2 and 
0.5% xylose.   
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4.2.7 MreB cannot be detected by Western blotting in JB114, JB115 and 
mreBΔ20, though can be detected at low levels in an overexpression strain 
Immunoblot analysis of MreB expression in JB114 and JB115 revealed that the mutated 
copy of mreB was either not being expressed or was unstable as MreB could not be 
detected in the cell lysates of these two strains, nor in the lysate of an mreBΔ20 strain in 
the 168CA background. As an alternative method to detect the MreBΔ20 protein, a 
Pxyl-gfp-mreBΔ20 was constructed to overexpress the GFP-linker mutant copy of MreB in 
a 168CA wild type background. Upon expression a low level of GFP-MreB with the partial 
deletion could be observed in the relevant strains (figure 4.9). This indicates that the 
partial deletion maybe resulting in an unstable protein that is prone to degradation.  
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Figure 4.9.  Western blotting against MreB in the mutant strains (A) and the 
overexpression strains (B). Arrows indicate the expected position of MreB and GFP-MreB 
where appropriate. A). MreB could only be detected in the wild type strain (LR2) and not 
in JB114, JB115 or an MreB-null strain (JB133). Cell lysate prepared from cells grown in 
PAB supplemented with 20mM MgCl2 and 0.5% xylose reached an OD600=0.3 B). Western 
blot against GFP-MreB held under an inducible Pxyl promoter. Strains JB185 (168CA 
gfp-mreB), JB186 (168CA gfp-mreBΔ20), JB187 (ΔmreB gfp-mreB) and JB188 (ΔmreB 
gfp-mreBΔ20) were grown in LB +/- 0.5% xylose.  
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4.2.8 Localisation of MreBΔ20 in walled cells and in L-forms 
To further investigate any potential role MreBΔ20 may be playing the localisation of the 
protein was examined in vitro. In both a 168CA wild type background and in an mreB-
null background, the MreBΔ20 construct did not form filaments, but instead remained 
diffuse in the cytoplasm during exponential growth. As the cells progress into late 
exponential/stationary phase the protein began to aggregate to form foci throughout 
the cell (figure 4.10). These foci appear to be distributed randomly, and do not localise 
to important landmarks such as the cell poles, division septa and so on. Taken with the 
earlier work, it can be concluded that the 60bp deletion in mreB is resulting in a non-
functional protein that is effectively equivalent to a complete knock out of the protein.  
As these results were performed in the walled state, it is a reasonable assumption that 
the null-phenotype observed for MreBΔ20 would carry over to the L-form state. 
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Figure 4.10. Localisation of GFP-MreB and GFP-MreBΔ20 in a wild type (168CA [A]) and 
mreB-null background (B). The wild type copy of GFP-MreB forms the characteristic 
helical filaments in both the wild type (JB185) and mreB-null (JB187) strains when 
expression is induced with 0.5% xylose. The GFP-MreBΔ20 copy remains cytoplasmic with 
a tendency to aggregate into foci in both the wild type (JB186) and mreB-null (JB188) 
strains when expression is induced with 0.5% xylose. Scale bar=3μm  
+0.5% xylose +0.5% xylose 
P
xyl 
gfp-mreB P
xyl 
gfp-mreB
Δ20
 
B 
189 
 
4.2.9 Both mreBΔ20 and ΔmreB can grow in low sucrose environments, though at 
a lower efficiency than the original mutant strains 
The effect of ΔmreB on the ability of L-forms to grow with minimal osmoprotection was 
carried out early on in the investigation when the mreBΔ20 mutation was first identified 
in JB114 and JB115. However, L-forms of the ΔmreB derivative of LR2 (JB133) was not 
able to grow in 0.05 M MSM/NB. It was therefore suspected that the partial deletion 
possessed either a gain or loss of function that enabled it to grow under these 
conditions. However, upon reconstruction and testing of the mreBΔ20 mutation it was 
realised that both the ΔmreB and mreBΔ20 constructs were able to grow in low sucrose, 
but far less reliably than either JB114 or JB115 (figure 4.11). Both JB114 and JB115 could 
grow in 0.05 M MSM/NB in roughly 95% of inoculations, whereas the ΔmreB and 
mreBΔ20 derivatives could only grow following about 50% of inoculations. This suggested 
a possible role for the secondary mutations that JB114 and JB115 carried. This possibility 
was confirmed by the observation that the null mutant in the JB114 and JB115 
background was able to grow in 0.05 M MSM/NB in a similar manner to the original 
mutant strains (figure 4.12). It was considered that L-forms of the ΔmreB (JB133) strain 
might be able to grow in the presence of low sucrose only when they had acquired the 
necessary mutations. To examine this possibility, the L-forms of JB133 generated from 
these experiments were sequenced to identify any secondary mutations. Thus far, no 
mutations of interest have been discovered, indicating that the secondary mutations 
may facilitate, but are not essential for growth with minimal osmoprotection.  
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Figure 4.11. L-forms derived from an mreB-null strain (JB133) and a mreBΔ10 strain 
(JB150) are able to grow to a similar OD600 as L-forms derived from the osmomutant 
strains JB114 and JB115 in 0.05 M MSM/NB. L-forms were diluted 10-3 into 0.05 M 
MSM/NB from cultures grown in 0.5 M MSM/NB. Cultures were incubated at 30°C and 
the OD600 measured after 10 days. 
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Figure 4.12. The osmomutant strains JB114 and JB115 can still grow in 0.05 M MSM/NB 
when mreB is completely deleted (JB134 and JB135 respectively). L-forms were grown 
until dense in 0.5 M MSM/NB and then diluted 10-3 into 0.05 M MSM/NB. Cultures were 
incubated at 30°C for 10 days at which point the OD600 was measured.  
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4.2.10 L-forms of the ΔmreB mutants can grow in the complete absence of 
osmoprotection 
As discussed earlier, L-forms of both JB114 and JB115 can grow in the complete absence 
of supplemented osmoprotection (MgCl2, maleic acid and the osmolytes in NB 
notwithstanding) following an intermediate step of growth in 0.05 M MSM/NB. The 
ability of JB133 (ΔmreB in the LR2 background) to grow at the intermediate step 
remained as reliable as reported in the previous section. Furthermore, once grown in 
0.05 M the null mutant, JB133, was able to achieve a low level of growth (figure 4.13), in 
a similar fashion to the two original mutant strains (figure 4.3). This provided further 
evidence that ΔmreB was sufficient for growth in these conditions.  
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Figure 4.13. mreB-null L-forms can grow in the complete absence of osmoprotection in a 
similar fashion to the original mutant strains JB114 and JB115. A). L-forms were diluted 
2x10-3 from a culture grown in 0.05M MSM/NB and incubated at 30°C. OD600 was 
measured after 15 days. B).The presence of L-forms in the ΔmreB culture was verified 
using light microscopy. Scale bar=3μm. 
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4.2.11 Deletion of ftsE does not improve the efficiency of the low osmotic growth 
of ΔmreB 
The matter of the secondary mutations and the ease by which JB114 and JB115 grew in 
0.05M MSM/NB in comparison to the ΔmreB strain was of some interest. Among the 
secondary mutations present was a mutation in ftsE. FtsE is an important protein; it is an 
ABC transporter that is involved in the autolysin activity, regulation of cell wall turnover 
and has been associated with the actin cytoskeleton (Dominguez-Cuevas et al., 2013). 
Any potential role in L-forms was therefore of some curiosity. After the strain carrying an 
ftsE deletion was constructed in a ΔmreB background (JB184) its ability to grow as an 
L-form in low sucrose concentrations was tested. Whilst able to grow in these 
conditions, its ability to grow was much like the ΔmreB single mutant. Testing of the 
ΔftsE single mutant (JB183) revealed it was unable to grow at low osmolarities, thus 
supporting the idea that MreB (or its absence) was the main driving force of the 
phenotype (figure 4.14).  
When the ΔftsE ΔmreB double mutant was examined in its walled state, it was clear that 
the mutant did not possess the same growth inhibition that separated the JB114 strain 
from JB115 and ΔmreB (figure 4.15.B). Further, microscopy revealed a disturbed cell 
morphology, but a cell morphology that was identical to that of ΔmreB as opposed to 
JB114 (figure 4.15.A). From this work it was concluded that FtsE did not play any role in 
the observed phenotypes of JB114 either in the walled form or in the L-form. 
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Figure 4.14. L-forms derived from ΔftsE single mutants (JB83) are unable to grow in 
0.05M MSM/NB. L-forms derived from the LR2 ΔmreB ΔftsE double mutants (JB184) are 
able to grow in low sucrose in a manner identical to ΔmreB single mutants (JB133).   
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Figure 4.15. Effect of the deletion of ΔftsE on the morphology (A) and growth rate (B). 
A). Cell morphology of the wild type (LR2; [i]), JB114 (ii), ΔmreB (JB133; [iii]), ΔftsE 
(JB183; [iv]) and ΔftsE ΔmreB (JB184; [v]) during early exponential and mid-exponential 
phases. Cells were grown at 37°C in PAB supplemented with 0.5% xylose and 20mM 
MgCl2. Membranes were visualised with FM5-95 dye. Scale bar=3μm. B). Growth rate of 
the wild type (LR2), ΔftsE (JB183), ΔmreB (JB133) and ΔftsE ΔmreB (JB184) at 37°C in PAB 
supplemented with 0.5% xylose and 20mM MgCl2.  
  
198 
 
4.2.12 Absence of MreB changes membrane properties 
It has previously been demonstrated that MreB creates islands with increased fluidity 
and that a triple deletion of all the three MreB homologues significantly elevates the 
overall membrane fluidity (Strahl et al., 2014). Taken alongside the historic L-form 
literature in which changes to the membrane were observed (Montgomerie et al., 1973), 
and the recent discovery that L-form proliferation requires increased membrane fluidity 
(Mercier et al., 2012), the hypothesis was that loss of mreB results in a change in 
membrane fluidity that enable the L-forms to grow with minimal osmoprotection.  
When overall membrane fluidity was measured using Laurdan generalised polarisation 
(GP), it turned out that none of the osmo-resistant mutant strains tested either in the 
walled-form or L-form exhibited any significant change in membrane fluidity in 
comparison to the wild type (LR2) (figure 4.16). The Laurdan GP experiments showed 
that there was no overall change in the membrane fluidity. However, it was possible that 
loss of MreB influenced the membrane composition. To investigate this, the fatty acid 
compositions of the strains in the L-form state were analysed using gas chromatography 
(table 4.1). Surprisingly, JB114, ΔmreB and mreBΔ20 all showed increased fatty acid 
length (more C17 species and fewer C15 species) relative to the parent strain, a result that 
would typically lower the membrane fluidity (figure 4.17.B). Intriguingly, JB115 has a 
similar fatty acid composition to the parent strain. However, the theoretical decrease in 
membrane fluidity in the three strains is offset by an increase in the percentage of 
anteiso fatty acids as compared to iso fatty acids (figure 4.17.A). The anteiso species 
carry a methyl group on their third-to-last carbon molecule, compared to the iso species 
in which the methyl group is carried on the penultimate carbon molecule. Placement of 
the carbon on the third to last position results in a significantly more fluid molecule than 
that of the iso species. Again, this change in the fatty acid composition is not seen in the 
JB115 strain. Taken together, it appears that loss of mreB does affect the membrane 
composition, with the deletion resulting in an increase in the fatty acid chain length. It is 
not obvious whether this phenotype allows L-forms to grow with minimal 
osmoprotection or whether it is a side effect of the loss of an important membrane 
protein. That JB115 possesses a membrane that is almost identical to the parental strain 
suggests that the latter guess is probably correct. 
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Figure 4.16. Overall membrane fluidity as measured by Laurdan GP of the wild type 
(LR2), JB114, JB115, mreBΔ20 (JB150), ΔmreB (JB133), ΔftsE (JB183) and ΔftsE ΔmreB 
(JB184) when grown as rods (A) and as L-forms (B). Decrease in the Laurdan GP value 
represents an increase in membrane fluidity. Treatment with membrane fluidiser 
(30 mM benzyl alcohol) was used as a positive control for increased membrane fluidity. 
The graphs depict the average values and standard deviations from three independent 
measurements. 
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Fatty Acid Wild type JB114 JB115 ΔmreB mreB
Δ20
 
C
14:0 
iso 3.2±0.13 1.08±0.02 4.61±0.12 1.48±0.20 1.28±0.18 
C
15:0 
iso 15.2±0.26 11.3±0.65 15.0±0.71 10.0±1.20 10.0±1.50 
C
15:0 
anteiso 35.0±1.80 35.8±0.52 36.0±0.49 37.7±1.00 37.6±0.46 
C
16:0
 4.9±0.50 5.4±0.12 6.2±0.48 3.3±0.45 4.0±0.98 
C
16:0 
iso 9.5±0.14 5.2±0.03 12.3±0.03 7.53±0.96 6.36±0.79 
C
17:0 
iso 12.7±0.22 13.7±0.14 11.1±0.07 12.9±0.72 13.2±0.82 
C
17:0 
anteiso 13.0±0.08 20.1±0.86 11.3±0.70 21.7±2.15 23.0±2.205 
C
18:0 
iso 1±0.11 <1 <1 <1 <1 
C
18:0
 1.91±0.105 2.84±0.12 1.98±0.35 1.49±0.13 2.44±0.57 
>C
18
 <1 1.98±0.57 <1 1.34±0.33 1.69±1.19 
sum 96.4% 97.5% 98.4% 98.5% 100% 
  
C17/C15 0.51±0.02 0.72±0.02 0.44±0.02 0.73±0.03 0.76±0.05 
<16/≥16 1.26±0.08 0.98±0.01 1.30±0.01 1.00±0.01 0.95±0.05 
iso/anteiso 0.86±0.04 0.55±0.03 0.91±0.04 0.55±0.08 0.52±0.07 
  
Laurdan GP 0.66±0.00 0.66±0.01 0.67±0.02 0.67±0.01 0.69±0.01 
Table 4.1. The fraction of fatty acids which contribute to more than 1% of the overall 
fatty acid content are presented as mean and standard deviation of duplicate 
measurements. The corresponding in vivo Laurdan GP values are presented as mean and 
standard deviation of three independent measurements. Strains used: Bacillus subtilis 
LR2 (L-form wildtype), JB114 (osmomutant), JB115 (osmomutant), JB133 (ΔmreB) and 
JB150 (mreBΔ20). 
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Figure 4.17. Graphical representation of data of the presented in table 4.1. A). the ratios 
between the iso and anteiso forms of the fatty acids of the different strains and 
B). the ratios between the chain lengths of the fatty acids as presented in the table. High 
iso/anteiso or high long chain/short chain ratios indicate reduced fluidity.   
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4.3 Discussion 
In many regards, the work into the role that MreB plays on cells that lack a cell wall and 
how its absence enables L-forms to grow in the complete absence of osmoprotection 
has raised as many questions as it has answered. Upon identification of the in-frame 
deletion of MreB in the mutant strains it was hoped that this mutation might represent 
either a specific gain or loss of function. It now appears that the mutation is functionally 
identical to a null-mutation, with the in-frame deletion preventing disruption of the 
essential downstream genes; mreC and mreD. Despite this conclusion, this work has 
demonstrated that deletion of mreB is sufficient for L-forms to grow in low osmolarities; 
conditions that include the complete absence of osmoprotection. Such results fly in the 
face of what we should expect for L-forms, as it would be expected that turgor would 
result in cell death. To render this even more exciting, it suggests a novel role for MreB 
that is independent of the cell wall synthesis it has traditionally been involved in.  
Recent work by (Schirner et al., 2015) has shown that lipid II is required for the 
formation of the MreB filaments on the cell membrane. The strain used in this work, 
LR2, grows as an L-form as a result of a depletion of MurE. As described earlier, MurE is 
involved in Lipid II synthesis. Therefore, depletion of MurE should be resulting in the 
disassociation of the MreB filaments. Dissociated from the filaments, MreB is no longer 
localising and positioning the biosynthetic complexes it interacts with. It is therefore not 
a stretch to presume that outside its normal filaments in the wall-less L-forms, MreB is 
inactive. However, by demonstrating that deletion of MreB plays a role in cells lacking a 
peptidoglycan cell wall it implies an additional role for MreB that is independent of the 
cell wall. What this precise role is remains unclear, but recent discoveries, as well as 
work presented here suggest a role in the regulation of the cell membrane. 
It has recently been shown that MreB, along with its homologues help to organise the 
cell membrane (Strahl et al., 2014, Strahl and Hamoen, 2010). When MreB assembles 
into filaments it results in the formation of regions of increased fluidity, whilst loss of all 
the MreB homologues results in an overall increase in membrane fluidity. How MreB 
affects the cell membrane is unclear. Peripheral proteins have been shown to possess 
the ability to induce lipid domains (Garcia-Saez et al., 2007, Cornell and Taneva, 2006), 
though this requires binding of the lipid bilayer by intercalating amphipathic helices. 
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Such features are absent in the MreB homologues present in Gram-positive organisms 
(Salje et al., 2011). Despite this, it’s within reason that one of the many interacting 
partners of MreB could be responsible. Alternatively, it’s possible that MreB helps to 
organise the membrane by directly interacting with the lipid head groups and disrupting 
the electrostatic interactions between the different lipid head groups (Mbamala et al., 
2005). Changes in the makeup of the membrane naturally affect its properties. For 
instance, increased viscosity will limit protein diffusion (Lee, 2004). 
At this point in time it was not possible to establish whether the increase in fatty acid 
length as well as the change in the branching of the fatty acids were allowing the 
L-forms to grow in the low osmolarities or were merely the result of the loss of an 
important membrane-associated protein. Further, with the complexity of the complexes 
formed by MreB, it’s entirely possible that either a known or unknown interaction 
partner is responsible for the ability of L-forms to survive in low osmolarities.  
The fatty acid profile of JB115 renders making of any hypotheses related to the changes 
in membrane troublesome due to the surprising difference to the other mutant strains 
and the similarity to the parent strain.   
In general, there are three probable explanations for the ability of the L-forms to grow in 
low osmolarities when mreB is deleted. Firstly, the loss of mreB enables the L-forms to 
retain some degree of turgor. As detailed earlier, it is assumed that L-forms are 
effectively isotonic with their environment due to their inability to maintain turgor. 
Therefore, when L-forms enter the low osmolarity medium they are unable to constrain 
their cellular machinery, resulting in cell death. It is possible that without MreB, the 
membrane is altered to an extent by which the L-form cells are able to maintain some 
degree of turgor, allowing them to maintain a functioning cellular machinery. 
The second possibility is that the loss of MreB affects the uptake of K+, with a lower 
cytoplasmic K+ concentration reducing the amount of turgor generated by the cell, 
enabling the L-forms to survive in low osmolarities. It was demonstrated in the work of 
Strahl et al. 2015, that many different proteins are localised by the presence of the RIFs 
organised by the presence of MreB. It is conceivable that the loss of these RIFs could 
result in disruption of the K+ uptake systems.  
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The other alternative is that the deletion of MreB enables the L-forms to survive when 
the cellular cytoplasm is isotonic with the low osmolarity medium, thereby removing the 
need for the cells to maintain turgor for survival. However, there is no clear mechanism 
through which loss of MreB could enable this process.  
It may be beneficial not to look towards in vivo studies of MreB and the bacterial 
membrane, but instead turn towards some of the work in the field of synthetic biology. 
One of the myriad aims of synthetic biology is to create the simplest form of life. To 
explore the problem, giant vesicles are often used (Walde et al., 2010). These are simple 
lipid structures that separate an aqueous solute core from the surrounding aqueous 
environment. Such systems have been used to investigate and explore how primordial 
cells may have survived before the evolution of the bacterial cell wall. Like living cells, 
when these vesicles are placed in hypotonic conditions, water can readily cross the lipid 
membrane (Fettiplace and Haydon, 1980) whereas the passive movement of the solutes 
across the membrane is far slower (Deamer and Bramhall, 1986). As with living cells, this 
creates an osmotic gradient across the membrane resulting in an influx of water into and 
swelling of the vesicle. The membranes can only tolerate a certain degree of expansion 
(Needham and Nunn, 1990), at which point pores begin to form in the membrane (Ertel 
et al., 1993). Instead of lysis, a biophysical process has been observed wherein the 
transient pores allow for the release of solutes (Sandre et al., 1999). The release relaxes 
the membrane tension, enabling the pores to be resolved and preventing catastrophic 
lysis. The ability to resolve the pores depends on the osmotic pressure and the 
properties of the membrane (Ertel et al., 1993). Further, it has been shown that the 
swelling and release of solutes promotes changes in the membrane (Oglecka et al., 
2014). It’s possible that the absence of the membrane ordering effect by MreB in the 
osmoresistant L-forms enables the cells to survive and grow using such a biophysical 
process reported by the synthetic biologists.  Again, such hypotheses are merely 
speculation.  
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5 A novel screen for inhibitors of LtaS 
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5.1 Introduction 
5.1.1 Lipoteichoic acid 
The Gram positive cell envelope consists of a classical cytoplasmic membrane 
surrounded by a thick peptidoglycan cell wall. The wall serves to protect the bacterium 
from external assault, to restrain the cell membrane against the effects of turgor and to 
provide shape to the cell. Peptidoglycan is a complex mesh of crosslinked glycan strands 
(Vollmer and Bertsche, 2008). The cell envelope is further enriched in Gram-positive 
bacteria with teichoic acids (TA). These are similar in overall mass to the peptidoglycan, 
but far less well understood. The teichoic acids are anionic polymers that can either be 
attached to the wall (WTAs) or to the lipid head groups in the membrane (LTAs) 
(Neuhaus and Baddiley, 2003). There have been several proposed roles for the TAs, 
including: cation homeostasis (Heptinstall et al., 1970, Schirner, 2009), placement of 
cellular machinery such as the division apparatus (Schirner, 2009, Formstone et al., 
2008), efficient protein secretion (Nouaille et al., 2004), pathogenicity (Morath et al., 
2001, Fittipaldi et al., 2008), biofilm formation (Gross et al., 2001) and antibiotic 
resistance (Kristian et al., 2003, Kovacs et al., 2006). 
In many bacteria the WTAs and LTAs contain the same repeat units, though they have 
distinct genetic and biochemical synthetic pathways (Fischer, 1988). The two subject 
species in this work, Bacillus subtilis 168CA and Staphylococcus aureus RN4220 both 
have LTAs composed of repeat units of glycerol-phosphate (Gro-P), though in RN4220 
the repeat unit of the WTA is ribitol-phosphate. These TAs can be further modified by D-
alanylation (Neuhaus and Baddiley, 2003). In both species the WTA synthetic pathway is 
encoded by the tagA-F operon, with identified proteins for each catalytic step. The 
synthetic pathway of LTA is less well understood, though our understanding has 
significantly increased in recent years. The main synthase, LtaS, was discovered initially 
in S. aureus, with a homologue identified in B. subtilis (Grundling and Schneewind, 
2007b). The synthase catalyses the formation of poly (Gro-P) as well as the attachment 
to the lipid head group. 
Protein localisation studies have revealed that the WTA synthetic enzymes appear to 
colocalise with the MreB cytoskeleton in B. subtilis (Formstone et al., 2008), whereas 
LtaS localises at the site of division and sporulation (Schirner, 2009). Taken together, it 
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provides a strong indication that WTA is involved in elongation, whilst LTA is involved in 
division.  
Interestingly, while the WTA synthetic pathway is largely dispensable in both S. aureus 
and B. subtilis (though mutants deficient in WTA exhibit reduced pathogenicity and 
viability), LTA is essential for growth at temperatures over 30°C in S. aureus but not in 
B. subtilis. It should be noted that in B. subtilis cells, whilst each system is dispensable, 
jointly they are essential (Schirner et al., 2009).  
5.1.2 Redundancy of LTA synthases in Bacillus subtilis 
S. aureus carries only a single copy of ltaS, whereas B. subtilis has three additional 
paralogues – yqgS, yvgJ and yfnI. Unlike S. aureus, in B. subtilis ltaS can be deleted, with 
only limited effects on the growth of the cell. Combinations of double or triple deletions 
of the paralogues have a moderate effect on the health of the cells, but otherwise they 
remain viable. Interestingly, double mutants of ltaS and yqgS are completely blocked in 
sporulation (Schirner, 2009), indicating a sporulation specific role for yqgS. yfnI appears 
to be involved in LTA production during a σM-mediated stress response (Kingston et al., 
2013).  
5.1.3 The MreB homologue Mbl 
In rod-shaped bacteria such as B. subtilis the cell wall is modelled and sculptured through 
a series of interactions by the actin homologue MreB. This protein forms helical filaments 
along the cell periphery, where it interacts with and directs the elongation machinery. In 
a similar fashion to the LTA synthases, B. subtilis possesses two additional homologues, 
Mbl (MreB-like) and MreBH (MreB homologue). All three appear to have overlapping, 
partially redundant functions, though some specialised roles have been ascribed to them 
(Kawai et al., 2009, Dominguez-Cuevas et al., 2013). Cells that have lost MreB or one of its 
homologues exhibit a progressive increase in cell diameter, ultimately leading to lysis. 
However, cell viability can be restored by the addition of high concentrations of Mg2+, 
though the role of the magnesium is currently unclear (Challis, 2014). In the absence of 
magnesium, mbl-null mutants can acquire suppressor mutations that enable the growth 
of the strains in a magnesium-independent fashion. Using transposon mutagenesis 
(Schirner, 2009, Schirner and Errington, 2009) were able to identify several of these 
suppressor mutations. One of these mutations was the loss of ltaS. 
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It is not clear how ΔltaS suppresses the magnesium dependency of Δmbl. One plausible 
explanation is that loss of anionic LTA increases the availability of magnesium in the cell, 
as less is sequestered by LTA at the cell surface. This hypothesis is supported by results 
that show ΔltaS cells are highly sensitive to even low concentrations of the toxic cation 
Mn2+.  
5.1.4 Drug discovery 
Antibiotic resistance of Staphylococcus aureus is an ever increasing problem, with 
resistance to β-lactams wide spread (MRSA), and emerging resistance to glycopeptides 
(VISA) (Menichetti, 2005). The increase in resistance results in a greater number of 
therapeutic failures leading to a rise in the morbidity and mortality associated with such 
infections. Novel antibiotics are required to combat the increasing burden of antibiotic-
resistant infections. 
For the development of novel antibiotics, a suitable drug target is required. The optimal 
targets should: (i) only be present in bacteria, not in eukaryotes; (ii) be easily accessible 
to the antibiotic and remain unaffected by the reach of multidrug efflux pumps. To this 
extent β-lactams and glycopeptides fulfilled all these criteria as their targets in the 
peptidoglycan synthesis machinery are extracellular and unique to bacteria. Attempts to 
find other such extracellular, essential targets have been problematic.  
The lipoteichoic acid synthase in S. aureus is an attractive potential target for antibiotic 
development. Firstly, the synthase is essential for the growth of the bacterium under 
physiological conditions. Secondly, the catalytic head group of the synthase lies outside 
the cell (Schirner et al., 2009, Grundling and Schneewind, 2007b), rendering it accessible 
to antibiotics. In addition, LtaSSa as an antibiotic target has previously been validated 
from a small molecule inhibitor screen (Richter et al., 2013). In the same work, they 
were unable to isolate any mutants resistant to their inhibitor, further increasing the 
attractiveness of LtaS as a target.  
Almost two-thirds of antibiotics currently in use were originally isolated from bacteria 
belonging to the phylum Actinobacteria (Berdy, 2012). The actinomycetes are a rich 
source of antibiotics as well as antifungals, antiparasitics and anticancer agents, due to a 
highly complex secondary metabolism. Actinomycetes can be isolated from almost all 
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terrestrial and marine environments; it is thought that the production of secondary 
metabolites gives a competitive advantage against other bacteria in these niches. The 
work presented here was carried out in collaboration with Demuris limited, an antibiotic 
discovery company with a diverse, dereplicated collection of over 10,000 actinomycete 
strains. The observation that loss of LtaS in B. subtilis enables magnesium-independent 
growth of a Mbl null strain was developed into an assay to screen for potential inhibitors 
of LtaS and was subsequently patented (Errington J, 2009). Through use of this method 
and the Demuris collection we show that potential inhibitors of LtaS can be isolated.   
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5.2 Results 
5.2.1 Validation of the LtaS inhibition assay  
As discussed in the Introduction, loss of ltaS is sufficient to enable the growth of a Δmbl 
strain in the absence of high levels of magnesium. An assay was previously set up in the 
lab to screen extracts derived from the Demuris actinomycetes collection for activity 
against LtaS (Errington J, 2009). The hypothesis was that an inhibitory compound should 
allow a Δmbl strain to grow in the absence of magnesium. The assay developed is 
described in section 2.5.4.14; however, in brief: in a 96 well plate 10 μl actinomycetes 
extract was added to 190 μl of nutrient broth containing a 10-4 dilution of a stationary 
phase Δmbl strain (OD600 approx 7.0-9.0) and grown with shaking at 37°C for 16 h in a 
plate reader, with the OD600 measured every 6 min. The previous work with this assay 
was based on use of a Δmbl mutation in the B. subtilis 168ED background, which was 
recently discovered to carry multiple unexpected mutations (Dominguez-Cuevas et al., 
2012). Thus, the deletion of mbl was recreated in a 168CA background and tested in the 
established assay with a variety of different magnesium concentrations. The strain 
(JB84) responded to the varying concentrations of magnesium in the same manner as 
reported for the deletion in the 168ED background (figure 5.1). For the purposes of this 
work the highest concentration of MgCl2 used, 20 mM, was used as a positive control, 
and 0 mM MgCl2  (i.e. no addition) as a negative control. In many of the tests growth was 
observed in the negative control wells at later time points, probably representing the 
emergence of mutants with suppressor mutations. On occasions in which the negative 
control showed unusually rapid growth the experiment was terminated. Space 
permitting, a blank was also included; if not, results were blanked against the negative 
control.  
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Figure 5.1. Growth rate of the Δmbl strain JB84 in the presence of varying 
concentrations of MgCl2. Cells were diluted 10-4-fold in nutrient broth and grown for 
16 h in a plate reader at 37°C.  
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5.2.2 Identification of activity in the crude extracts from actinomycetes strains 
DEM30616, DEM29435 and DEM30549 
The previous screen (Kim & Errington, unpublished) had highlighted 5 strains with 
possible activity against LtaS (figure 5.2), each with a distinct appearance. To confirm the 
production of possible LtaS inhibitors each strain was grown on GYM plates at 30°C. 
Once robust growth was achieved the plates were crushed, frozen and centrifuged. The 
supernatants were tested in the established assay. Activity was observed for three of the 
strains: DEM30616, DEM30549 and DEM20435 (figure 5.3). Despite several repeats, 
activity was not observed for the other two strains. Absence of growth in wells treated 
with the supernatant from the other strains indicate that growth restoration is not a 
result of the carry-over of magnesium from the growth medium. As growth of the strains 
on solid medium intrinsically limits the scalability in the production of an active 
compound, the three remaining strains were tested for production of the active 
compound in liquid medium. Unfortunately, regardless of when the medium was 
harvested and despite multiple repeats, activity was never detected for DEM29435. Of 
the remaining strains DEM30549 was relatively difficult to grow, whereas DEM30616 
grew in planktonic culture rapidly and robustly. As such DEM30616 was taken forward 
for purification of an active compound. Addition of culture supernatant from DEM30616 
filtered through a 0.45 μm low-binding filter was sufficient to restore the growth of the 
Δmbl strain in the established assay (figure 5.4). 
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Figure 5.2. Colony and cell morphology of the five strains grown on GYM media at 30°C 
that were isolated in the screen by Byung-Yong Kim. The strains highlighted in red had 
the activity against LtaS verified in the established Δmbl growth assay.  
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Figure 5.3. Growth of Δmbl (JB84) after treatment with extract from crushed GYM plates 
of DEM30616, DEM30549 and DEM20435. Results are illustrative of two biological 
replicates, each with eight technical replicates. Graph is composed of data from 
different, but comparable experiments.  
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Figure 5.4. Δmbl (JB84) can grow in the absence of magnesium when treated with the 
culture supernatant from DEM30616 grown in GYM media at 30°C. Δmbl (JB84) cells 
were diluted 10-4 in nutrient broth and grown in a plate reader at 37°C. 
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5.2.3 Production of the active compound peaks at day 6 of growth of DEM30616 
 To characterise the time course for production of the active compound DEM30616 was 
first grown in 50 ml GYM for 7 days at 30°C, then diluted 10-1 into 500 ml GYM. This 
culture was then grown for 11 days at 30°C, with 10 ml aliquots of culture removed 
every day after the third day. The aliquots were filter sterilised, stored at -20°C until all 
samples had been collected, and then tested in the established assay. Figure 5.5 shows 
that activity peaked after six days, then fell to background by the 10th day. The early 
peak in activity seen at day 3 could be a result of the dilution at the start of the 
experiment.  
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Figure 5.5.  Growth of Δmbl (JB84) after treatment with the filtered extract from 
DEM30616 grown in GYM. Negative control represents growth of JB84 in the absence of 
supplemented Mg2+; positive control represents growth of JB84 when treated with 
20 mM Mg2+. OD600 shown is at t834. Standard deviation of eight technical replicates.  
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5.2.4 16S sequencing identifies DEM30616 as a novel species 
To further characterise strain DEM30616, the 16S rRNA gene was sequenced. Genomic 
DNA was isolated from DEM30616 growing in GYM media using a DNeasy kit (Qiagen). 
The DNA was amplified and Sanger sequenced. The identification of phylogenetic 
neighbours was carried out by BLASTN searches against the EzTaxon 16S database. The 
sequences obtained were exported for use in Mega (v.6.06) and the sequences aligned 
using ClusterW. The phylogenetic tree was constructed using the neighbour-joining 
method of (Saitou and Nei, 1987).  
The closest taxon to DEM30616 in the EzTaxon similarity search was found to be 
Streptomyces drozdowiczii (GenBank accession no. AB249957), whose sequence was 
99.79% identical, differing in 3 nucleotides. The relationship between DEM30616 and 
Streptomyces drozdowiczii, and to the phylogenetically nearest taxa can be seen in 
figure 5.6. None of the taxa in the clade have previously been reported to produce 
antimicrobial compounds (Zucchi et al., 2012, Semedo et al., 2004). 
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Figure 5.6. Phylogenetic subtree for a selected set of taxa calculated using Mega v6.06 
from complete 16S rRNA sequences using the (Saitou and Nei, 1987) neighbour-joining 
method, illustrating the taxonomic position of DEM30616 relative to species found most 
similar by an EzTaxon search. Percentages at the nodes represent the levels of bootstrap 
support (n=1000).  
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5.2.5 Active compound purification  
5.2.5.1 Ethyl acetate extraction 
In preliminary solvent extraction experiments with ethyl acetate the active compound 
remained in the aqueous phase (figure 5.7), therefore this purification step was omitted 
in the future, with reverse phase chromatography used instead to crudely purify the 
active compound. 
 
Figure 5.7. The aqueous and solvent fractions from an ethyl acetate extraction tested 
against Δmbl (JB84). 10 μl of each fraction was added to a total volume of 200 μl. Graph 
is illustrative of the results of two purifications each with two biological replicates and 
8 technical replicates. 20 mM MgCl2 was used as the positive control; no 
supplementation was the negative. 
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5.2.5.2 Reverse phase chromatography 
An aliquot (30-50 ml) of filtered supernatant was loaded onto a C18 30 g silica SNAP 
Biotage column and eluted with methanol (325 ml; 13 CV) at a flow rate of 25 ml/min 
with a fraction size of 10 ml. Methanol in the fractions was removed using a centrifugal 
evaporator under pressure (40 mBar, 1725 rpm). After removal of the solvent, fractions 
were tested in the established assay. Elution of the active material was bimodal in 
distribution across the fractions, with peaks in activity around fractions 15 and 23. The 
positions of the fractions with greatest activity varied between purification, but the 
bimodal distribution remained constant. In addition the first peak was usually sharper, 
with only a single fraction exhibiting activity, whereas the second group of active 
fractions tended to show a peak then a gradual decline (figure 5.8). For clarity, the first 
active compound will be referred to as DEM30616-A, and the second as DEM30616-B. 
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Figure 5.8. Absorbance of the fractions during reverse-phase chromatography from a 
gradient of 0-100% methanol. Red rectangles indicate the fractions that contained active 
material. Different colours represent theoretical compounds annotated by the computer 
software. Graph representative of two biological replicates, each with eight technical 
replicates. Fractions that contained no active material were indistinguishable from the 
negative control and were omitted for clarity. 
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5.2.5.3 HPLC separations of DEM30616-A and DEM30616-B 
To further purify the compounds the active fractions were run on an Agilent 1260 
Infinity HPLC system. The fractions were loaded onto an Agilent Phenomenex column 
(150x4.50 mm; 4 μm) attached to an integrated pre-column. A 200μl sample of each 
active fraction was run on a linear gradient from 0-100% over 45 minutes (H2O (0.1% 
formic acid): acetonitrile (0.1% formic acid)) at a flow rate of 1 ml/min with UV/vis 
detection at 254 nm, and were collected every 25 seconds. Acetonitrile was removed 
using a centrifugal evaporator under pressure. After removal of the solvent the fractions 
were tested against Δmbl in the assay. Unfortunately, despite several repeats, HPLC 
separation of DEM30616-A yielded only low level, albeit reproducible activity, in a single 
fraction (figure 5.9A). In contrast, two of the HPLC fractions of DEM30616-B retained the 
majority of their activity following purification (figure 5.9B).  
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Figure 5.9. HPLC separation of the Biotage fraction 15 (A) and fraction 23 (B) yield active 
material with varying levels of activity. The two compounds purified from fraction 23 
eluted 60 seconds apart. Graphs representative of two biological replicates with a 
minimum of four technical replicates. Fractions that contained no active material were 
indistinguishable from the negative control and were omitted for clarity.  
0.3
0.4
0.5
0.6
0.7
0.8
0.9
1
1.1
1.2
0 100 200 300 400 500 600 700 800 900
O
D
6
0
0
Time (mins)
DEM30616-A
20mM
0mM
0
0.1
0.2
0.3
0.4
0.5
0.6
0.7
0.8
0.9
1
0 100 200 300 400 500 600 700 800 900
O
D
6
0
0
Time (mins)
DEM30616-B1
DEM30616-B2
20mM
0mM
A 
B 
225 
 
5.2.6 Mass spectroscopy identifies DEM30616-A of the compounds as Coelichelin  
As reported previously, the activity seen in the semi-pure fraction was being lost 
following HPLC purification.  Despite the activity being very low, it could be reproduced, 
suggesting that the fraction contained the compound of interest. Analysis by HPLC, 
revealed the fraction was suitable for analysis by mass spectroscopy (figure 5.10). The 
main peak in the mass spectral trace, at 566 Da, was used to search the dictionary of 
natural products. The search returned several possible compounds, one of which was 
the siderophore, coelichelin. This identity was confirmed by comparison of the MS/MS 
fragmentation pattern of the isolated compound to the fragmentation pattern of 
coelichelin as these were largely identical. 
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Figure 5.10. MS of the active compound purified present in DEM30616-A (A). MS/MS 
analysis of the mass at 566 (B). MS/MS data of the fragmentation of the mass at 566 
is very similar to that reported previously of desferricoelichelin (C) (Zucchi et al., 
2012). MS was performed by Joe Gray.  
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5.2.7 Sequencing and analysis of the DEM30616 genome reveals the presence of a 
homologue of the cch cluster of Streptomyces coelicolor 
Coelichelin was identified in one of the first genome mining screens in the Streptomyces 
model organism, S. coelicolor (Zucchi et al., 2012, Challis and Ravel, 2000). This work 
identified coelichelin as a siderophore with a tri-hydroxamate structure (figure 5.11.A). 
That a siderophore could have an effect on LtaS was somewhat surprising. However, it 
has been shown that another naturally derived siderophore with the same backbone, 
foroxymithine (figure 5.11.B), is able to act as an inhibitor of the angiotensin I converting 
enzyme (ACE) by chelating the zinc. It has since been demonstrated that coelichelin is 
also able to act as an ACE inhibitor, presumably by a similar function (Challis, 2014).  
To probe DEM30616 further and identify potential biosynthetic clusters, the genome 
was sequenced on the MiSeq platform. Unfortunately, the coverage from the 
sequencing was too low for de novo assembly, however it was possible to assemble the 
DEM30616 genome against the S. coelicolor A3(2) reference genome. A complete cch 
cluster, responsible for coelichelin synthesis in S. coelicolor, could be identified in 
DEM30616 with a roughly 85% level of similarity.  
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Figure 5.11. The structure of coelichelin (A) and its analogue foroxymithine (B).  
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5.2.8 Foroxymithine, a compound with a similar backbone to coelichelin has no 
restorative effect on Δmbl 
Coelichelin is not commercially available, though compounds with similar 
tri-hydroxamate structures are. One of these is foroxymithine. With a similar 
tri-hydroxamate structure, it was conceivable that foroxymithine could have similar 
inhibitory effect on LtaS as coelichelin appears to have. A range of foroxymithine 
concentrations were tested, but no restorative effect on the growth of the Δmbl strain 
was observed (data not shown).  
5.2.9 A sensitivity to iron could explain the effect of coelichelin on Δmbl 
As an alternative way to investigate the possible role of a siderophore in alleviating the 
magnesium dependence of Δmbl, strains 168CA and Δmbl (supplemented with 20 mM 
MgCl2) were treated with a range of concentrations of FeCl3. Surprisingly, the Δmbl 
strain was significantly more sensitive to increased iron concentration than the wild type 
strain (figure 5.12). This suggests that the results seen with coelichelin may be a result of 
reduced iron toxicity on the Δmbl strain, rather than a reduction in the magnesium 
dependence/inhibition of LtaS.  
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Figure 5.12. Growth of the wild type (168CA) and Δmbl (JB84) strains in the presence of 
varying concentrations of FeCl3. To sustain Δmbl growth, cultures were supplemented 
with 20 mM Mg2+.  
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5.2.10 DEM30616-B may be an ester with structural homology to the glycolipid 
anchor of LTA 
Further purification of the DEM30616-B peak by preparative HPLC yielded two fractions 
with strong, reproducible activity in the established assay. Both fractions were sent for 
mass spectroscopy. In both cases the identification was less straightforward than that of 
coelichelin, with a number of possible compounds sharing the same mass. Several of 
these compounds could be disregarded, as the UV/vis traces for the two purified active 
compounds indicated a low level of conjugation; therefore, candidates with a high level 
of conjugation could be ignored. The identity of the compounds was investigated by the 
heuristic filtering of the mass spectroscopy peaks (Semedo et al., 2004). From the data 
obtained it is possible to determine the possible elemental formulae that adhere to the 
LEWIS and SENIOR chemical rules (Miessler and Tarr, 2011, Senior, 1951). In brief, these 
rules filter against formulae that are unlikely to exist or would be highly unstable in 
nature. The chemical formula can be further probed by examination of the relative 
abundance of the different isotopes in the compounds of interest. Finally, the 
fragmentation peaks obtained from the mass spectroscopy (figure 5.13) were screened 
against the predicted fragmentation patterns of compounds contained in the dictionary 
of natural products. Combined use of these techniques suggested the possible identity 
of one of the compounds as an ester of a fatty acid, hexanoic acid, and a sugar, β-D-
xylopyranosyl-(1→6)-β-D-glucopyranosyl. The identity of the second compound from the 
HPLC separation could be another sugar: 3',4',5,7-Tetrahydroxyflavone; 7-O-[α-L-
Rhamnopyranosylamino-(1→6)-6-deoxy-β-D-glucopyranoside].  
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Figure 5.13. Purification of the active compound(s) from the fractions containing the 
second peak of activity following reverse phase chromatography. HPLC profiles of the 
fractions in wells C11 (A) and D11 (B). MS of the compounds present in fraction C11 (C) 
and fraction D11 (E). MS/MS fragmentation of the dominant peaks of C11; 411 (D) and 
D11; 594 (F). HPLC and mass spectroscopy were performed as described in materials and 
methods. Mass spectroscopy was performed by Dr. Joe Gray.  
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To validate the presence of the compounds a fresh culture of DEM30616 was grown and 
the supernatant harvested. Using the same extraction and purification steps (reverse 
phase chromatography and HPLC) as described previously, it was possible to isolate a 
single fraction that had activity in the Δmbl assay. Identity of the compound was 
confirmed to be DEM30616-B via mass spectroscopy. The second compound was not 
recovered.  
The structure of the first compound was of particular interest as it appears not dissimilar 
from the structure of the glycolipid anchor to which the glycerol phosphate (Gro-P) 
subunits are attached to by the LtaS enzyme (figure 5.14). In principle, the compound 
might work either by directly inhibiting LtaS or by being incorporated into LTA in such a 
way as to render it non-functional.   
Anecdotally, the compound appears highly stable, with little-to-no loss of activity over 
time (3+ months) when stored at -20°C. Further, neither repeated cycles of freeze-thaw 
nor overnight storage at room temperature appeared to affect the activity of the 
compound in the Δmbl recovery assay.  
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Figure 5.14. Chemical structure of the diacyl-glycerol (DAG) subunit of LTA (A) and the 
predicted structure of the active compound (B). The hexanoic acid is displayed adjacent 
to the sugar residues as the oxygen it is bound to is unknown.  
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5.2.11 The compounds do not work by inducing suppressor mutations in the assay 
strain 
It was possible that the compounds in the screen were promoting the development of 
suppressor mutations that enable the Δmbl strain to grow independent of magnesium. 
To examine this issue, at the completion of the growth assay, the cells from the wells 
treated with 20 mM Mg2+ and the compound were used to inoculate fresh media +/- 
20 mM MgCl2 to an OD600=0.05 and were grown for 2 hours at 37°C. The cells from both 
wells remained dependent on the presence of high levels of magnesium for healthy 
growth; removal of magnesium rendered the cells sick (figure 5.15). This showed that 
the Δmbl cells treated with the compound remained dependent on magnesium in the 
absence of the compound. 
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Figure 5.15. Δmbl (JB84) cells remain dependent on magnesium following growth with 
the compound. Cells were grown for 16 hours in the established assay. At the end point 
cells from the test wells and the positive control wells were diluted to OD600=0.05 in 
fresh media +/- 20mM MgCl2 and were grown for two hours at 37°C. Scale bar = 3 μm  
N
B
+2
0
m
M
 M
g
2
+
 
P
h
ase co
n
trast 
P
h
ase co
n
trast
 
M
em
b
ran
e
 
M
em
b
ran
e
 
N
B
 
238 
 
5.2.12 Treatment with the compound restores the morphology of Δmbl cells 
As described previously, in the absence of magnesium Δmbl cells are very sick, becoming 
fat with a twisted morphology. In the presence of magnesium, the disturbances to 
morphology are largely alleviated, though the cells remain smaller than the wild type 
(Schirner et al., 2009). When ltaS is disrupted in a Δmbl background growth is restored 
to that of the wild type (Schirner et al., 2009). Therefore, examination of the 
morphology of the Δmbl cells treated with the DEM30616-B compound might provide 
insights into the effect the compound has on cells. In agreement with Jones et al. 2001, 
figure 5.16.B demonstrates that Δmbl cells grown in the presence of magnesium, whilst 
viable, form shorter, fatter cells. In contrast, the Δmbl cells grown without magnesium 
supplementation are very sick, with gross morphological changes (figure 5.16.C). Whilst 
the micrographs depict growth, such clusters of cells were infrequently found.  
Interestingly, the morphology of the Δmbl cells treated with the DEM30616-B compound 
appeared to take on a more wild type morphology. The alleviation of the growth defects 
was limited to the early- and mid-exponential phases. These observations supported the 
notion that the compound targets LtaS. As growth continued the cells treated with 
compound became progressively sicker, resulting in aberrant cell shapes and lysis. This 
drop in fitness may have arisen as a result of the compound irreversibly binding to its 
target, being metabolised or otherwise being exhausted.  
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Figure 5.16.  Morphology of Δmbl (JB84) cells at various time points when grown with 
the DEM30616-B compound (A), with 20mM MgCl2 (B) or grown in just nutrient broth 
(C). Membranes were visualised by staining with FM5-95. Scale bar = 3 μm  
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5.2.13 Treatment with the compound slightly impairs the growth of wild type 168CA 
but renders it exquisitely sensitive to Mn2+ 
One of the phenotypes reported for the ΔltaS mutant of B. subtilis is a high degree of 
sensitivity to the cation Mn2+ (Schirner et al., 2009). As an additional test as to whether 
DEM30616-B targets LtaS, the B. subtilis wild-type strain was treated with the 
compound, in the presence or absence of added 0.05 mM Mn2+. Strikingly, the 
combination of Mn2+ and compound completely abolished growth of the wild type strain 
(figure 5.17), again consistent with the notion that the compound acts on LtaS. 
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Figure 5.17. Treatment with the compound DEM30616-B abolishes the ability of the wild 
type (168CA) to grow in the presence of 0.05mM Mn2+. Cells were diluted 10-4 in 
nutrient broth and grown for 20 hours in a plate reader at 37°C.  
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5.2.14 The compound has a minimal effect on growth of a ΔltaS mutant 
If the compound worked by inhibiting LtaS it was anticipated that treatment of a ΔltaS 
strain with the compound would give no further growth inhibition beyond that already 
induced by the loss of LtaS. A ΔltaS strain, along with strains bearing deletions of two of 
the paralogues, ΔyqgS and ΔyfnI, were treated with 10 μl of DEM30616-B. Growth of 
both the “minor” paralogues was substantially affected by presence of the compound, 
whereas growth of the ΔltaS strain was more or less unaffected (figure 5.18). Note that 
the ΔltaS strain used in this work was significantly slower growing than the wild type 
strain (168CA). This is in contrast with the earlier work that reports little difference when 
ltaS is deleted in B. subtilis (Schirner, 2009). 
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Figure 5.18. Growth of ΔltaS (JB25), ΔyqgS (JB27), ΔyfnI (JB24) and the wild type (168CA) 
in the presence and absence of compound DEM30616-B. Growth was significantly 
reduced in the strains with a functional copy of the primary synthase, LtaS, whereas the 
ΔltaS strain was largely unaffected. All the strains were diluted 10-4 and grown in LB at 
37°C.  
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5.2.15 The compound has a bacteriostatic effect on the growth of Staphylococcus 
aureus 
Unexpectedly, preliminary investigations using the filtered extract from DEM30616 
cultures improved the growth of S. aureus over that of the untreated cells (figure 
5.19.A). However, treatment of S. aureus with the purified DEM30616-B compound 
revealed that the compound significantly slowed the growth of cells (figure 5.19.B). 
Examination of the morphology of the cells treated with the compound by microscopy 
did not reveal any morphological changes (figure 5.19.D). This is in contrast to the 
results of depletion studies, which demonstrated that LtaS is essential for proper 
envelope assembly (Grundling and Schneewind, 2007b).  
An earlier study had found that S. aureus ΔltaS mutants were viable when grown at 
30°C, but not at 37°C (Oku et al., 2009). This temperature sensitivity was used previously 
to identify potential small molecule inhibitors of LtaS (Richter et al., 2013). When 
S. aureus was grown with the DEM30616-B compound at 30°C, a reduction in the growth 
rate was observed, but no clear temperature dependence could be seen (figure 5.19.C). 
The reason for this discrepancy remains unknown.   
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Figure 5.19. The effect of the compound on Staphylococcus aureus. A). Treatment with 
the filtered supernatant from DEM30616 improves the growth of S. aureus (RN4220). B). 
Growth rate of S. aureus (RN4220) is reduced in the presence of the compound. Cells 
were diluted 10-4 in nutrient broth and grown at 37°C in a plate reader. * indicates time 
points at which the experiment was paused and 5 μl removed for microscopy. C).  D). 
Microscopy of S. aureus in the presence or absence of the compound at a selection of 
the time points illustrated by a * in (A). Membrane was stained with FM5-95 dye.  
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5.2.16 Scaling up of production for compound purification 
To purify more of the active DEM30616-B compound was grown until dense in 500 ml 
GYM before being fed into a bioreactor containing 16 L fresh GYM. Dissolved oxygen, 
rpm and temperature were monitored and controlled during the growth. The pH was 
followed. 15 ml samples were taken twice daily for six days. The bioreactor used did not 
have the equipment necessary to monitor glucose levels during growth. Instead, these 
were measured after the conclusion of the growth from the samples taken. 
The presence of the compound was checked in the established assay on the fifth day. In 
contrast to the earlier work carried out at a smaller volume in which the greatest activity 
was observed on day 6, the activity peaked after four days of growth (figure 5.20.D). The 
production of the compound appeared to correlate with the entry into stationary phase 
(figure 5.20.A) and a drop in pH (figure 5.20.C). The drop in glucose levels appeared to 
be a function of the growth and entry into stationary phase (figure 5.20.B). 
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Figure 5.20. Changes in optical density (A), glucose concentration (B), pH (C) and activity 
of the supernatant in the Δmbl assay (D) during growth of DEM30616 in a bioreactor. 
Activity of the supernatant represents growth of Δmbl after 650 minutes in the assay 
blanked against the negative control (no addition of Mg2+). Growth of DEM30616 in the 
bioreactor was performed by Ryan Sweet of Demuris ltd.  
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5.3 Discussion 
As a result of the frequent use and misuse of antibiotics, levels of resistance in the 
human microbiome are increasing inexorably. For S. aureus, drug resistance in the form 
of MRSA is associated with elevated levels of mortality and morbidity. With the transfer 
of vancomycin from the enterococci to S. aureus (Weigel et al., 2003), followed by the 
development of linezolid and daptomycin resistance (Arbeit et al., 2004, Stevens et al., 
2002) there is a high demand for novel antibiotics targeting S. aureus. In addition, LTA 
has been implicated as playing an important role in the pathogenesis of other important 
Gram-positive pathogens such as Listeria monocytogenes (Abachin et al., 2002). In both 
of S. aureus and L. monocytogenes, lipoteichoic acid is essential for robust growth 
(Webb et al., 2009, Grundling and Schneewind, 2007b), rendering it an attractive target 
for new antibiotics.  
In this work, we propose and validate a new screening method for the discovery of novel 
antimicrobial compounds. Much of the natural product screening of the past thirty years 
has been hindered by the repeated isolation of known antibiotic classes (Baltz, 2008). 
Pre-existing methods for identifying antibiotics hinge on the ability of the compound to 
kill bacteria. Different screening methods may use reporter strains (Czarny et al., 2014) 
or differential killing (Richter et al., 2013), but ultimately they still seek compounds that 
kill the bacteria in the screen, and thus run the risk of repeated isolation of known 
compounds. What makes the screen used in this investigation different is that it 
identifies natural products that improve the growth of the assay strain. This therefore 
eliminates the possibility of identifying known compounds. In addition, because of the 
selectivity of the screening, there is greater confidence that the compound is indeed 
acting on LtaS.  
Of course, such a screen, hinging as it does on LtaS being essential for the growth of 
species such as S. aureus, but also that its loss is a suppressor for the Δmbl phenotype of 
B. subtilis, does mean that the method cannot be widely applied in the search for novel 
antibiotics. It therefore is more suited for the development of compounds for academic 
uses. Many genes when deleted sicken the cell and promote the development of 
suppressor mutations. Unfortunately, it is unlikely that many of these suppressor 
mutations are in turn essential for the growth and development of the bacterial cell as 
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ltaS is. However, the suppressor mutations themselves are often of interest in the 
understanding of bacterial physiology. Development of compounds targeting the gene 
products of the suppressors may help improve research into these pathways.  
Due to the limited quantity of active material at the time of writing it was not possible to 
carry out experiments to more definitively confirm the activity of the compound against 
LtaS. Upon acquisition of more active material it would be hoped to expand upon the 
indirect evidence presented in this investigation by demonstrating via immunoblotting 
that treatment with the compound will disrupt LTA synthesis in a heterologous host 
(Grundling and Schneewind, 2007b, Richter et al., 2013). In addition, a greater quantity 
of the compound will allow for the complete identification of the compound 
DEM30616-B by H1-NMR or X-ray crystallography. The current hypothetical structure of 
DEM30616-B allows us to make predictions about its mechanisms of action. The 
compound, an ester of a fatty acid and a sugar group, resembles the structure of the 
DAG subunit onto which the LtaS molecule attaches the poly Gro-P chain. It could 
therefore be hypothesised that the compound is occupying the active site of the LtaS 
enzyme. Alternatively, it is possible that the compound acts as a substrate during LTA 
synthesis, but that the resulting molecule is non-functional. Of course, such theories 
remain entirely speculative until the structure of the compound is solved. In turn, it may 
even be possible to co-crystallise the compound with the catalytic head group of LtaS. 
The compound identified in this work is not the first to be found to potentially inhibit 
the function of LtaS. That accolade belongs to the small molecule identified in the work 
of (Richter et al., 2013). However, the DEM30616-B compound would be the first 
isolated from a natural source. In addition, the earlier small molecule the use of the 
small molecule previously identified is of limited medical use due to the instability of the 
molecule. It is hoped that the compound identified in this work is more stable.  
The current evidence suggests that the compound DEM30616-B is targeting LTA 
synthesis. It does remain possible that the compound is actually targeting another 
process, as several suppressor mutants were identified in the study that inspired this 
work (Schirner et al., 2009). In such an event, the compound may lose its medical 
relevance, but will remain of interest as ultimately, it enables the growth of mbl mutants 
in conditions that are not normally permissive. Whilst our knowledge of mbl and the 
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actin-like cytoskeleton is improving, it remains a conflicted field (Errington, 2015). Use of 
the compound may enable more light to be shed on this intriguing protein. Whilst not of 
direct relevance to the scope of this work, it was of some interest that a sensitivity to 
iron was observed in the Δmbl background, particularly as such a sensitivity to iron has 
not been previously reported. As this was beyond the remit of the work, it was not 
pursued further.  
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6. Summary and general discussion 
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6.1 L-form growth in low osmolarities can be facilitated by the loss of MreB  
A long standing question regarding L-form biology is their natural relevance. L-forms 
have been studied extensively in a laboratory setting in which high levels of 
osmoprotectant must be maintained to ensure continued survival. This contrasts with 
reports in which L-form-like bodies have been observed in association with plant and 
animal tissues. In such conditions, the continued survival of L-forms would not be 
expected, resulting in the massive lysis of the cells. The historical literature reported that 
L-forms could be adapted to low osmolarities, but the characterisation of these L-forms 
was very limited due to the lack of effective techniques at that time. Work by (Leaver et 
al., 2009) established a reproducible method for generating L-forms derived from the 
Gram positive model organism Bacillus subtilis. Inspired by this work, the decision was 
made to revisit the issue of the survival of L-forms in low osmolarities.  
In chapter 3, a variety of different techniques to adapt L-forms to low osmolarities were 
trialled, with the development of a novel adaptation method enabling the generation of 
L-forms that were able to grow and survive in conditions containing minimal 
concentrations of sucrose or salt. Whole genome sequencing of these strains revealed a 
number of mutations. Whilst the most exciting mutation, an in-frame deletion in mreB, 
was explored in chapter 4 as a proof of principle the involvement of a deletion of scoC in 
allowing L-forms to grow in low osmolarities was confirmed. ScoC is a transcriptional 
repressor that is involved in several processes, among which is the repression of the Opp 
polypeptide transport system. It has previously been demonstrated that the Opp system 
is involved in the osmotic stress response, via the import of proline rich peptides 
(Zaprasis et al., 2013). As MreB became the primary focus of this work, the role of scoC 
was not further explored in this thesis. However, it provides an interesting avenue for 
any further research in this area as the expectation would be that to survive in low 
osmolarities L-forms would need to deplete their pools of compatible solutes, not 
increase them.  
The effects of mreB mutations on the ability of L-forms to grow in low osmolarities was 
investigated at length in chapter 4. The 60bp in-frame deletion identified in two of the 
osmo-resistant L-form mutants were initially considered to represent a gain or loss of 
function. However, this was not the case and the mutation was in all likelihood, resulting 
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in an unstable protein. Consistent with this result, rigorous testing revealed that ΔmreB 
strains were able to grow in low osmolarities, though far less reliably than the original 
mutant strains. This discrepancy was likely an effect of the secondary mutations present 
in the mutant strains. Remarkably, it was demonstrated that L-forms carrying either the 
partial deletion or a complete deletion of mreB were able to survive in not just minimal 
levels of osmoprotection, but in the complete absence of supplemented 
osmoprotection.  
 As the work stands, it is not possible to assign a clear role to mreB in the L-form state. It 
could have been speculated that MreB forms filaments that interact with the membrane 
and thus restrict the membrane reacting to an increase in turgor. However, the current 
view is that MreB forms filaments that are not as extensive as once thought. Recent 
work has demonstrated that the formation of these filaments is dependent on the 
presence of lipid II, a compound that should be absent in the L-form strain used. It is 
therefore presumed that under the conditions present in the L-forms the MreB would be 
existing as cytoplasmic monomers (Schirner et al., 2015). It had also been previously 
demonstrated that MreB helps to organise the membrane of the cell, with loss of the 
three MreB homologues resulting in an increase in membrane fluidity (Strahl et al., 
2014). As membrane fluidity had been previously been implicated in L-form survival in 
low osmolarities (Harold, 1964, Montgomerie et al., 1973) it was hypothesised that a 
change in fluidity was in effect here. This proved not to be the case, as the test results 
showed no difference in the membrane fluidity between any of the strains tested. 
Changes in the membrane profile have been observed, though it is not currently known 
if this is a cause or effect of the loss of a major membrane associated protein.  
Although it was not possible within the time frame of this investigation to understand 
the effect the loss of MreB is having on the L-form cells, this work has nevertheless 
suggested additional roles for this important protein. Traditionally, MreB has only been 
associated with the control and regulation of peptidoglycan synthesis, though it has 
been implicated in the regulation of the membrane. Discovery that the loss of MreB 
contributes to a phenotype in a cell lacking peptidoglycan was therefore an exciting and 
unexpected result. It strongly suggests the existence of functions outside those 
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associated with directing cell wall synthesis. As yet these functions are unknown and 
mere speculation.  
In the future, it may prove possible to utilise the techniques and results generated in this 
work to explore the potential roles L-forms may play in infections of both plants and 
animals. In the past, much of the research into these processes have compromised of 
case studies and have been unable to prove a direct causation between L-forms and the 
various disease associations suspected. In part, the research into this area has been 
stymied by the inability of L-forms to grow robustly in plant or animal tissues or in the 
media associated with these tissues. The research presented in this thesis may enable 
these problems to be addressed in a robust and reproducible manner. 
6.2 Use of a novel screening method to identify an inhibitor of LtaS 
In chapter 5, a potential inhibitor of LtaS identified through a novel screening protocol 
from a unique collection of actinomycetes was verified and purified. The compound was 
produced by a novel Streptomyces strain, strain DEM30616, which has minimal 
relatedness to any known antibiotic producing strains. Identification of a compound 
validates both the screening method and the belief that actinomycetes still represent a 
vast reservoir of potential antimicrobial products. The active compound was isolated 
and purified, with the results of the mass spectroscopy allowing the compound to be 
tentatively identified as an ester of fatty acid and a sugar group. Interestingly, this 
structure mimics that of the DAG subunit that anchors the poly gro-P chain of LTA into 
the cell membrane. This structure enabled the prediction of a mechanism of action. The 
most likely proposal is that the compound replaces DAG within the active site, 
preventing the formation of LTA. Another possibility is that the compound is 
incorporated into LTA, replacing DAG, but that the resulting LTA molecule is somehow 
unable to perform its normal functions. Such predictions assume that the isolated 
compound is indeed inhibiting the formation of LTA. The evidence presented in 
chapter 5 is compelling, though the tests performed constitute an indirect measure of 
LtaS inhibition.   
Ongoing work is primarily focussed on the scaling up of the production of the active 
compound from the strain DEM30616. By acquiring a greater quantity of the compound 
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it will enable the identification of the compound; this will likely be carried out either by 
H1-NMR or by crystallisation. As the crystal structure of the catalytic domain of LtaS has 
already been solved (Schirner et al., 2009), it may be possible to predict the compound 
binding site and the accompanying mechanism of action.   
Acquisition of a greater quantity of the compound will also allow for more experiments 
to be performed to confirm that the compound acts by inhibiting the formation of LTA. 
The work demonstrated in this thesis has indicated indirectly through a number of 
different techniques that the compound is inhibiting the production of LTA. Further 
experiments could involve the examination of the effect of the compound on the 
sporulation of B. subtilis; it has been demonstrated previously that a B. subtilis ΔltaS 
ΔyqgS double mutant is defective in sporulation (Schirner et al., 2009). However, the 
gold standard will be the direct observation of the loss of LTA in bacteria treated with 
the compound. Such a method has been previously described, with levels of LTA or WTA 
able to be monitored by immunoblotting. In brief, this method involves the expression 
of the lipoteichoic acid synthetic pathway in a heterologous host that does not normally 
produce LTA, such as E. coli (Richter et al., 2013, Grundling and Schneewind, 2007b).  
In addition, a pure compound will enable for the quantitation of the dosage dependence 
for S. aureus and B. subtilis growth. As it stands, the dosage dependence reported in this 
work is qualitative, with doses used measured relative to each other. On a grander 
scheme, with the assumption that action against LtaS is confirmed, it will be of interest 
to examine the effect the compound may play against Gram positive pathogens in 
animal infection models. In the event that the compound is not suitable for clinical 
application the compound may well prove useful for academic use. Treatment with an 
LtaS inhibitor will prove useful for transient depletion of LTA, or to study LTA function in 
species in which the synthetic enzyme has not been identified. 
In the somewhat unlikely event that the compound is shown not to have a role in the 
inhibition of LtaS, it will still enable the exploration the bacterial cytoskeleton. No matter 
what the actual target of the compound is, it certainly alleviates the magnesium 
dependence exhibited by Δmbl strains. It could therefore be considered that the 
compound could enable further study into the function of the cytoskeleton.   
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Appendices 
Appendix 1. Solutions and buffers 
Name Composition 
Blocking buffer 5% milk powder in PBS 
 0.1% Tween20 
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CAA (casamino acids) 20% casamino acids 
 
DNA loading dye 0.04% bromphenol blue in 50% glycerol 
 
Ferric ammonium citrate 2.2mg/ml Ferric ammonium citrate 
 
RF1 100 mM RbCl 
 50 mM potassium acetate 
 10 mM CaCl2 
 15% glycerol 
 
RF2 10 mM MOPS 
 10 mM RbCl2 
 75 mM CaCl2 
 15% glycerol 
 
SMM (Spizizen minimal medium) 1.4% K2HPO4 
 0.2% (NH4)2SO4 
 0.6% KH2PO4 
 0.2% sodium citrate 
 0.02% MgSO4 
 
Solution E 40% D-glucose 
 
Solution F 1 M MgSO4 
Solution H 50 mM MnSO4 
 
SSC 0.15 M NaCl 
 0.01M sodium tricitrate 
 Adjust to pH 7.0 
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Staining solution A 60g (NH4)2SO4  final conc. 8% 
 15ml phosphoric acid 85% (final conc. 
1.6%) 
  
Staining solution B 1.6% Coomassie brilliant blue (G) 
 
50x TAE buffer 2 M Tris pH 8.0 
 50 mM acetic acid 
 100 mM EDTA 
 
TE buffer 10 mM Tris pH 8.0 
 1 mM EDTA 
 
Transfer buffer (for semi-dry transfer) 3 g Tris 
 14.4 g glycine 
 150 ml methanol 
 Fill up to 1 L with dH2O 
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Appendix 2. Growth media 
Name Composition 
Competence medium 10 ml SMM 
 0.125 ml solution E 
 0.1 ml tryptophan solution 
 0.06 ml solution F 
 0.01 ml CAA 
 0.005 ml ferric ammonium citrate 
 
GYM medium 4 g glucose 
 4 g yeast extract 
 10 g malt extract 
 Adjust pH to 7, fill up to 1 L with dH2O; 
autoclave 
 
LB medium 10 g Tryptone 
 5 g Yeast extract 
 10 g NaCl  
 Adjust pH to 7, fill up to 1 L with dH2O; 
autoclave 
 
MSM 365 g sucrose 
 4.64 g MgCl2 
 8.13 g maleic acid 
 Adjust pH to 7, fill up to 1 L with dH2O; 
autoclave 
 
Nutrient agar 28 g Oxoid Nutrient agar 
 fill up to 1 L with dH2O; autoclave 
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Nutrient broth 13 g Oxoid Nutrient broth 
 fill up to 1 L with dH2O; autoclave 
 
PAB medium 17.5 g Oxoid antibiotic medium no. 3 
 fill up to 1 L with dH2O; autoclave 
 
Starvation medium 10 ml SMM 
 0.125 ml solution E 
 0.06 ml solution F 
 
Appendix 3. Oligonucleotides 
Name Sequence (5’-3’) Construction 
oJB33 AATTTAATTTCCGCGGGCATCATCGGAGGAGCAG pJB1 
oJB34 AAGGGAATTTGGATCCGAGCCTTGCTAAGCTGAGCC pJB1 
oJB35 AAGGGAATTTAAGCTTCCGTATGACCTGAATATTAATG pJB1 
oJB36 AAGGGAATTCTCGAGCGACGAATTGTCGGAAG pJB1 
oJB43 AACCCAAGAGCTCTGAATTCGCGGCCGCAGATC JB158 
oJB44 GCCGCGAACCAGGGAATGAGAATAGTGAATGG JB158 
oJB50 AACAGAACCGAGCTCCCGGCAGCGGTTAACTGG JB140 
oJB51 AACCCAAGGATCCATCAGCTGGCACCTTCC JB140 
oJB63 CCACCCAGGATCCCGACAGCGGAATTGACTCAAGC  
oJB64 GAAGAAAGGGAATTCGCGGGCAGTGAGCGCAACG  
oJB77 CCAACCCGAATTCCCTTTCGTCGCAATGGTTTGTG pJB2 
oJB78 CCAACCCGGATCCCTTTATCGACATCATGAAGC pJB2 
oJB84 CGCGATTAAAATGGAAATCGGATCTGCAG pJB3/pJB4 
oJB85 CGATTTCCATTTTAATCGCGTCATCCATCTC pJB3/pJB4 
LENm1 GCGTGTTTATTTGCCGC JB158 
LENm2 TCGTAGTCTAGAGTGTTACAAATATCCTTTTTCC JB158 
LENm3 TCGTAGTCTAGAATTTGTAACACTTTTTTTTCGTCGAATTAAGC JB158 
LENm4 CATAGCCCTGCAAAACCA JB158 
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Oligonucleotides used for verification of mutations identified in the whole genome 
sequencing are not listed. They were typically designed approximately 25-50bp each 
side of the predicted mutation.  
Appendix 4. Table of mutations 
LR2 
Region Type Reference Allele Zygosity Count Coverage Frequency Gene 
165749 Deletion C - Homozygous 105 107 98.130841   
165751 Deletion C - Homozygous 104 104 100   
165825^16
5826 Insertion - C Homozygous 94 99 94.949495   
166037^16
6038 Insertion - T Homozygous 75 80 93.75   
166344 Deletion G - Homozygous 52 52 100   
557865^55
7866 Insertion - T Homozygous 45 48 93.75   
608214^60
8215 Insertion - A Homozygous 31 37 83.783784   
961817 SNV G A Homozygous 111 111 100 ssuB 
1317152^1
317153 Insertion - GT Homozygous 105 105 100   
1317153^1
317154 Insertion - T Homozygous 100 104 96.153846   
1372773 SNV C A Homozygous 39 41 95.121951   
1581413 SNV T C Homozygous 81 85 95.294118 mraW 
1581669 SNV A G Homozygous 78 78 100 ftsL 
1581749 SNV G C Homozygous 72 74 97.297297 ftsL 
1582629 SNV A G Homozygous 65 68 95.588235 pbpB 
1582646 SNV C A Homozygous 77 78 98.717949 pbpB 
1582727 SNV C G Homozygous 73 73 100 pbpB 
1584096..1
584097 MNV AA GG Homozygous 41 41 100 pbpB 
1584099..1
584101 MNV AAG TCC Homozygous 41 41 100   
1586307 SNV A C Homozygous 28 30 93.333333   
1586533 SNV A G Homozygous 92 92 100 murE 
1867634 SNV G A Homozygous 77 78 98.717949   
1891914 SNV C G Heterozygous 22 71 30.985915 xylA 
1891914 SNV C C Heterozygous 48 71 67.605634 xylA 
2097080^2
097081 Insertion - A Homozygous 48 56 85.714286   
2271424 SNV T C Homozygous 113 116 97.413793 uvrX 
2271505 SNV C T Homozygous 114 114 100 uvrX 
2271523 SNV A C Homozygous 92 95 96.842105 uvrX 
2480646..2
480647 MNV TA AT Homozygous 125 125 100   
2480654 Deletion T - Homozygous 124 126 98.412698   
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2480667 Deletion T - Homozygous 128 128 100   
2526904 Deletion T - Homozygous 111 114 97.368421 xseB 
2579550..2
579551 MNV TC GT Heterozygous 18 52 34.615385 pstA 
2579550..2
579551 MNV TC TC Heterozygous 34 52 65.384615 pstA 
2579554 SNV C T Heterozygous 11 48 22.916667 pstA 
2579554 SNV C C Heterozygous 35 48 72.916667 pstA 
2579564..2
579569 MNV TGGCGC 
AAAA
AA Heterozygous 15 61 24.590164 pstA 
2579564..2
579569 MNV TGGCGC 
TGGC
GC Heterozygous 44 61 72.131148 pstA 
2581726^2
581727 Insertion - T Homozygous 99 106 93.396226   
3010782 SNV G A Homozygous 85 86 98.837209 ytkK 
3178443 SNV T C Homozygous 31 32 96.875 
rrnB-
16S 
3391676 SNV A G Homozygous 82 84 97.619048 gerAA 
3391685 SNV T C Homozygous 78 80 97.5 gerAA 
3770058^3
770059 Insertion - A Homozygous 66 75 88   
3935823 Deletion T - Homozygous 78 79 98.734177   
4005693 SNV A C Homozygous 59 61 96.721311   
4095811 SNV C T Homozygous 84 88 95.454545 yxbD 
4155390^4
155391 Insertion - A Homozygous 114 115 99.130435   
4189058 Deletion A - Heterozygous 65 173 37.572254   
4189058 SNV A A Heterozygous 104 173 60.115607   
4189063^4
189064 Insertion - A Heterozygous 60 176 34.090909   
4189063^4
189064 Insertion - - Heterozygous 114 176 64.772727   
4189071 SNV T A Heterozygous 57 159 35.849057   
4189071 SNV T T Heterozygous 99 159 62.264151   
4189087 SNV C T Heterozygous 62 151 41.059603   
4189087 SNV C C Heterozygous 82 151 54.304636   
4189100 SNV C T Heterozygous 56 144 38.888889 tetL 
4189100 SNV C C Heterozygous 82 144 56.944444 tetL 
4189102 SNV T A Heterozygous 55 152 36.184211 tetL 
4189102 SNV T T Heterozygous 94 152 61.842105 tetL 
4189127 SNV T A Heterozygous 37 128 28.90625 tetL 
4189127 SNV T T Heterozygous 91 128 71.09375 tetL 
4189135^4
189136 Insertion - A Heterozygous 33 126 26.190476 tetL 
4189135^4
189136 Insertion - - Heterozygous 92 126 73.015873 tetL 
4189139^4
189140 Insertion - CA Heterozygous 28 120 23.333333 tetL 
4189139^4
189140 Insertion - - Heterozygous 92 120 76.666667 tetL 
284 
 
4189141^4
189142 Insertion - ATTC Heterozygous 28 118 23.728814 tetL 
4189141^4
189142 Insertion - - Heterozygous 90 118 76.271186 tetL 
4189145 SNV G A Heterozygous 27 101 26.732673 tetL 
4189145 SNV G G Heterozygous 71 101 70.29703 tetL 
 
M1 
Region Type Reference Allele Zygosity Count Coverage Frequency Gene 
14808 SNV A C Heterozygous 86 210 40.95238 
rrnO-
5S 
14808 SNV A A Heterozygous 124 210 59.04762 
rrnO-
5S 
96240 SNV G A Heterozygous 166 569 29.17399   
96240 SNV G G Heterozygous 402 569 70.65026   
372434..37
2435 MNV GT CG Heterozygous 150 517 29.01354 nucA 
372434..37
2435 MNV GT GT Heterozygous 367 517 70.98646 nucA 
522503..52
2504 
Replaceme
nt AA T Heterozygous 142 449 31.62584 rsbW 
522503..52
2504 MNV AA AA Heterozygous 307 449 68.37416 rsbW 
1075057 SNV C A Homozygous 95 95 100 trpP 
1075060^1
075061 Insertion - G Homozygous 120 120 100 trpP 
1075064 SNV A C Homozygous 147 147 100 trpP 
1075066 SNV A T Homozygous 158 158 100 trpP 
1104996 Deletion C - Homozygous 254 255 99.60784 aprE 
1104999^1
105000 Insertion - A Homozygous 229 230 99.56522 aprE 
1523004 Deletion T - Heterozygous 192 484 39.66942 adeC 
1523004 SNV T T Heterozygous 292 484 60.33058 adeC 
1523007 Deletion C - Heterozygous 192 487 39.42505 adeC 
1523007 SNV C C Heterozygous 295 487 60.57495 adeC 
1765777 SNV C A Heterozygous 357 603 59.20398   
1765777 SNV C C Heterozygous 246 603 40.79602   
1891754 SNV A G Heterozygous 144 568 25.35211   
1891754 SNV A A Heterozygous 424 568 74.64789   
1891785 SNV C T Heterozygous 214 663 32.27753   
1891785 SNV C C Heterozygous 449 663 67.72247   
1891794 SNV A T Heterozygous 215 661 32.52648   
1891794 SNV A A Heterozygous 446 661 67.47352   
1891801 SNV G T Heterozygous 237 696 34.05172   
1891801 SNV G G Heterozygous 459 696 65.94828   
1891821..1
891823 MNV AAA GGG Heterozygous 147 665 22.10526   
1891821..1
891823 MNV AAA AAA Heterozygous 518 665 77.89474   
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2722642 SNV T G Heterozygous 165 459 35.94771 yrdQ 
2722642 SNV T T Heterozygous 294 459 64.05229 yrdQ 
2722646 SNV G A Heterozygous 201 491 40.93686   
2722646 SNV G G Heterozygous 289 491 58.85947   
2722649 SNV A C Heterozygous 215 497 43.25956   
2722649 SNV A A Heterozygous 282 497 56.74044   
2722663^2
722664 Insertion - T Heterozygous 222 508 43.70079   
2722663^2
722664 Insertion - - Heterozygous 286 508 56.29921   
2988777 SNV A G Heterozygous 331 594 55.72391 accD 
2988777 SNV A A Heterozygous 263 594 44.27609 accD 
3422547..3
422548 MNV AC GG Heterozygous 217 547 39.67093 yvgJ 
3422547..3
422548 MNV AC AC Heterozygous 329 547 60.14625 yvgJ 
4084771^4
084772 Insertion - A Heterozygous 178 451 39.46785   
4084771^4
084772 Insertion - - Heterozygous 273 451 60.53215   
 
JB114 
Region Type Reference Allele Zygosity Count Coverage Frequency Gene 
96240 SNV G A Heterozygous 62 211 29.38389   
96240 SNV G G Heterozygous 149 211 70.61611   
372434..37
2435 MNV GT CG Heterozygous 49 191 25.65445 nucA 
372434..37
2435 MNV GT GT Heterozygous 142 191 74.34555 nucA 
1349537^1
349538 Insertion - CA Homozygous 94 94 100 pit 
1523004 Deletion T - Heterozygous 64 134 47.76119 adeC 
1523004 SNV T T Heterozygous 70 134 52.23881 adeC 
1523007 Deletion C - Heterozygous 64 139 46.04317 adeC 
1523007 SNV C C Heterozygous 75 139 53.95683 adeC 
1765777 SNV C A Heterozygous 114 233 48.92704   
1765777 SNV C C Heterozygous 119 233 51.07296   
1891754 SNV A G Heterozygous 60 240 25   
1891754 SNV A A Heterozygous 180 240 75   
1891785 SNV C T Heterozygous 101 306 33.00654   
1891785 SNV C C Heterozygous 205 306 66.99346   
1891794 SNV A T Heterozygous 92 293 31.39932   
1891794 SNV A A Heterozygous 201 293 68.60068   
1891801 SNV G T Heterozygous 91 278 32.73381   
1891801 SNV G G Heterozygous 187 278 67.26619   
1891822..1
891823 MNV AA GG Heterozygous 49 222 22.07207   
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1891822..1
891823 MNV AA AA Heterozygous 173 222 77.92793   
2722642 SNV T G Heterozygous 75 124 60.48387 yrdQ 
2722642 SNV T T Heterozygous 49 124 39.51613 yrdQ 
2722646 SNV G A Heterozygous 86 134 64.1791   
2722646 SNV G G Heterozygous 48 134 35.8209   
2722649 SNV A C Heterozygous 94 140 67.14286   
2722649 SNV A A Heterozygous 46 140 32.85714   
2722663^2
722664 Insertion - T Heterozygous 95 139 68.34532   
2722663^2
722664 Insertion - - Heterozygous 44 139 31.65468   
2814260..2
814273 Deletion 
GAATGCG
GCCGACG - Homozygous 98 98 100 yrvM 
2861122..2
861181 Deletion 
TTCAGCCG
TACGGTCA
CCGATCAT
CAGATTGT
ACGTTTTT
CTGATGTA
GTTGATAA
TCGC - Heterozygous 65 83 78.31325 mreB 
2861122..2
861181 MNV 
TTCAGCCG
TACGGTCA
CCGATCAT
CAGATTGT
ACGTTTTT
CTGATGTA
GTTGATAA
TCGC 
TTCA
GCCG
TACG
GTCA
CCGA
TCAT
CAGA
TTGT
ACGT
TTTT
CTGA
TGTA
GTTG
ATAA
TCGC Heterozygous 18 83 21.68675 mreB 
2988777 SNV A G Heterozygous 84 174 48.27586 accD 
2988777 SNV A A Heterozygous 90 174 51.72414 accD 
3056567^3
056568 Insertion - T Homozygous 104 104 100 ytzB 
3422547..3
422548 MNV AC GG Heterozygous 83 198 41.91919 yvgJ 
3422547..3
422548 MNV AC AC Heterozygous 115 198 58.08081 yvgJ 
3624985 SNV C A Homozygous 105 105 100 ftsE 
4084771^4
084772 Insertion - A Heterozygous 128 279 45.87814   
4084771^4
084772 Insertion - - Heterozygous 151 279 54.12186   
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JB115 
Region Type Reference Allele Zygosity Count Coverage Frequency Gene 
125099 SNV C A Homozygous 528 532 99.24812 rpoB 
171331 SNV T G Heterozygous 130 304 42.76316   
171331 SNV T T Heterozygous 174 304 57.23684   
2072630 SNV T G Heterozygous 90 218 41.2844 yobL 
2072630 SNV T T Heterozygous 126 218 57.79817 yobL 
2072633 SNV T A Heterozygous 90 210 42.85714 yobL 
2072633 SNV T T Heterozygous 120 210 57.14286 yobL 
2072636 SNV A G Heterozygous 88 200 44 yobL 
2072636 SNV A A Heterozygous 112 200 56 yobL 
2072639 SNV G A Heterozygous 86 190 45.26316 yobL 
2072639 SNV G G Heterozygous 104 190 54.73684 yobL 
2072645 SNV A G Heterozygous 88 198 44.44444 yobL 
2072645 SNV A A Heterozygous 110 198 55.55556 yobL 
2072648 SNV A T Heterozygous 78 170 45.88235 yobL 
2072648 SNV A A Heterozygous 92 170 54.11765 yobL 
2072651 SNV T C Heterozygous 80 186 43.01075 yobL 
2072651 SNV T T Heterozygous 106 186 56.98925 yobL 
2072669 SNV A G Heterozygous 40 132 30.30303 yobL 
2072669 SNV A A Heterozygous 92 132 69.69697 yobL 
2276476 SNV A T Heterozygous 60 170 35.29412 yokI 
2276476 SNV A A Heterozygous 110 170 64.70588 yokI 
2861115..2
861174 Deletion 
TAATCGCT
TCAGCCGT
ACGGTCAC
CGATCATC
AGATTGTA
CGTTTTTC
TGATGTAG
TTGA - Homozygous 378 378 100 mreB 
3056567^3
056568 Insertion - T Homozygous 332 336 98.80952 ytzB 
3812832^3
812833 Insertion - C Homozygous 270 274 98.54015 rpoE 
4187758..4
187759 MNV TG AT Heterozygous 142 568 25 tetB 
4187758..4
187759 MNV TG TG Heterozygous 426 568 75 tetB 
4188346 SNV G T Heterozygous 138 510 27.05882 tetB 
4188346 SNV G G Heterozygous 368 510 72.15686 tetB 
4188623 SNV C T Heterozygous 106 466 22.74678 tetB 
4188623 SNV C C Heterozygous 358 466 76.82403 tetB 
4189141^4
189142 Insertion - A Heterozygous 58 280 20.71429 tetL 
 
  
288 
 
JB116 
Region Type Reference Allele Zygosity Count Coverage Frequency Gene 
502452 SNV G C Homozygous 81 83 97.59036 ydbI 
1070342 SNV A T Heterozygous 17 44 38.63636   
1070342 SNV A A Heterozygous 27 44 61.36364   
2530296 Deletion T - Homozygous 59 60 98.33333 yqhY 
2579550 SNV T G Heterozygous 6 17 35.29412 pstA 
2579550 SNV T T Heterozygous 10 17 58.82353 pstA 
4188023 SNV A T Heterozygous 33 143 23.07692 tetB 
4188023 SNV A A Heterozygous 107 143 74.82517 tetB 
4188041 SNV G A Heterozygous 33 135 24.44444 tetB 
4188041 SNV G G Heterozygous 99 135 73.33333 tetB 
4188077 SNV A G Heterozygous 29 130 22.30769 tetB 
4188077 SNV A A Heterozygous 98 130 75.38462 tetB 
4188089 SNV C A Heterozygous 32 135 23.7037 tetB 
 
JB117 
Region Type Reference Allele Zygosity Count Coverage Frequency Gene 
96240 SNV G A Heterozygous 65 191 34.03141   
96240 SNV G G Heterozygous 126 191 65.96859   
372434..37
2435 MNV GT CG Heterozygous 49 180 27.22222 nucA 
372434..37
2435 MNV GT GT Heterozygous 131 180 72.77778 nucA 
1523004 Deletion T - Heterozygous 93 168 55.35714 adeC 
1523004 SNV T T Heterozygous 75 168 44.64286 adeC 
1523007 Deletion C - Heterozygous 93 168 55.35714 adeC 
1523007 SNV C C Heterozygous 75 168 44.64286 adeC 
1731572 Deletion A - Homozygous 102 102 100   
1765777 SNV C A Heterozygous 166 275 60.36364   
1765777 SNV C C Heterozygous 109 275 39.63636   
1891785 SNV C T Heterozygous 114 372 30.64516   
1891785 SNV C C Heterozygous 258 372 69.35484   
1891794 SNV A T Heterozygous 112 376 29.78723   
1891794 SNV A A Heterozygous 264 376 70.21277   
1891801 SNV G T Heterozygous 119 371 32.07547   
1891801 SNV G G Heterozygous 252 371 67.92453   
2456435 Deletion T - Homozygous 87 88 98.86364 ansA 
2530296 Deletion T - Homozygous 88 88 100 yqhY 
2722642 SNV T G Heterozygous 96 210 45.71429 yrdQ 
2722642 SNV T T Heterozygous 114 210 54.28571 yrdQ 
2722646 SNV G A Heterozygous 112 230 48.69565   
2722646 SNV G G Heterozygous 118 230 51.30435   
2722649 SNV A C Heterozygous 118 243 48.55967   
2722649 SNV A A Heterozygous 125 243 51.44033   
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2722663^2
722664 Insertion - T Heterozygous 125 232 53.87931   
2722663^2
722664 Insertion - - Heterozygous 107 232 46.12069   
2988777 SNV A G Heterozygous 84 185 45.40541 accD 
2988777 SNV A A Heterozygous 100 185 54.05405 accD 
3315400..3
315489 Deletion 
AGCCGAG
GCGTTTGC
TGAAGCTG
ATGTCCTC
GTCTGTAA
TTTGGGAG
ATCCCCTT
TACTTTGA
CGTCTTCC
AGATCCAC
GTTCATCG
AGA - Heterozygous 77 101 76.23762 hom 
3315400..3
315489 MNV 
AGCCGAG
GCGTTTGC
TGAAGCTG
ATGTCCTC
GTCTGTAA
TTTGGGAG
ATCCCCTT
TACTTTGA
CGTCTTCC
AGATCCAC
GTTCATCG
AGA 
AGCCG
AGGCG
TTTGC
TGAAG
CTGAT
GTCCT
CGTCT
GTAAT
TTGGG
AGATC
CCCTTT
ACTTT
GACGT
CTTCC
AGATC
CACGT
TCATC
GAGA Heterozygous 24 101 23.76238 hom 
3422547..3
422548 MNV AC GG Heterozygous 83 216 38.42593 yvgJ 
3422547..3
422548 MNV AC AC Heterozygous 132 216 61.11111 yvgJ 
4084771^4
084772 Insertion - A Heterozygous 134 295 45.42373   
4084771^4
084772 Insertion - - Heterozygous 161 295 54.57627   
 
JB118 
Region Type Reference Allele Zygosity Count Coverage Frequency Gene 
96240 SNV G A Heterozygous 67 194 34.53608   
96240 SNV G G Heterozygous 127 194 65.46392   
372434..37
2435 MNV GT CG Heterozygous 59 175 33.71429 nucA 
372434..37
2435 MNV GT GT Heterozygous 116 175 66.28571 nucA 
1523004 Deletion T - Heterozygous 71 172 41.27907 adeC 
1523004 SNV T T Heterozygous 101 172 58.72093 adeC 
1523007 Deletion C - Heterozygous 71 168 42.2619 adeC 
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1523007 SNV C C Heterozygous 97 168 57.7381 adeC 
1765777 SNV C A Heterozygous 189 299 63.2107   
1765777 SNV C C Heterozygous 110 299 36.7893   
1891754 SNV A G Heterozygous 62 281 22.06406   
1891754 SNV A A Heterozygous 219 281 77.93594   
1891785 SNV C T Heterozygous 122 362 33.70166   
1891785 SNV C C Heterozygous 240 362 66.29834   
1891794 SNV A T Heterozygous 116 374 31.01604   
1891794 SNV A A Heterozygous 258 374 68.98396   
1891801 SNV G T Heterozygous 123 384 32.03125   
1891801 SNV G G Heterozygous 261 384 67.96875   
2456435 Deletion T - Homozygous 94 94 100 ansA 
2530296 Deletion T - Homozygous 83 83 100 yqhY 
2722642 SNV T G Heterozygous 114 203 56.15764 yrdQ 
2722642 SNV T T Heterozygous 89 203 43.84236 yrdQ 
2722646 SNV G A Heterozygous 125 224 55.80357   
2722646 SNV G G Heterozygous 99 224 44.19643   
2722649 SNV A C Heterozygous 136 231 58.87446   
2722649 SNV A A Heterozygous 95 231 41.12554   
2722663^2
722664 Insertion - T Heterozygous 139 228 60.96491   
2722663^2
722664 Insertion - - Heterozygous 89 228 39.03509   
2988777 SNV A G Heterozygous 132 223 59.19283 accD 
2988777 SNV A A Heterozygous 91 223 40.80717 accD 
3422547..3
422548 MNV AC GG Heterozygous 84 228 36.84211 yvgJ 
3422547..3
422548 MNV AC AC Heterozygous 144 228 63.15789 yvgJ 
4084771^4
084772 Insertion - A Heterozygous 173 314 55.09554   
4084771^4
084772 Insertion - - Heterozygous 141 314 44.90446   
 
JB119 
Region Type Reference Allele Zygosity Count Coverage Frequency Gene 
2456435 Deletion T - Homozygous 115 116 99.13793 ansA 
2530296 Deletion T - Homozygous 131 131 100 yqhY 
 
JB120 
Region Type Reference Allele Zygosity Count Coverage Frequency Gene 
96240 SNV G A Heterozygous 49 184 26.63043   
96240 SNV G G Heterozygous 135 184 73.36957   
372434..37
2435 MNV GT CG Heterozygous 47 177 26.55367 nucA 
372434..37
2435 MNV GT GT Heterozygous 130 177 73.44633 nucA 
291 
 
490580 SNV G T Heterozygous 36 119 30.2521   
490580 SNV G G Heterozygous 80 119 67.22689   
1523004 Deletion T - Heterozygous 93 176 52.84091 adeC 
1523004 SNV T T Heterozygous 83 176 47.15909 adeC 
1523007 Deletion C - Heterozygous 92 177 51.9774 adeC 
1523007 SNV C C Heterozygous 85 177 48.0226 adeC 
1765777 SNV C A Heterozygous 114 215 53.02326   
1765777 SNV C C Heterozygous 101 215 46.97674   
1891785 SNV C T Heterozygous 103 350 29.42857   
1891785 SNV C C Heterozygous 247 350 70.57143   
1891794 SNV A T Heterozygous 94 320 29.375   
1891794 SNV A A Heterozygous 226 320 70.625   
1891801 SNV G T Heterozygous 96 329 29.17933   
1891801 SNV G G Heterozygous 233 329 70.82067   
2456435 Deletion T - Homozygous 97 97 100 ansA 
2530296 Deletion T - Homozygous 80 80 100 yqhY 
2722642 SNV T G Heterozygous 91 195 46.66667 yrdQ 
2722642 SNV T T Heterozygous 104 195 53.33333 yrdQ 
2722646 SNV G A Heterozygous 105 216 48.61111   
2722646 SNV G G Heterozygous 110 216 50.92593   
2722649 SNV A C Heterozygous 111 217 51.15207   
2722649 SNV A A Heterozygous 106 217 48.84793   
2722663^2
722664 Insertion - T Heterozygous 112 225 49.77778   
2722663^2
722664 Insertion - - Heterozygous 113 225 50.22222   
2797830 SNV T G Homozygous 100 100 100 yrzL 
2988777 SNV A G Heterozygous 117 214 54.6729 accD 
2988777 SNV A A Heterozygous 97 214 45.3271 accD 
3422547..3
422548 MNV AC GG Heterozygous 88 201 43.78109 yvgJ 
3422547..3
422548 MNV AC AC Heterozygous 113 201 56.21891 yvgJ 
4084771^4
084772 Insertion - A Heterozygous 132 297 44.44444   
4084771^4
084772 Insertion - - Heterozygous 165 297 55.55556   
 
JB121 
Region Type Reference Allele Zygosity Count Coverage Frequency Gene 
96240 SNV G A Heterozygous 48 155 30.96774   
96240 SNV G G Heterozygous 106 155 68.3871   
118116 SNV G A Homozygous 123 124 99.19355 nusG 
171331 SNV T G Heterozygous 35 142 24.64789   
171331 SNV T T Heterozygous 107 142 75.35211   
372434..37
2435 MNV GT CG Heterozygous 77 195 39.48718 nucA 
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372434..37
2435 MNV GT GT Heterozygous 117 195 60 nucA 
490580 SNV G T Heterozygous 23 101 22.77228   
490580 SNV G G Heterozygous 76 101 75.24752   
1523004 Deletion T - Heterozygous 79 181 43.64641 adeC 
1523004 SNV T T Heterozygous 102 181 56.35359 adeC 
1523007 Deletion C - Heterozygous 79 182 43.40659 adeC 
1523007 SNV C C Heterozygous 103 182 56.59341 adeC 
1765777 SNV C A Heterozygous 133 229 58.0786   
1765777 SNV C C Heterozygous 96 229 41.9214   
1891754 SNV A G Heterozygous 72 219 32.87671   
1891754 SNV A A Heterozygous 147 219 67.12329   
1891785 SNV C T Heterozygous 99 268 36.9403   
1891785 SNV C C Heterozygous 169 268 63.0597   
1891794 SNV A T Heterozygous 97 268 36.19403   
1891794 SNV A A Heterozygous 171 268 63.80597   
1891801 SNV G T Heterozygous 104 274 37.9562   
1891801 SNV G G Heterozygous 170 274 62.0438   
1891821..1
891823 MNV AAA GGG Heterozygous 63 248 25.40323   
1891821..1
891823 MNV AAA AAA Heterozygous 185 248 74.59677   
1987120 SNV G C Heterozygous 78 103 75.72816 ppsB 
1987120 SNV G G Heterozygous 25 103 24.27184 ppsB 
2456435 Deletion T - Homozygous 89 90 98.88889 ansA 
2530296 Deletion T - Homozygous 106 107 99.06542 yqhY 
2722642 SNV T G Heterozygous 72 179 40.22346 yrdQ 
2722642 SNV T T Heterozygous 107 179 59.77654 yrdQ 
2722646 SNV G A Heterozygous 80 190 42.10526   
2722646 SNV G G Heterozygous 110 190 57.89474   
2722649 SNV A C Heterozygous 83 187 44.38503   
2722649 SNV A A Heterozygous 104 187 55.61497   
2722663^2
722664 Insertion - T Heterozygous 89 167 53.29341   
2722663^2
722664 Insertion - - Heterozygous 78 167 46.70659   
2988777 SNV A G Heterozygous 138 237 58.22785 accD 
2988777 SNV A A Heterozygous 98 237 41.35021 accD 
3422547..3
422548 MNV AC GG Heterozygous 75 185 40.54054 yvgJ 
3422547..3
422548 MNV AC AC Heterozygous 110 185 59.45946 yvgJ 
4084771^4
084772 Insertion - A Heterozygous 46 121 38.01653   
4084771^4
084772 Insertion - - Heterozygous 75 121 61.98347   
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JB122 
Region Type Reference Allele Zygosity Count Coverage Frequency Gene 
96240 SNV G A Heterozygous 51 196 26.02041   
96240 SNV G G Heterozygous 145 196 73.97959   
372434..37
2435 MNV GT CG Heterozygous 55 188 29.25532 nucA 
372434..37
2435 MNV GT GT Heterozygous 133 188 70.74468 nucA 
490580 SNV G T Heterozygous 33 138 23.91304   
490580 SNV G G Heterozygous 103 138 74.63768   
1523004 Deletion T - Heterozygous 86 162 53.08642 adeC 
1523004 SNV T T Heterozygous 76 162 46.91358 adeC 
1523007 Deletion C - Heterozygous 88 163 53.98773 adeC 
1523007 SNV C C Heterozygous 75 163 46.01227 adeC 
1765777 SNV C A Heterozygous 173 272 63.60294   
1765777 SNV C C Heterozygous 99 272 36.39706   
1891754 SNV A G Heterozygous 67 258 25.96899   
1891754 SNV A A Heterozygous 191 258 74.03101   
1891785 SNV C T Heterozygous 111 331 33.53474   
1891785 SNV C C Heterozygous 220 331 66.46526   
1891794 SNV A T Heterozygous 105 337 31.15727   
1891794 SNV A A Heterozygous 232 337 68.84273   
1891801 SNV G T Heterozygous 101 334 30.23952   
1891801 SNV G G Heterozygous 233 334 69.76048   
2427538 SNV C G Homozygous 82 82 100 ypzK 
2456435 Deletion T - Homozygous 86 86 100 ansA 
2530296 Deletion T - Homozygous 92 93 98.92473 yqhY 
2722642 SNV T G Heterozygous 81 173 46.82081 yrdQ 
2722642 SNV T T Heterozygous 92 173 53.17919 yrdQ 
2722646 SNV G A Heterozygous 105 196 53.57143   
2722646 SNV G G Heterozygous 91 196 46.42857   
2722649 SNV A C Heterozygous 109 201 54.22886   
2722649 SNV A A Heterozygous 92 201 45.77114   
2722663^2
722664 Insertion - T Heterozygous 113 188 60.10638   
2722663^2
722664 Insertion - - Heterozygous 75 188 39.89362   
2797830 SNV T G Homozygous 106 106 100 yrzL 
2988777 SNV A G Heterozygous 100 185 54.05405 accD 
2988777 SNV A A Heterozygous 85 185 45.94595 accD 
3422547..3
422548 MNV AC GG Heterozygous 81 214 37.85047 yvgJ 
3422547..3
422548 MNV AC AC Heterozygous 133 214 62.14953 yvgJ 
4084771^4
084772 Insertion - A Heterozygous 127 285 44.5614   
4084771^4
084772 Insertion - - Heterozygous 158 285 55.4386   
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JB125 
Region Type Reference Allele Zygosity Count Coverage Frequency Gene 
2456435 Deletion T - Homozygous 94 96 97.91667 ansA 
2530296 Deletion T - Homozygous 85 85 100 yqhY 
2579550 SNV T G Heterozygous 7 32 21.875 pstA 
2579550 SNV T T Heterozygous 22 32 68.75 pstA 
2797830 SNV T G Homozygous 87 88 98.86364 yrzL 
4189139^4
189140 Insertion - A Heterozygous 22 98 22.44898 tetL 
 
JB126 
Region Type Reference Allele Zygosity Count Coverage Frequency Gene 
176141 SNV T C Homozygous 14 14 100 
rrnG-
23S 
176143 Deletion T - Homozygous 16 17 94.11765   
176185^17
6186 Insertion - C Homozygous 20 21 95.2381   
2456435 Deletion T - Homozygous 46 46 100 ansA 
2530296 Deletion T - Homozygous 56 57 98.24561 yqhY 
2579556 SNV A T Heterozygous 7 18 38.88889 pstA 
2579556 SNV A A Heterozygous 11 18 61.11111 pstA 
2579560..2
579561 MNV GC TG Heterozygous 7 20 35 pstA 
2579560..2
579561 MNV GC GC Heterozygous 13 20 65 pstA 
2579564..2
579568 MNV TGGCG 
AAAA
A Heterozygous 8 23 34.78261 pstA 
2579564..2
579568 MNV TGGCG 
TGGC
G Heterozygous 15 23 65.21739 pstA 
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